Search

A Influenza A (H1 N1) Master Update Ver 9.8 June 16 2009

Loading...

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

0 comments

Post a comment

    Post a comment
    Embed Video
    Edit your comment Cancel

    Notes on slide 1

    3 Favorites

    A Influenza A (H1 N1) Master Update Ver 9.8 June 16 2009 - Presentation Transcript

    1. Pandemic (H1N1) 2009 Virus (Quadruple Reassortment) “The 2009 Pandemic!” By Michael Fraser RN Of Irish First Point Responder Institute “Republic of Ireland” Medical Management of Biological Casualties 7/18/2009 Revised and Modified 18/07/2009
    2. Mission of Presentation “To provide the people of Ireland a universal teaching aid to respond to Pandemic (H1N1) 2009 Virus” 7/18/2009 2
    3. Virus Names Associated Pandemic Influenza 2009 • Swine-Origin Influenza Virus (S-OIV) (US) • North-American Influenza (Mexico) (WHO,OIE) • Swine Influenza A(H1N1) • A(H1N1) • Novel Influenza A(H1N1) • Nouvelle Grippe A (H1N1) Spanish • A(H1N1)-SOIV (swine origin influenza virus) • Influenza A(H1N1)swl (Swine like) (US/CDC) • Influenza A(H1N1)swol (Swine origin like) • Influenza A (H1N1)v (Virus) May 3 2009 (ECDC) • Influenza A(H1N1) May 8 2009 (WHO) • Influenza A(Pandemic H1N1) virus (WHO/NRVESS) • Influenza A(H1N1)qr (Quadruple Reassortment) (IFPRI) • July, 7, 2009, Update: • Official name by (WHO, FAO and OIE): “Pandemic (H1N1) 2009” ? Official abbreviation : – A(H1N1)v (ECDC) – A(H1N1) 09 (AUS), – P/A(H1N1) 09 or P(H1N1) 09 (IFPRI) 7/18/2009 Virus will be referred to at different points of Presentation! 3
    4. “Pandemic (H1N1) 2009” Objectives • Identify Who pandemic Phases In relation to too European and Irish Alert Levels • Identify Global Health Regulation for Ireland • Biological triage • Identify global and Irish Influenza Surveillance Systems • Overview of new mitigation strategies from WHO,DOHC briefing! • Pandemic Influenza A(H1N1) 09 Virus Worldwide Epidemiology • Surveillance processes and systems • Zoonosis of Swine Pandemic Influenza A(H1N1) 09 Virus Signs and Symptom Post-mortem findings, Past Outbreaks and differences of Swine Inflyenza Virus (SIV) and Pandemic Influenza A(H1N1) 09 Virus /Seasonal Influenza Virus • Influenza virus antigenic shift and drift • Categorizing Influenza Virus “Viral Nomenclature • Emergence of Some Influenza Viruses in Humans • Swine Influenza (SIV) Reassortment • Swine Influenza Host Range • Pathogenesis of Triple Reassortment and Quadruple Reassortment 7/18/2009 4
    5. “Pandemic (H1N1) 2009” Objectives • Containment and mitigation definition and strategies • Public health “containment" and “mitigation” management • Reporting Pandemic Influenza A(H1N1) 09 Virus in “containment” and “mitigation” phases • Infection Control and Prevention for Health Care Facilities • Epidemiological Risk Factors Influenza A(H1N1) • Specific Investigational Triggers confirmed Pandemic Influenza A(H1N1) 09 Virus • Irish resources for Pandemic Influenza A(H1N1) 09 Virus • Pandemic Influenza A(H1N1) 09 Virus Transmission, Personal Prevention, Human Signs and Symptoms, High Risk Groups, Diagnosis, Case Definitions 7/18/2009 5
    6. “Pandemic (H1N1) 2009” Objectives Continued • Recommended Initial PPE Protection Levels for all levels of response • Handling Human Remains (HHR) • Pandemic Influenza A(H1N1) 09 Virus Antivirals Treatment Schedule,Adverse Effects • Special Considerations for Children • Pregnancy • Typical Antiviral Clinic Process Flow Chart • Post Exposure Prophylaxis (PEP) • Pandemic Influenza A(H1N1) 09 Virus Irelands Laboratories Overview, Specimen Collection, Laboratory Precautions, • Shipping Infectious Substances (WHO “E-tool” guidelines) • Infection Control In Health Care Setting • Environmental Waste 7/18/2009 6
    7. “Pandemic (H1N1) 2009” Objectives Continued • Vaccine development process and timeline • Antiviral treatments and considerations ,(PIEG) On Antivirals Algorithms during “containment” and “mitigation” phases • School outbreaks and containment and mitigation strategies • Residential day camps recommendations for the surveillance of Influenza-like illness • Bioethics • Infection Prevention and Control Guidance for the Ambulance Service • Pandemic Influenza A(H1N1) 09 Virus Business Continuity with checklist • Case Studies Spain. England, and Mexico “Estimated Ratio” • Closing Discussion 7/18/2009 7
    8. World Health Organization (WHO) Pandemic Phase Advisories 11 June 2009 Influenza pandemic alert raised to Phase 6 The Director-General of WHO Dr Margarat Chan has On April 27 2009 The World therefore decided to raise the level of influenza On April 29, the Emergency Health Organisation raised its pandemic alert from phase 5 to phase 6. Committee had their third pandemic alert level to 4, verifying human-to-human "The world is now at the start of the meeting, and decided to raise the pandemic alert level to five, swine flu, hours after the first British cases of the disease were 2009 influenza pandemic," the second-highest level, confirmed. April 28 2009 indicating that a pandemic is WHO flu expert Keiji Fukuda "imminent," and that human- pointed out that it is too late to to-human transmission cases contain the swine flu have been recorded in multiple "Containment is not a feasible countries. operation. Countries should now focus on mitigating the effect of the virus,” 3 to 4 Phase 4 to 5 Phase April 27 2009 April 29 2009 7/18/2009 8 Avian Influenza H5N1 Phase 1-3
    9. World Health Organization (WHO) Pandemic Phase Advisories Phase 6 Rationale • World Health Organization has raise the H1N1 flu virus pandemic alert level from Phase Five to Phase Six. In doing so the WHO underscored: • The decision is based on the spread of the virus and not the severity of illness it causes. The virus has caused sustained community level outbreaks in more than three countries across two WHO regions • In general, the “Pandemic (H1N1) 2009” flu virus continues to cause moderate illness globally with most people affected recovering at home without medical treatment. • For instance in Ireland most infections to date have been mild! • Future severity assessments would reflect one or a combination of the following factors: – changes in the virus – underlying vulnerabilities – limitations in health system capacities 7/18/2009T 9
    10. World Health Organization (WHO) New Mitigation Strategy for Phase 6 (July, 7,2009 Update) • Strategy to change from containment to mitigation • Public health intervention to clinical intervention • Universal contact tracing to specific contact tracing • Antiviral administration from local DPH to influenza centres/pharmacies • New mitigation resources will be available soon from the World Health Organization! – (Thursday, 16, July, 2009) http://www.who.int/mediace ntre/Pandemic_h1n1_presstr anscript_2009_07_07.pdf 7/18/2009 10
    11. International Health Regulations • Following 2003 SARS, the World Health Organization (WHO) revised the International Health Regulations • IHR contains an operational definition of a “public health emergency of international concern” that triggers increased control responsibilities for nations • 194 countries worldwide 7/18/2009 11
    12. International Health Regulations (IHR) 2005 • New influenza virus sub‐types and clusters of unknown and unusual disease are notifiable to WHO in accordance with the Annex 2 decision instrument of the IHR (2005) 7/18/2009 12
    13. Global Pandemic Curve First confirmed Case in Spain was the catalyst in WHO activating Influenza Pandemic Phase 5 Australia Phase 6 7/18/2009 13
    14. MADRID – “Spain Became the First Country in Europe” Pandemic (H1N1) 2009 • MADRID --In Catalonia Spain, officials confirmed the first European case of an infection in a person who had not (recently) travelled to Mexico, in a person whose girlfriend had done so, the second WHO region to experience transmission of this strain of H1N1 • As of June 15 2009 Europe reported its first death in Scotland in a 38 year old pregnant women – Had premature baby boy in June but the baby has died however he June 14 2009 tested negative for Influenza A(H1N1) First and second death – 2nd death- They were an unnamed 73-year-who died on Saturday night in Europe! after 15 days in intensive care • As of June 27 2009, Europe has reported it 3rd death – Girl aged 9 dies in Birmingham hospital June 27 2009 Third death in Europe! • As of June 30 2009, Europe has reported its 3rd Death • A 19-year-old girl died of of the H1N1 influenza Tuesday in Madrid – The girl, of North African origin, who also suffered from asthma, was June 30 2009 28 weeks pregnant. Doctors performed a caesarean section on her on Fourth death in Europe! Monday due to the seriousness of her condition • All deaths in Europe have occurred in the United Kingdom and Spain (17 deaths) 7/18/2009 14
    15. Who Pandemic Phases and Recommended Actions 7/18/2009 15
    16. Who Pandemic Phases and Irelands Recommended Actions 7/18/2009 16
    17. Bioevent Disasters SEIRV Triage Model Categories • Susceptible • Exposed • Infectious • Removed • Vaccinated 7/18/2009 17
    18. “Biological Triage” Mitigation High Transmissibility • Influenza Mitigation: Susceptible • Identify & treat primary infections Exposed Infectious • Preventative Goal: • Prevent and delay secondary Removed infections Vaccinated  Prevent and delay clustered in-country transmissions  Keeping in mind the severity of the influenza virus country by New ECDC “containment vs delayed” article country (High Transmissibility = Low or no containment therefore “delay” transmissions in WHO phase 4-6 ) According to WHO: Influenza A(H1N1) Secondary attack rate of 22-33% 7/18/2009 18 compared to 5-15% for seasonal influenza
    19. EU Alert Levels in WHO Phase 6 EU alert level Description EU Alert Level One No confirmed human cases infected with the pandemic virus in any EU Member State EU Alert Level Two One or more confirmed human case(s) infected with the pandemic virus in any EU Member State EU Alert Level Three A confirmed outbreak (transmission) with the pandemic virus in any EU Member State EU Alert Level Four Widespread transmission in EU Member States 7/18/2009 19
    20. “Pandemic (H1N1) 2009” Epidemiology Five-year-old Edgar Hernandez, known as "patient zero" survived the earliest documented case of swine flu. “April 2 2009” 7/18/2009 20
    21. WHO “Pandemic Influenza A(H1N1) 09 Virus” Confirmed Cases and Deaths • As of 17:00 GMT, July , 6, 2009, 137 countries have officially reported 94,512 cases of Pandemic (H1N1) 2009 virus infection, including 429 deaths 7/18/2009 “WHO” Last report due to new mitigation strategy! 21
    22. Irish Alert Levels In WHO Phase 6 Irish Alert Level Description Irish Alert Level 1 Cases only outside Ireland (in a country or countries with or without extensive Irish travel/trade links Irish Alert Level 2 New virus isolated in Ireland June 11 2009 Irish Alert Level 3 Outbreak(s) in Ireland Irish Alert Level 4 Widespread activity in Ireland First Confirmed case In Dublin Ireland April 3 2009 7/18/2009 22
    23. “Pandemic (H1N1) 2009” Outbreak In Ireland as of July ,17, 2009 Country Confirmed cases of In-country Deaths human swine Transmission influenza Ireland 153 15 0 (April 30 2009 1stcase) Northern 34 NA 0 Ireland (May 1 2009 1st case) Influenza A(H1N1) Infection July ,17, 2009 Weekly Surveillance Report DOHC FAQ’s As of July, 11, 2009 ECDC 130,733 702 June 11 2009 Dr Tony Holohan, Chief Medical Officer of the Department of Health & Children said : • “notwithstanding the increase in level by the WHO, people in Ireland can be reassured that there is no increase in the risk to them. Irish cases are low in number and are regarded as mild. The Department and the HSE are satisfied that the actions we are taking are proportionate in the current circumstances but contingency plans are in place, if required. However, again, we would like to remind people to help themselves avoid infection through personal health protection measures, including washing their hands thoroughly and sneezing into a tissue and disposing of it immediately’” 7/18/2009 23
    24. “Pandemic (H1N1) 2009” Infection Weekly Surveillance Report Number of confirmed cases of Pandemic Influenza A(H1N1) 09 by week number, in Ireland by as of July, 17, 2009 (“Week 28” and “Total” updated daily) Influenza Surveillance Confirmed Cases Week Number 17 1 18 0 19 0 20 0 21 2 22 9 23 1 24 4 25 16 26 34 27 50 28 25 7/18/2009 Total 153 24
    25. “Pandemic (H1N1) 2009” Outbreak In Ireland By Age, Gender and Transmission Mode Update as of July ,11 ,2009 from Weekly Surveillance Report Age Male Female Total Antiviral In-Country Out-of-Country Homecare Hospitalizations Treatment Transmission Transmission 0-4 6 3 9 9 3 2 3 0 5-9 2 2 4 4 0 4 2 0 10-14 2 3 5 5 1 2 1 0 15-19 5 6 11 11 0 7 7 0 20-24 15 8 23 23 1 19 20 0 25-29 4 13 17 17 1 15 17 0 30-34 5 4 9 9 0 8 8 0 35-39 5 4 9 9 0 8 5 0 40-44 5 3 8 4 0 4 4 0 45-49 2 3 5 5 0 4 3 0 50-54 2 4 6 6 0 6 6 0 55-59 2 2 4 4 0 5 2 1 60-64 0 2 2 2 0 1 1 0 65+ 2 3 5 5 0 2 2 0 School 28+ 28 0 Outbreak Total 57 60 117 117+ 9 need updating 97 81 1 (Update 5) 7/18/2009 25
    26. “Pandemic (H1N1) 2009” “First One Hundred and Seventeen Report” “Chief Medical Officer's Press Conference July, 16, 2009” at www.DOHC.ie Policies and Procedures Overview Transmission Overview • Regionally sporadic cases of mild severity • 8 cases occurred by in-country transmission • “Containment strategies” changed to “mitigation strategies” • 96 cases occurred by out of country transmission for Thursday, July, 16, 2009 • I04 Confirmed Cases • Public Health: • 5 Hospitalization (No Ventilation or deaths) – Clinically contract tracing rather than laboratory tracing • 15 cases under age of 15 years old – Public health invention to general treatment intervention • 4 cases over 65 – No contract tracing • 89 cases between 15 -64 • More females than males • General Practitioners: – Will diagnose and prescribe antivirals by case by case • H1N1 Influenza reporting will be incorporated in normal influenza surveillance via CIDR sentinel physicians • Laboratory : • Shift from viral testing to only testing specific cases • Antivirals : • Will be assessed on severity of case rather than general prophylaxis – No resistance to Tamiflu in Ireland – Tamiflu resistance has occurred in three cases reported China, Japan, Denmark • Vaccines: – Influenza A(H1N1)v vaccine available in August September 2009 – Dissemination of vaccine planning and implementation of the programme is a planning priority – Seasonal vaccine is encouraged for all groups July, 14, 2009 DOHC GP Briefing for “Mitigation” Policy changes! http://www.dohc.ie/issues/swine_i nfluenza/letter_med_pract_140709 .pdf?direct=1 7/18/2009
    27. “Pandemic (H1N1) 2009” The Top Ten List as of July, 17, 2009 Top 10 Confirmed Cases of Circulating Avian Countries with Pandemic Influenza Influenza H5N1 in Pandemic Influenza A(H1N1) 09 Humans A(H1N1) 09 1. United States 40,617 No activity 2. Mexico 12,645 (ECDC) No Activity 3. Australia 11,194 Sporadic 4. Chile 10,491 No activity 5. Canada 10,156 No activity 6. England 9,718 No activity 7. Thailand 4,047 Sporadic 8 Philippines 3,341 Sporadic 9. Argentina 3,056 No activity 10. Japan 2,668 Sporadic 53. Ireland 153 No activity 7/18/2009 27
    28. ECDC Reported cumulative number of confirmed cases and of in-country transmission of influenza A(H1N1)v as of 16, July, 2009, 17:00 hours (CEST) in the EU and EFTA countries Country Confirmed cases Cumulative Cumulative Deaths among reported in the number of number of in- confirmed cases last 24h confirmed cases country transmission Austria 13 48 0 Several countries have now announced concentrating on mitigation measures and this usually implies focused Belgium - 124 4 laboratory testing. For these countries, the reported numbers of cases presented in this report will severely Bulgaria - 17 - underestimate the true incidence in the country and will Cyprus - 297 - not be comparable to countries still recommending laboratory tests of all suspected influenza cases. Czech Republic - 21 - Denmark 9 86 4 Estonia 2 19 2 Finland 14 125 - France 17 481 19 Hot Spots in Red Germany 71 834 107 Greece - 323 - Hungary - 26 1 Iceland - 7 1 Ireland 5 153 4 Italy - 224 4 Latvia - 6 - Luxembourg - 13 - Malta - 84 Netherlands - 164 21 Norway 22 105 1 Poland - 35 1 Portugal 9 111 - Romania - 56 6 Slovakia 1 31 1 Slovenia 4 32 Spain - 1099 127 2 Sweden 38 238 187 Switzerland 6 184 - United - 9,718 380 15 Kingdom 7/18/2009 28 Total 208 14,659 655 17
    29. Influenza A(H1N1)v Outside (EU) and EFTA ECDC Tables July, 17, 2009 Confirmed - 130,733 Deaths - 702 7/18/2009 29
    30. Distribution of Confirmed Cases of influenza A(H1N1)v Virus Infection in EU and EFTA countries, • Distribution of confirmed cases of influenza A(H1N1)v infection by date of notification, EU and EFTA countries, 29 April to 14 July 2009 (n = 14,041) • The values of the columns represent the day of notification (from 00:00 till 24:00). The sharp increase observed in the reports received on June 30 and July 10 represent batch reporting from the UK in the previous days. http://ecdc.europa.eu/en/files/pdf/Health_topics/Situation_Report_0 90714_1700hrs.pdf 7/18/2009 30
    31. ECDC June 3rd 2009 Cumulative Epidemic Curve: ECDC SITUATION REPORT Influenza A(H1N1) infection Update 03 June 2009, 17:00 hours CEST “The trend analysis using a semi-logarithmic scale, shows a rapid increase in the number of cases in the Americas (AMRO) as well as in the European region (EURO) since end of April 2009. The increase in the Western Pacific WHO Region (WPRO) was initially less significant but showed a sharp increase in the third week of May, in relation with cases reported from Japan. The trend in the WPRO Region suggests faster increase in the reported cases in the past 8 days, when compared with the AMRO and EURO Regions, due to the rapid spread of the infection in Australia. The South East Asian WHO Region (SEARO) reported the first cases three weeks after the alert of WHO on 25 April and the Eastern Mediterranean Region (EMRO, which is including some countries of the African continent) four weeks after the 25 April. The trend in the number of reported cases from SEARO seems to be similar to the one from WPRO during the last week.” July, 29, 2009 Wikipedia: A semi- logarithmic chart of laboratory-confirmed A(H1N1) influenza cases by date according to WHO reports 7/18/2009 31
    32. “Pandemic (H1N1) 2009” Americas Outbreak 2009 • As of 17, July, 2009, a total of 84,125 confirmed cases of the pandemic (H1N1) 2009, including 674 deaths, have been notified in 34 countries of the Americas July , 17, 2009 PAHO Reporting MWF 7/18/2009 32
    33. “Pandemic (H1N1) 2009” Outbreak In The United States 2009 The date of the onset of symptoms of the first confirmed case was 28 March 2009 in the United States. U.S. Human Cases of H1N1 Flu Infection July ,17, 2009, 11:00 AM ET 40,617 confirmed cases 263 Deaths US Not reporting all cases! 2009 US Swine Flu Summary: First Death Inside the US April 27, 2009 First Death of US Citizen May 5, 2009 Number of People Hospitalized 770 (as of June 4) CDC is reporting every Fridays 7/18/2009 33
    34. “Pandemic (H1N1) 2009” Americas Outbreak • Influenza Viruses Isolated by WHO/NREVSS Collaborating Laboratories 2008 - 2009 Season June, 27, 2009 Week ending June 27 2009 7/18/2009 Week 25 34
    35. Pandemic Influenza A(H1N1) 09 Virus México Outbreak 2009 As of July, 17, 2009 (PAHO) Aguascalientes - 94 Hidalgo - 242 Morelos - 95 Querétaro - 141 Baja California - 79 Jalisco - 333 Nayarit - 73 Quintana Roo - 57 Baja California Sur - 8 As of July ,15 2009 San Luis Potosí - 372 Laboratory confirmed cases - 11,966 Deaths - 121 Campeche- 38 Sinaloa - 8 Chiapas - 55 Sonora - 66 Chihuahua - 58 Tabasco - 246 Tamaulipas - 68 Coahuila - 2 Tlaxcala - 69 Colima - 26 Veracruz - 321 Durango- 19 Federal District -1824 Nuevo León- 64 Yucatan - 97 Guanajuato - 79 Mexico State - 280 Oaxaca - 79 Guerrero - 214 Zacatecas - 237 Michoacán - 156 Puebla - 59 7/18/2009 35 Individual regions #’s are days behind
    36. “Pandemic (H1N1) 2009” Outbreak in Canada • As of 15 July, 2009, a total of 10,156 laboratory-confirmed cases of Pandemic (H1N1) 2009, including 1,115 hospitalizations and 45 deaths, have been reported in Canada from all provinces and territories. As of today, Canada will no longer be releasing individual confirmed cases of H1N1 flu virus three times weekly. Instead, the existing FluWatch surveillance program will be enhanced in order to give a more robust analysis of the national picture in Canada Yukon - 1 Nunavut - 405 North West Territories - 14 Newfoundland - 44 British Columbia – 382 Deaths - 1 Prince Edward Island - 5 Alberta- 1,348 Death - 3 Nova Scotia - 330 Saskatchewan – 859 Deaths - 3 New Brunswick - 42 Manitoba - 831 Deaths - 6 Ontario – 3,636 Quebec- 2,259 Deaths - 15 Deaths - 17 7/18/2009 Quebec searches systematically for influenza H1N1 among all ILI 36 hospitalized patients which may explain high numbers
    37. “Pandemic (H1N1) 2009” Outbreak in Canada 423 hospitalizationsas June 17 2009have been Juneepidemic curve, is up to date as Canada of is The following graph, also known as Date/specimen collection dateand 19 deaths 423 hospitalizations and 2009: 13 deaths As ofdeaths 10, 19 deaths have been anJune 8th, 2009. The graph July, 423 hospitalizations and 19deaths have been available only for hospitalizations and 394 34/39 laboratory-confirmed cases of 8 2009 reported among hospitalizations and 39 deaths illustrates the coursegraph, also The following of the reportedof894 laboratory-confirmed cases As among 2009 July,3, and 725/894 hospitalized cases reported among laboratory-confirmed cases current H1N1 flu virus outbreak in known as an epidemic Canada. It shows either the date 663 hospitalizations when symptoms of H1N1 fluas of curve, is up to date virus began or, 1,this date The not June if 2009. was graph and 29 deaths 538 hospitalizations and 25 illustrates the course of available, the date when a specimen was collected, for each the current H1N1 flu virus of the laboratory-confirmed cases. deathsJuly 2009.beennote that onset As of 14 have (Please reported outbreak in Canada. It date/specimen collection date is available shows the date when among35/45 deaths and 927/1,115 only for laboratory- symptoms of H1N1 flu hospitalized cases). virus began for each of the confirmed cases laboratory-confirmed cases. 7/18/2009 37
    38. “Pandemic (H1N1) 2009” United Kingdom Outbreak According to ECDC 9,718 Confirmed Cases and 17 deaths as of July, 16, 2009 New reporting system in UK as of Scotland- 1217 July, 2,2009 Death - 3 Northeast - 47 Northern Ireland - 34 Yorkshire and Humberside - 143 North West - 97 East Midlands - 147 East of England - 411 Wales - 34 London – 1,939 West Midlands – 2,582 Death - 1 Death - 1 South West - 198 South East - 598 7/18/2009 38 Map will not be updated after July 3, 2009
    39. “Pandemic (H1N1) 2009” Australia Outbreak 2009 11,194 Laboratory confirmed cases and 29 deaths as of July, 16, 2009 Northern Territory – 799 Death - 2 Queensland – 2,987 Death - 1 Western Australia – 739 Death - 1 New South Wales – 2,469 Deaths - 10 First case: 9 May 2009 First death : Australian Capital Territory - 383 South Australia – 1,190 Death - 2 Tasmania – 225 Victoria – 2,402 Death - 1 Death -12 7/18/2009 Reporting daily! 39
    40. “Pandemic (H1N1) 2009” Japan Outbreak 2009 • A of July, 16, 2009 Japan has reported 3,441 confirmed cases of Pandemic Influenza A(H1N1) 09 May 21 2009 Japan notified 67 new confirmed cases in past 24 hours, representing a 32% increase in cases according to ECDC (n-532) 7/18/2009 40
    41. “Pandemic (H1N1) 2009” Spain Outbreak 2009 As of July, 15, 2009, a total of 1099 laboratory-confirmed cases and 127 In- La Rioja country transmissions of Pandemic Influenza A(H1N1) 09 flu virus have been reported and 2 deaths Asturias Cantabria Pais Vasco Galicia Navarre Castile and Leon Aragon Community of Madrid Catalonia Extremadura Castile-La Manchu Balearic islands Still updating regions on next report Valencia Community Region of Murcia Canary Islanders Melilla Andalusia 7/18/2009 41
    42. Estimates of the Basic Reproductive Rate (Ro) • There have already been several estimates of the basic reproductive rate (Ro), which all lie between 1 and 2; the range 1.4 to 1.9 being most probable. • The basic reproduction number is the mean number of secondary cases a typical single infected case will cause in a population with no immunity to the disease in the absence of interventions to control the infection. • It is often denoted R0. When R0 < 1 the infection will die out in the long run (provided infection rates are constant); but if R0 > 1 the infection will be able to spread in a population • See case study “How to they Do it” Pandemic (H1N1) 2009 Virus Estimates of the Basic Reproductive Rate in Mexico” 7/18/2009 42
    43. Zoonosis Swine Influenza Virus (SIV) “Zoonotic diseases are those diseases transmitted between animals and people and thus compromising public health as well as endangering livelihoods by affecting their livestock.” 7/18/2009 43
    44. Global Early Warning System for Major Animal Diseases, including Zoonoses (GLEWS) • The Global Early Warning System for Major Animal Diseases, including Zoonoses (GLEWS) is a joint FAO, World Organisation for Animal Health (OIE) and WHO initiative to improve the early warning capacity to animal disease threats for the benefit of the international community • Certain animal health events with potential public health implications are included in the scope of the International Health Regulations (2005) (IHR(2005)) • Intersectoral collaboration, including between the veterinary, food safety and public health sectors is needed to effectively address the prevention of zoonotic diseases 7/18/2009 44
    45. (GLEWS) Zoonotic and Non-Zoonotic Diseases • Zoonotic • Non zoonotic • Anthrax • African Swine Fever (ASF) • Bovine Spongiform Encephalopathy (BSE) • Classical Swine Fever (CSF) • Brucellosis (B. melitensis) • Contagious Bovine Pleuropneumonia (CBPP)* • Crimean Congo Hemorrhagic Fever • Foot and Mouth Disease (FMD)* • Ebola Virus • Peste des Petits Ruminants (PPR) • Foodborne diseases • Rinderpest – Stomatitis/Enteritis • Highly Pathogenic Avian Influenza (HPAI) • Japanese Encephalitis • Marburg Hemorrhagic Fever • New World Screwworm • Nipah Virus • Old World Screwworm WHO States : • Q Fever GLEWS is a joint system that builds on the added value of • Rabies combining and coordinating the alert mechanisms of FAO, • Rift Valley Fever* (RVF) OIE and WHO for the international community and stakeholders to assist in prediction, prevention and control of • Sheep Pox*/Goat Pox animal disease threats, including zoonoses, through sharing • Tularemia of information, epidemiological analysis and contribute to • Venezuelan Equine Encephalomyelitis joint field missions to assess and control the outbreak. • West Nile Virus 7/18/2009 45
    46. Irelands Governmental Lead Agencies, Groups and Committees Emergency/Incident Type Lead Lead Response Principal Other Potential Remarks Government Agency as per Support Support Roles Department Framework Role Animal Infectious Diseases DAFF DF (DOD) Local Authorities HSE role relates Diseases (Animal) HSE (DEHLG) to zoonotic AGS (DJELR) diseases; DFA infectious animal CD (DOD) diseases with a DTRANS human health (IRCG/MSO/Shipping) dimension DAST • Strategic Emergency Planning Guidance – Lead, Principal and Other Support Roles: • DAFF (Department of Agriculture Fisheries & Food) • DEHLG (Department of the Environment Heritage & Local Government) • DOD (Department of Defence) • HSE (Health Service Executive) • DTRANS (Department of Transport) • IRCG (Irish Coast Guard) • MSO (Marine Service Office)DAST (Department of Arts, Sport & Tourism) 7/18/2009 46
    47. Swine Influenza (SIV) Past Outbreak History • 1918 (H1N1) – Spanish flu (H1N1viruses like swine flu) Possible emergence from swine or an avian host of a mutated H1N1 virus Pandemic with >20 -40 million deaths globally • 1976 (H1N1) – United Sates/New Jersey Virus enzootic to US swine herds since or before 1930 – One Adult with Severe Pneumonia • 1988 Swine Influenza United States/Wisscosin Swine Virus – Pregnant Women dead after exposure to infected pig (Emergency c-section performed and saved baby) • 1993 Swine Influenza ((H3N2) The Netherlands Swine Influenza-ressortant between old human H3N2(1973-75 similarities) and avian H1N1 – 2 Children with mid disease. Father suspected into have transmitted the virus from close contact with pigs • 1958-2005 Case report summary – 19 US, 6 Czechoslovakia, 4 nether land, 3 Russia, 3 Switzerland ,1 Canada (17% mortality rate) Case report summary • 2005-2009- 11 sporadic cases of infection in humans with triple-reassortant swine influenza A H1 (See Genetic Components of Triple-Reassortant Swine Influenza A (H1) • 2009 Novel H1N1 Strain influenza A virus: Avian to Pig, Pig to Human, Human to Human transmissions • 2009- Novel H1N1 Strain influenza virus – Human-to-Pig Transmission of the Novel H1N1 Strain influenza virus in a swine herd in Alberta • 2009- Saskatchewan, Canada . Human to pig and pig to human transmission? • A strain of swine influenza virus was detected in two workers on a pig farm – Further investigations are ongoing including on a third possible case! 7/18/2009 47
    48. Swine Influenza A (Hsw1N1) Past Outbreak in United States • 1976 U.S. outbreak • In early 1976, the novel A/New Jersey/76 (Hsw1N1) influenza virus caused severe respiratory illness in 13 soldiers with 1 death at Fort Dix, New Jersey President Ford A/Victoria/75 (H3N2) spread simultaneously, also receives swine caused illness, and persisted until March flu vaccination • 230 soldiers were infected with the A/New Jersey virus • Vaccine Controversy; • 20-40 million vaccinated in US – Overall, there were about 500 cases of Guillain-Barré syndrome (GBS), resulting in death from severe pulmonary complications for 25 people, according to Dr. P. Haber – “Nachamkin et al (2008) found that inoculation of the 1976 swine flu vaccine, as well as the 1991-1992 and 2004-2005 influenza vaccines, Video from 1976 into mice prompted production of antibodies to antiganglioside (anti- Swine Influenza GM1), which are associated with the development of GBS. They proposed that further research regarding influenza vaccine Outbreak components is warranted to determine how these components elicit 7/18/2009 antiganglioside effects” (Source E-medicne) 48
    49. Genetic Components of Triple-Reassortant Swine Influenza A (H1) • Triple-Reassortant Swine Influenza A (H1) Viruses Isolated from 11 Patients between December 2005 and February 2009 in the United States Triple-Reassortment Swine H1N1 Triple-Reassorment Swine Influenza Virus H1N2 Influenza Virus (Pts 1-6 and 8-11) (Pt 7 2009) Note Pt 8 visited a Pig Fair (genetic ressortment H1N2) PB2 PB2 PB1 PB1 PA PA HA HA NP NP NA NA M M NS NS http://content.nejm. org/cgi/reprint/NEJM oa0903812.pdf Triple -Reassortment Classical swine, North American Lineage Avian, North American Lineage Human (Seasonal )H3N2 7/18/2009 Human (Seasonal )H1N1 49
    50. Zoonosis Swine Influenza Virus (SIV) • Two types of virus have been isolated in Ireland : 1. H1N1 was isolated for the first time in November 1991 – The H1N1 isolated in Ireland, is different from the strains circulating in Europe and elsewhere, and probably represents a separate introduction of an avian strain into Irish pigs. It is serologically related to Weybridge 79 and OMS/2899/82 2. H3N2 was isolated for the first time in June 1993 – The H3N2 virus isolated is serologically related to OMS/3633/84 • Existence of H1N2 in Irish pigs has so far been scantly detected by % of seropositive sows (HI), 2002-03 *SIV subtype isolated in Ireland revealed the following: – Ireland – H1N1: 17.8* The novel A/H1N1 Influenza virus at the interface between humans and animals Swine influenza virus. Colorized – transmission electron micrograph H3N2: 4.2* What needs to be done in Europe? Brussels, 9 June 2009 (37,800X) of the A/New Jersey/76 (Hsw1N1) virus under plate magnification. Image taken during the virus' first – H1N2: 0.6 developmental passage through a chicken egg. Courtesy of the CDC/Dr. E. Palmer; R.E. Bates. 7/18/2009 50
    51. Swine Influenza in Pigs Virus Subtypes • Influenza A was first recognized as a clinical illness in pigs in 1918, which coincided with the 1918-1919 influenza pandemic in humans • H1N1 influenza A virus was first isolated from pigs in the United States in 1930. • H1N2 viruses that resulted from reassortant between the triple reassortant H3N2 viruses and classical H1N1 swine viruses have been isolated occasionally in the United States. • Avian H4N6 virus was recognized in pigs in Canada in 1999, but spread beyond the original farm of detection was not identified. • A novel H3N1 influenza virus was isolated from pigs in the United States in the mid 2000s; this virus may have risen from reassortment of an H3N2 turkey isolate, a human H1N1 isolate, and currently circulating swine influenza viruses 7/18/2009 51
    52. Swine Influenza (SIV) Signs and Symptoms In Swine • Symptoms of infected pigs include: – Fever (102-106°F) – Depression – Coughing (barking) – Sneezing – Difficulty breathing – Red or inflamed eyes – Lack of appetite – Discharge from the nose or eyes – Reduced fertility or abortion (boars and sows) – Mortality up to 15% 7/18/2009 52
    53. Swine Influenza (SIV) Differential Diagnosis In Swine • The following diseases must be considered in the differential diagnosis: – Aujeszky's disease – Atrophic rhinitis – Enzootic (mycoplasmal) pneumonia – Actinobacillus pleuropneumoniae • (serotype 1-2-4-7-9-11, serotype 2, serotype 1-9-11 or serotype 4-7) – Bacterial pneumonia due to Pasteurella or Haemophilus spp. 7/18/2009 53
    54. Swine Influenza (SIV) Porcine Diagnostic • Veterinary diagnostic kits: • Influenza A Antibody Competition ELISA kit • Influenza A Antigen Capture Kit • The kit detects antibodies directed against the A nucleoprotein in a wide range of species (avian, porcine, equine), including wild and zoo animals. 7/18/2009 54
    55. Swine Influenza (SIV) Post-mortem findings In Swine • Post-mortem findings include: • The lesions are confined to the respiratory system and are not very specific. • Hyperaemic of the mucosa of the respiratory tract • Excess production of mucus • Atelectasis and emphysema of the cardiac and apical lobes of the lungs, • Enlarged bronchial and mediastinal lymph nodes • In fatal cases there may be an acute interstitial pneumonia “An overview on swine influenza” ptt Pictures Normal Normal Normal Lungs Infiltration of Desquamation of Abnormal Lungs neutrophils epithelial cells Normal Lungs 7/18/2009 55
    56. Swine Influenza (SIV) Examples of Vaccines For Porcine! • Schering-Plough Animal Health Corporation: MaxiVac Excells • Novartis : PneumoSTAR® SIV Swine Vaccine • Pfizer Animal Health: FluSure vaccine 7/18/2009 56
    57. Swine Influenza (SIV) European Vaccine List Name Virus strains Type Antigenic dose (company) Gripovac A/New Jersey/8/76 (H1N1) split H1N1 : ≥ 1,7 HI units (Merial) A/Port Chalmers/1/73 (H3N2) H3N2 : ≥ 2,2 HI units Suvaxyn Flu A/sw/Netherlands/25/80 (H1N1) whole virus H1N1 : 4 μg HA (Fort Dodge) A/Port Chalmers/1/73 (H3N2) H3N2 : 4 μg HA Gripork A/sw/Ollost/84 (H1N1) whole virus H1N1 : 3 x 107 EID50 H3N2 : 2,5 x 107 EID50 (Hipra) A/Port Chalmers/1/73 (H3N2) Respiporc Flu A/sw/Belgium/230/92 (H1N1) whole virus H1N1 : ≥ 256 HA units H3N2 : ≥ 256 HA units (IDT) A/sw/Belgium/220/92 (H3N2) Respiporc Flu3 A/sw/Haselunne/2617/03 (H1N1) whole virus H1N1 : ≥107 TCID50 A/sw/Bakum/1769/03 (H3N2) (IDT) A/sw/Bakum/1832/00 (H1N2) H3N2 : ≥107 TCID50 H1N2 : ≥107 TCID50 Slide List From Prof. Kristien Van Reeth Laboratory of Virology, Faculty of Veterinary Medicine “An overview on swine influenza” ptt 7/18/2009 57
    58. National Biosecurity Importation of Swine In Ireland Directives • Swine- are prohibited to be imported from non-EU countries, except in compliance with Directive 72/462/EEC. • Licence issued in accordance with the Importation of Livestock Orders, 1970 to 1992 (S.I. No. 296 of 1970 and S.I. 298 of 1992). 7/18/2009 58
    59. “Pandemic (H1N1) 2009” Food Safety of Pork “INFOSAN” • Paris, 7 May 2009 • Joint FAO/WHO/OIE Statement on influenza A(H1N1) and the safety of pork • Influenza viruses are not known to be transmissible to people through eating processed pork or other food products derived from pigs. • Heat treatments commonly used in cooking meat (e.g. 70°C/160°F core temperature) will readily inactivate any viruses potentially present in raw meat products. Authorities and consumers should ensure that meat from sick pigs or pigs found dead are not processed or used for human consumption under any 7/18/2009 circumstances.! 59
    60. “Pandemic (H1N1) 2009” Prevention Department of Agriculture and Food and Fisheries (DAFF) • Agriculture and Food and fisheries (DAFF) will institute biosecurity measures • These control measures focus on animal health issues and aim to prevent any further spread of the disease among animals 7/18/2009 60
    61. Irish BIosecurity Measures For Pig Farms: • Normal biosecurity measures on pig farms Include: • Limit the access to essential personnel (farm employees, veterinarians and essential service people) • Implement policies that prevent employees who present signs of flu-like illness from having contact with the pigs or other people on the holding • Prevent access of international visitors or people who have recently returned from international travel, particularly from swine influenza affected regions, into your holding • Implement a shower-in/shower-out procedure and the use of farm- specific clothing and footwear for employees entering the holding • At minimum, employees should don farm footwear and completely wash hands and arms before having contact with the pigs • Enforce heightened personal hygiene practices including frequent hand washing for all people in contact with pigs 7/18/2009 61
    62. Biosecurity On Pig Farms $ Profits $ QUALITY ASSURANCE REDUCED MEDICATION REDUCED MORTALITY IMPROVED REDUCED ZOONOSIS REDUCED DISEASE PERFORMANCE BIOSECURTY 7/18/2009 62
    63. Swine Influenza Virus (SIV) Transmission • Swine diseases can be spread in a number of ways, including: • Through diseased swine or healthy swine incubating disease • Through animals other than swine (farm animals, pets, wild birds and other wildlife, vermin and insects) • On the clothing and shoes of visitors and employees moving from farm-to-farm • In contaminated feed, water, bedding and soil • From the carcasses of dead animals • On contaminated farm equipment and vehicles • In airborne particles and dust blown by the wind An Egyptian policeman wears a mask as he stands guard in front of a pick up truck full of pigs at the main slaughterhouse in Cairo April 30, 2009 7/18/2009 63
    64. Zoonosis Swine Influenza Virus (SIV) How Can Pigs Be protected? • The following actions can potentially prevent swine influenza: • Vaccinating animals • Ensuring farm workers maintain good hygiene • Following strict biosecurity practices • Providing adequate ventilation in barns • Identifying and segregating sick animals as early as possible 7/18/2009 64
    65. Limit the Risk of Transmission SIV On Pig Farms 1. Decreasing the spread of SIV includes: 2. Traffic control 3. Isolation 4. Sanitation 5. Herd health management 6. Program maintenance 7. Ensue Personal Protection Equipment(PPE) onsite and an active fit testing program 8. Application of HACCP (Hazard Analysis of Critical Control Points) 7/18/2009 65
    66. Swine Influenza Virus (SIV) Traffic control: • Traffic control: • Anyone exhibiting signs of respiratory illness should avoid contact with animals • Workers in swine facilities who have been exposed to influenza or someone diagnosed with influenza should avoid contact with animals until they have been checked by a healthcare worker • Avoid contact with swine outside regular employment • Control and restrict visitors' access to the herd • Require all visitors to wear clean boots, clothing and gloves and wash hands thoroughly on entry and exit • Prevent other animals from coming into contact with the herd • Maintain records of the movement of people, animals and equipment on and off the premises 7/18/2009 66
    67. Swine Influenza Virus (SIV) Isolation: • Isolation: • Only obtain new animals from reputable sources and limit the frequency of introducing new pigs to the herd • House newborn, weaned, feeder, and breeding pigs separately • Move pigs in groups during each production stage, in an all-in-all-out manner 7/18/2009 67
    68. Swine Influenza Virus (SIV) Sanitation: • Sanitation: • Routinely clean and disinfect buildings, barns, equipment, clothing and footwear • Designate a cleaning area for vehicles and equipment • Promptly dispose of dead pigs in a manner that minimizes the chance of spread of any disease • Implement a manure management program • Avoid borrowing equipment and vehicles from other farms 7/18/2009 68
    69. Swine Influenza Virus (SIV) Herd Health Management: • Herd health management: • Monitor herd health daily and employ veterinary services • Uniquely identify all groups of animals for traceability purposes (where they came from and where they are sold to) • In consultation with a veterinarian, consider vaccinating animals • Isolate sick pigs and immediately report any signs of illness to your veterinarian or the nearest Department of Agriculture office A Litter-Bed Pigpen for Breeding and Growing-Finishing Pigs. 7/18/2009 69
    70. Swine Influenza Virus (SIV) Program Maintenance: • Program maintenance: • Train all staff on your biosecurity program and monitor its effectiveness • Be aware of any diseases in your area and adjust your biosecurity program accordingly • Recommend farm workers discuss an annual flu vaccination with their doctor. – Vaccination may reduce the amounts of virus shed if infected during human influenza outbreaks, and limit the potential for human influenza virus infection of pigs. Full View of the The effectiveness of current human Litter-Bed Pig vaccines against this new strain is not known at this time Farm. 7/18/2009 70
    71. HACCP (Hazard Analysis of Critical Control Points) On PIG Farms • Application of HACCP (Hazard Analysis of Critical Control Points) procedures will help to identify areas of greatest risk to the business and allow for development of preventative strategies 7/18/2009 71
    72. A General Biosecurity Checklist For Swine 7/18/2009 72
    73. Veterinary Surveillance • This disease is a scheduled and notifiable disease in Ireland (Class B) • Porcine surveillance: The Department of Agriculture and Food and Fisheries (DAFF) (in collaboration with the porcine industry undertakes active and passive surveillance for porcine • Notification procedures is agreed between the department of Agriculture and Food and Fisheries the HSE in the event of Influenza being identified or highly suspected from porcine 7/18/2009 73
    74. Swine Influenza Virus (SIV) Pharmacovigilance for Veterinarians • EU Veterinary Suspected Adverse Reaction form for Veterinary and Health Professionals 7/18/2009 74
    75. Swine Influenza Virus (SIV) Preplanning for Veterinarians Visits: • The veterinarians should: • Prepare and plan the visit by Veterinarians Porcine log Book 2009 contacting the producer beforehand • Park in designated areas or as far as possible from animals • Keep a log book of farms visited 7/18/2009 75
    76. Swine Influenza Virus (SIV) Interim Recommendations For Veterinarians: • Use appropriate personal protective equipment: – FFP 2-3 respirator masks, gloves, impermeable coveralls, protective clothing and footwear and eye protection • Wash hands thoroughly after handling animals • Leave as you arrived and clean and sanitize vehicles and equipment • Dispose of protective equipment in a safe manner: – either leave it on the farm to be appropriately disposed or – remove it and place it in “contaminated materials” containers for transport to the office • Prioritize work by attending low-risk jobs first and then observe animals for concerns • Avoid or minimize contact with manure storage, feed supplies, and water supplies • Until more is known about how this illness affects swine, if swine influenza is suspected – do not travel to another swine farm for 48 hours 7/18/2009 76
    77. Swine Influenza Virus (SIV) Personnel Protection • On arrival at a site, personnel should: • Disinfect footwear in foot-bath • Put on washable or disposable protective clothing (footwear and overalls) • Wash hands • Before departure personnel should: • Disinfect footwear and protective clothing (or leave on site if disposable) • Wash hands • Contacts who work on pig farms should remain off work for 7 days as soon as diagnosis is suspected! 7/18/2009 77
    78. Veterinarians Donning and Doffing PPE 7/18/2009 78
    79. Veterinarians Donning and Doffing PPE (HPSC Resource) 7/18/2009 79
    80. Department of Agriculture Local District Veterinary Offices (DVO) COUNTY ADDRESS TELEPHONE Carlow Athy Road, Carlow 059 9170022 Cavan Farnham St., Cavan 049 4368200 Clare Government Offices, Kilrush Road, Ennis, Co. Clare 065 6866042 Cork North Hibernian House, 80A South Mall, Cork 01 4149900 Cork Central Hibernian House, 80A South Mall, Cork 01 4149900 Cork West Darrara, Clonakilty Co. Cork 023 36200 Donegal Meeting House St, Raphoe, Co. Donegal 074 9145298 Dublin/ St John’s House, High St, Tallaght, Co. Dublin 01 4149900 Wicklow East Galway Dockgate Building, Merchants Rd., Galway 091 507600 Kerry Spa Road, Tralee, Co. Kerry 066 7145052 Kildare/ Poplar House, Poplar Square, Naas, Co. Kildare 045 873035 Wicklow West Kilkenny Hebron Road, Kilkenny 056 7772400 Laois Abbeyleix Road, PortLaoise, Co. Laois 057 8674400 Leitrim Cranmore Road, Sligo 071 9682000 Limerick Houston Hall, Ballycummin Avenue, 061 500900 Raheen Industrial Estate, Raheen, Co. Limerick Longford Ballinalee Road, Longford 043 50020 Louth North Quay, Drogheda, Co. Louth 041 9838933 Mayo Michael Davitt House, Castlebar, Co Mayo 094 9035300 Meath Athlumney, Kilcairn, Navan, Co Meath 046 9082900 Monaghan Main Street, Ballybay, Co. Monaghan 042 9748800 Offaly Clonminch, Tullamore, Co. Offaly 057 9346037 Roscommon Convent Road, Roscommon 090 6630100 Sligo Cranmore Road, Sligo 071 9142023 Tipperary North St Conlon’s Road, Nenagh, Co. Tipperary 067 50014 Tipperary South Government Offices, Davis Street, Tipperary 062 80100 Waterford Govt. Offices, The Glen, Co. Waterford 051 301700 Westmeath Bellview, Dublin Road, Mullingar, Co. Westmeath 044 9339300 Wexford Vinegar Hill Lane, Enniscorthy, Co Wexford 053 9242008 7/18/2009 80
    81. EU Possible Quarantine Zones for Infected Pandemic Influenza A(H1N1) 09 Virus on Pig Farms Surveillance zones Surveillance zone (minimum of 10 km radius from the infected premises) Inplace for 30 days Protection Zone Quarantined Pig Farm Restricted zone (minimum of 1 -3 km radius from the infected premises) Controls must be kept in place for at least 21 days Infected Premises Restricted Zone Contaminated Porcine Farm There are no controls on people visiting the Zone Zone A Adapted from EU Quarantine for Avian Flu DAFF:Information on Avian Influenza Control Measures Buffer Zone 7/18/2009 81 Zone B
    82. Risk vs. Benefit Analysis for Decontamination Decontamination is defined as : What are the outcomes of “The process of removing or neutralising a hazard from the environment, property or life form. Its objectives are to prevent further harm and optimise the chance for natural stabilization? full clinical recovery or restoration of the object exposed to the contaminant”. Yes Can I change the outcomes No Do nothing except protect of natural stabilization by exposures! the intervention? What are the cost of the Risk intervention in terms of risk EXCEEDS Do nothing except protect versus benefit? benefit exposures! Benefit “Decontamination Process” EXCEEDS Refers to removal of clothing, neutralization of contaminate, verification of contaminate neutralization, and isolation of all contaminated waste. benefit Engage in intervention operations as long as the 7/18/2009 benefit exceeds the risk 82
    83. Quarantine Zones for Infected Pandemic Influenza A(H1N1) 09 Virus Pig Farms Agriculture and Food (DAF) will institute biosecurity measures . These control measures focus on animal health issues and aim to prevent any further spread of the disease among animals. Pending confirmation of the outbreak, if deemed necessary, all the porcine in the holding may be culled and destroyed. • Zone A : Infected premises • Buffer Zone: Surveillance zone • Risk vs. Benefit Analysis • The Surveillance Zone must stay in place for at least 30 days after the preliminary cleaning and disinfection of the infected • The Protection Zone must stay in place for at least 21 premises has been carried out. days after the preliminary cleaning and disinfection of • Identification of all porcine holdings the infected premises has been carried out, and then the • Prohibition on porcine fairs, markets, shows or other Zone becomes part of the Surveillance Zone gatherings • Killing and disposal of all porcine • Prohibition on the release of porcine, porcine products • Cleaning and disinfection of the premises Checkpoints will be • Destruction or treatment of manure, slurry and bedding put in place to control movements of • Tracing and destruction of porcine meat and carcasses vehicles transporting porcine or porcine produced during risk period related products • Epidemiological investigation and tracing of high-risk into/out of the Zones. contacts • Prohibition on porcine entering or leaving • Controls on people, vehicles and other things entering or leaving • Zone B: Free from Disease • Controls on re-stocking • A Further Restricted Zone may be declared outside the Surveillance Zone if this is considered necessary to control the disease. The measures to be applied in this Zone will be determined depending on a risk assessment 7/18/2009 carried out at the time. 83
    84. Maximum Decontamination Infected Premises Footbath Layout Level C & D Protection Boot Cover Tape & (PPE) Reduction Outer Glove Removal Glove Wash Segregated Removal (Hypothetical example ) Equipment Stripper/ 6 5 4 3 2 1 Drop Bagger Boot Cover Boot Cover & Removal Glove Rinse Zone A 7 Suit/Safety Boot Wash Canister or 9 8 Suit/Safety Boot Rinse Mask Change and Redress - Boot Cover/ Outer Gloves 10 Safety Boot Removal 11 Splash Suit Removal CONTAMINATION 12 Inner Glove Wash REDUCTION The contamination hazards at hazardous sites Inner Glove Rinse vary greatly, the methods of decontamination ZONE 13 may be adjusted by omitting, adding, or changing the stations identified to reflect the 14 Face Piece Removal contamination hazards at a site! 15 Inner Glove Removal These figures are adapted from the, NIOSH/OSHA/USCG/EPA Occupational Safety and Health Guidance Manual for 16 Inner Clothing Removal Hazardous Waste Site Activities. CONTAMINATION CONTROL LINE SUPPORT Dryer/ 17 18 Field 7/18/2009 Dresser 84 ZONE Wash
    85. Minimum WIND DIRECTION Decontamination Layout 20 Levels C & D Protection Redress: Boot Covers and Outer Gloves Zone A Decon 20 Solution Tank Change-Over Point (If needed) Infected Premises Remove Water Boots/Gloves and Decon Outer Outer Equipment Garments Garments Drop (For Disposal Remove and Off Site Boot Covers Decontamination) and Outer Gloves Footbath Plastic Sheet Can Zone A (10 gallon) Remove SCBA (If needed) Contamination Reduction Corridor 7/18/2009 85
    86. Basic Personnel Decontamination Vehicle decon “Contamination Reduction Corridor” Setup Vehicle decon Decon Water Solution Inner Washer Rinser Stripper Zone A Equipment glove Drop bagger removal Zone Contaminated Porcine Farm Entry Wash Rinse Can PPE Removal Exit (10 gallon Support Footbath Can Can Can Zone A 10 gallon 10 gallon 10 gallon Footbath if no Decon pools CRC setup Storage and Garbage Plastic (Tarp or Visqueen) Barrier tape and pylons Contamination Reduction Corridor 7/18/2009 86
    87. Vehicle Decontamination • Only allow essential vehicles onto the site. Staff, service vehicles etc. should be parked outside the perimeter. Insist that all vehicles that have to enter the site have been cleaned and disinfected beforehand • Vehicle cleaning and disinfection: • On arrival at the farm, wheels, wheel arches, outside and underside must be disinfected • Before leaving the farm, wheels, wheel arches, outside and underside must be washed and disinfected, ensuring that the World Trade Center/Ground Zero Vehicle Decontamination Wash surfaces are visibly ccontact with lean (must be dry) • Wash and disinfect all surfaces which may have come into contaminated material, such as: – Wheels, wheel arches, outside and underside – Trailer – Equipment (e.g. trolleys, crates, modules, delivery pipes, sheeting, covers) – Wipe areas of the driver’s cab that may have been contaminated, with disinfectant – Drivers should avoid contact with porcine or other porcine on premises outside the infected area for at least 3 days (72 hours) A list of approved disinfectants can be found at: http://www.agriculture.gov.ie 7/18/2009 87
    88. Food Safety Strategy for Ireland “National Control Plan 2007” 7/18/2009 88
    89. Swine Influenza and “Pandemic (H1N1) 2009” Swine influenza Pandemic (H1N1) 2009 • Swine influenza is • The Influenza Virus contains commonly transmitted genes from pig, bird and through direct contact or human influenza viruses, in close proximity with pigs. a combination that has never been observed before Secondary cases following anywhere in the world human-to-human • 2009 Quadruple transmission have been reassortment of three reported in the past but viruses—a human virus, an they have been very rare avian virus , and 2 porcine • 1998 Triple reassortment viruses 7/18/2009 89
    90. “Pandemic (H1N1) 2009” Microbiology • Influenza A viruses are negative-sense single-stranded RNA viruses • Family: Orthomyxoviridae • Genus: Influenza virus A • Enveloped virions are 80 to 120 nm in diameter, are 200 to 300 nm long, and may be filamentous – They consist of spike-shaped surface proteins, a partially host- derived lipid-rich envelope, and matrix (M) proteins surrounding a helical segmented nucleocapsid (6 to 8 segments) – The virus envelope glycoproteins (hemagglutinin [HA] and neuraminidase [NA]) are distributed evenly over the virion surface, forming characteristic spike-shaped structures; antigenic variations in these proteins form the basis of the classification system for influenza A virus subtypes – There are 16 different HA antigens (H1 to H16) and nine different NA antigens (N1 to N9) • Human disease historically has been caused by three subtypes of HA (H1, H2, and H3) and two subtypes of NA (N1 and N2) • More recently, human disease has been recognized to be caused by additional HA subtypes, including H5, H7, and H9 (all from avian origin) 7/18/2009 90
    91. Phylogenetic Comparison To Other Negative-sense RNA Viruses • Influenza strains are subtyped A, B, or C • Based on the relatedness of the matrix (M1) and nucleoprotein (NP) antigens 7/18/2009 91
    92. Influenza Virus Influenza Type A and Its Subtypes 3 integral membrane proteins that coordinate fusion are : 1. NA Pink - 2. HA Hemagglutinin 3. M2 Yellow - Neuraminidase CDC 7/18/2009 92
    93. Influenza Virus Influenza Type A Influenza A viruses are pleomorphic virions (that is, they vary in shape) They have negative-sense, single-stranded HA - hemagglutinin RNA and an RNA genome that is SEGMENTED There are eight RNA segments in influenza A NA - neuraminidase The nucleocapsid is helical Virions contain RNA polymerase packaged within the virus particle helical nucleocapsid (RNA plus These viruses are enveloped and have two NP protein) membrane glycoproteins: lipid bilayer membrane 1. HA - hemagglutinin - This is the attachment and fusion protein polymerase complex 2. NA - neuraminidase - This is important in release. It removes sialic acid from proteins of the virus and the host cell M1 protein M1 protein unnderlies the lipid bilayer, is the most abundant protein Genome organized in 7 or 8 segments. 3 integral membrane proteins that coordinate fusion are NA, HA, and M2 (not shown) NP protein important for subtyping NS protein, not shown, important for virulence 7/18/2009 93
    94. ORTHOMYXOVIRIDAE Influenza Type A (H1N1) PROPERTY ORTHOMYXOVIRIDAE Influenza A(H1N1) Genome segmented RNA synthesis nuclear Need for mRNA primer yes Hemagglutinin,neuraminidase Influenza A and B have both but on 2 different proteins (HA and NA) Syncytia formation no (HA functions at acid pH) 7/18/2009 94
    95. Replication of Influenza A Virus • 1. A virion attaches to the host cell membrane via HA and enters the cytoplasm by receptor-mediated endocytosis • • HA2 promotes fusion of the virus envelope and the endosome membranes • 2.The major envelope protein M1 dissociates from the nucleocapsid and viral RNA segments are translocated into the nucleus • 3. In the nucleus, the viral polymerase complexes transcribe (STEP 3a) and replicate (STEP 3b) the viral RNA segments • 4. Newly synthesized mRNAs migrate to cytoplasm where they are translated into viral proteins • 5a. Newly synthesised M1 viral proteins move to the nucleus - bind freshly synthesized 21 y y copies of viral RNA segments. • 5 b. Posttranslational processing of HA, NA, and M2 includes transportation via Golgi apparatus to the cell membrane • 6. The newly formed nucleocapsids migrate into the cytoplasm - interact via M1 with a region of the cell membrane where HA, NA and M2 have been inserted • 7. Then the newly synthesized virions bud from infected cell. NA destroys the sialic acid moiety of cellular receptors, thereby releasing the progeny 7/18/2009 virions 95
    96. “Pandemic (H1N1) 2009” Genetic Origins • HA (or H1): Hemagglutinine type 1 , swine, also in the 1918 influenza Catch host's cell receptors • NA (or N1): Neuraminidase type 1, swine, Eurasian, help start the infection • PA: avian, north America • PB1: human, likely from the 1993 H3N2 influenza • PB2: avian, from north America • NP: swine, north America • M: swine, Eurasia • NS: swine, north America – Non-structural proteins NEP (Nuclear Export Protein):, swine North America 7/18/2009 96
    97. Definition of Pandemic • The word “pandemic” comes from the Greek “pan-“, “all” + “demos”, “people or population” = “pandemos” = “all the people.” • A pandemic affects all (nearly all) of the people. • By contrast, “epi-“ means “upon.” An epidemic is visited upon the people. And “en-“ means “in.” An endemic is in the people. Technical report - Pandemic influenza 7/18/2009 97 preparedness in the EU/EEA
    98. Quadruple Reassortment Result Timeline of 2009 Hybrid “quadruple reassortant” new Pandemic Influenza A(H1N1) 09 Virus —a human No Vaccine virus, an avian virus , and 2 porcine viruses Emergence of Some “Pandemic (H1N1) 2009” Influenza Viruses in H1 Pandemic Influenza A(H1N1) 09 Virus 702 deaths Avian Humans Influenza Pandemic vaccines 1997: In Hong Kong, avian influenza A (H5N1) H5 Total of 262 Deaths 2009 WHO (Asiatic) Russian H9 1997-2009:avian influenza A (H9N2) Influenza H7 1980- 2003: Avian influenza A (H7N7) B Russian Flu (H2N2) 1889/1890 1 million Russian Flu (H2N2 A/USSR/90/77 (H1N1). 1900 Old Hong Kong Influenza H3N8? Asian 2002 Severer Acute Respiratory Virus (SARS-CoV) 774 deaths Influenza Old Hong Kong Regular vaccines Influenza H2 1957 (Asian Flu) 1-4 million deaths H2N2 Spanish “Triple reassortment” Influenza H3 H2 1968 (Hong Kong Flu) 1-4 million deaths H3N2 Aggressive H3N2 Hong Kong Swine to Human H1 1918 (Spanish Flu) (H1N1) 20-40 million deaths Influenza 1998/9 1918 1957 1968 1977 1993 1997 2003 2009 7/18/2009 By 1993, a bird flu virus had adapted to pigs, grabbed a few human flu 98 US 1976 Swine Influenza virus genes, and infected two young Dutch children, even displaying evidence of limited human-to-human transmission.
    99. Past & Potential Flu Pandemics Summary Epidemics/ Subtype Year Approx Approx Deaths Approx Estimated Severity of Pandemics Infected Mortality % Reproductive the Number (Ro) Pandemic (Asiatic) H2N2 1889/1890 unknown 1 million unknown Unclear Moderate Russian Flu Spanish flu H1N1 1918/1919 500 million 20-50 /?50 million 2.5 -10% 1.5-1.8 Severe + 2nd Wave 3.0-3.5 Asian flu H2N2 1956-58 45 million 1-4 million <0.2% 1.5 Severe Hong Kong flu H3N2 1968-69 50 million 1-4 million >0.2% 1.3-1.6 Moderate Avian flu H5N1 1990-today 433 262 61% 2.14 Severe Ongoing (still researching) SARS SARS-CoV 2002-03 8,096 774 9.6% 0.44-2.29 Severe 1,17 med Swine flu H3N2 1976 250-300 1 0.3% 1.09 Mild Pandemic H1N1 2009 130,733 702 (ECDC) <0.55% 1.2.-1.8 Moderate (H1N1) 2009 Ongoing CFR- 0.4 Med 1.5 (Mexico) Seasonal Flu A/H3N2, Yearly 1 Billion 250,000-500,000 <0.05% NA NA (Epidemic) A/H1N1, and B 7/18/2009 99
    100. Epidemiology of Ireland Spanish Influenza 1818-1819 • Ireland: 10,651 influenza • The deaths per 100,000 deaths registered by age group: (Unconfirmed 20000) under 5 years 295 – Male : 5,591 5-10 years 120 – Female: 5,060 10-15 years 103 • Mortality Rate: of 243 per 15-20years 223 100,000 population 20-25 years 329 – The mortality rate 25-35 years 380 varied by region: 35-45 years 239 • Leinster: 304 per 45-55 years 222 100,000 • Ulster: 302 per 1918 Flu Pandemic In 55-65 years 226 100,000 Ireland 65-75 years 221 • Munster: 159 per < 75 years 256 100,000 • Connaught: 114 per 100,000 7/18/2009 100
    101. Irelands Road to Pandemic Preparedness • 1999 -World Health Organisation (WHO) – “Influenza Pandemic Plan” • 2001- Ireland Developed – “A Model Plan for Influenza Pandemic Preparedness” • 2002- Plan was revised • 2004- Influenza Pandemic Preparedness Plan • 2005- WHO published – “WHO Global Influenza Preparedness Plan” • 2007 –Ireland Developed – “National Plan for Pandemic Influenza” 7/18/2009 101
    102. Scientific Models of the Impact of an Influenza Pandemic • USA: Pandemic Severity Index • United Kingdom: Empiric HPA Model Irelands “National Pandemic Influenza Plan” uses the HPA Model Health Protection Surveillance Centre 25-27 Middle Gardiner St Dublin 1, Ireland. t: +353 1 8765300 f: +353 1 8561299 e: hpsc@hse.ie Gani and Meltzer Model are also used See Website for download for to predict ICU rates and Ro rates in the National Pandemic Plan clinicians 7/18/2009 102
    103. Pre-Pandemic Planning: The Pandemic Severity Index 7/18/2009 103
    104. Pandemic Severity Index • The pandemic severity index levels are: • Category 1, CFR of less than 0.1% • Category 2, CFR 0.1% to 0.5% • Category 3, CFR 0.5% to 1% • Category 4, CFR 1% to 2% • Category 5, CFR 2% or higher 7/18/2009 104
    105. Pandemic Severity Index • Class I • A Class I pandemic is characterized by a widespread novel infection that, while it may cause sickness, does not create large scale deaths or economic impacts. The 1968 Flu is a good example of a Class I pandemic. Also, the current outbreak of Chikungunya could be considered a Class I pandemic. The observed death rate worldwide would not increase significantly from a Class I pandemic. • Class II • A Class II pandemic is characterized by a novel infection that has a low infection rate or a minimal case fatality rate and thus any serious effects on economies or overall mortality rates is minimized. The current HIV/AIDS pandemic can be considered a Class II pandemic. In any one year, a Class II pandemic would kill up to 1 million people. Pandemic (H1N1) 2009 is a Class 2 Pandemic June 12 2009 • Class III • A Class III pandemic is characterized by novel infection that spreads quickly but has a low total mortality rate. The 1918 pandemic would be considered a Class III pandemic. Note: between 50 - 100 million people died during the 1918 pandemic. A class III pandemic would kill approximately 2% of all humans or 120 million people. • Class IV • A Class IV pandemic is characterized by a novel infection that spreads quickly but has a medium level of mortality rates. The Black Death of 1347 - 1350 would be considered a Class IV pandemic. A Class IV pandemic would directly kill 40% of humans. A Class IV pandemic would kill 2.4 billion people. If Influenza A (H1N1) acquires the ability to easily infect humans to humans at the current CFR, it would be a Class IV pandemic. • Class V • A Class V pandemic is characterized by a novel infection that spreads quickly, has a high infection rate and a high mortality rate. There are no documented records of a Class V pandemic, but some experts believe that the new world indigenous peoples were affected by old world diseases in a Class V manner. A class V pandemic would directly kill off approximately 90% of living humans. A class V pandemic would kill 5.4 billion people. 7/18/2009 105
    106. Community Mitigation Strategy by Example on Pandemic Severity Scale 7/18/2009 106
    107. Irelands Pandemic Mitigation “Empiric HPA Model” • The Empiric HPA model outlines a single wave pandemic over 15 weeks with a peak of clinical cases and deaths occurring weeks six and seven . According to this model, just over 20% of cases and deaths occur in each of these weeks. 7/18/2009 107
    108. Irelands Mitigation Strategies • The following scenario has been adopted for planning purposes: • A cumulative clinical attack rate of between 25% and 50% of the population • A hospitalisation rate of between 0.55% and 3.70% • A case fatality rate of between 0.37% and 2.50% (equivalent to the 1957 and 1918 pandemics respectively) • Calculations are based on the Census 2006 Preliminary Report, which puts the Irish population at 4,234,925 7/18/2009 108
    109. Irelands Assumed Clinical Attack Rate: Scenario 1 • Scenario 1 • Irish population at 4,234,925 • Considers: – Clinical Attack Rate of 25% 1,058,731 cases – Hospitalisation Rate of 0.55% 5,823 over the 15 wks – Mortality Rate of 0.37% 3,917 deaths • Weekly number of cases, hospitalisations and deaths as predicted by the empirical model. 7/18/2009 109
    110. Irelands Assumed Clinical Attack Rate: Scenario 2 • Scenario 2 • Irish population at 4,234,925 • Considers : – Clinical attack rate of 50%: 2,117,463 cases – Hospitalisation rate of 3.7%: 78,346 over 15 wks – Mortality rate of 2.5%.: 52,937 deaths 7/18/2009 110
    111. WHO Phases 4 and 5 Irelands National Objectives • To assess the extent of human-to-human transmission and determine pandemic risk • To detect, notify and characterise additional clusters (including the identification of risk factors and other data concerning transmission as requested by WHO) • To assess the threat to human health and the impact of any control measures, and identify resources required for enhanced control • To determine and monitor public health resources required for pandemic response • Monitor the global situation (vaccine, antiviral availability, best practice recommendations) and estimate the impact of antiviral programmes (and vaccination programmes if used) 7/18/2009 111
    112. WHO Phase 4-6, Irish Alert Level 1 (Ireland Not Yet Affected) • 1.Establish surveillance of clinical conditions which have been linked to the novel virus abroad, but which are not necessarily part of the clinical criteria for routine influenza investigation • 2.Travellers returning from areas with pandemic activity should be provided with information and advised to seek medical attention if they become unwell. • 3.All doctors should be advised to ask patients presenting with respiratory illnesses about overseas travel • Samples should be collected for influenza detection and sent to the NVRL from all patients with respiratory illness who have: – Fulfilled the case definition for pandemic influenza orBeen hospitalised with viral pneumonia or – Travelled to areas of known or potential pandemic influenza activity in the week preceding onset of illness or;Have a flu-like illness and are family members or other close contacts of either of the above • 4.Departments of Public Health must immediately be notified of: – All cases who have been hospitalised with viral pneumonia (or other particular clinical features associated with the pandemic strain that form part of the case definition); and who have travelled to areas of known or potential influenza activity in the week preceding onset of illness and – Those who have a flu-like illness and are family members or other close contacts of a person in either of these categories 7/18/2009 112
    113. WHO Phase 4-6, Irish Alert Level 1 Once Ireland Is Affected! • As soon as the first cases of pandemic influenza are detected in the country the surveillance activities will be focused on: • Detecting community outbreaks • Tracking trends in influenza disease activity and identifying populations that are severely affected • Real-time reporting between he following is essential: – Healthcare institutions – Clinicians – Public Health – Sentinel General Practitioners – NRVL and Laboratories – Pharmacists – Etc. 7/18/2009 113
    114. Irelands Governmental Lead Agencies, Groups and Committees Emergency/Incident Type Lead Government Lead Principal Support Role Other Potential Support Remarks Department Response Roles Agency as per Framework Influenza Pandemic Influenza and DOHC HSE HSE Local Authorities Pandemic Other Public Health All members of the (DEHLG) Emergencies Interdepartmental CD (DOD) Steering Committee on Revenue Commissioners Public Health Emergency FSAI7 (DHC) Planning Current Pandemic Influenza Emergency Planning Roles and Responsibilities for the Pandemic (H1N1) 2009 7/18/2009 114
    115. Irelands Mitigation Strategies Current Pandemic Roles • “A national plan for pandemic influenza was put in place in January 2007, describing the health system’s response to a possible worldwide pandemic • Additionally The National Pandemic Expert Group has produced Expert Influenza Guidance in November 2008 which is currently being followed. It has met regularly, since an outbreak was first confirmed in Mexico, to assess the public health and clinical guidance to ensure an appropriate level of preparedness and response for Ireland • The Department is in close contact with the World Health Organisation, the European Centre for Disease Prevention and Control and our counterparts in the North of Ireland” Slide Cited From FAQs At DOHC Daily Report 7/18/2009 115
    116. Irelands Mitigation Strategies Current Pandemic Roles • “What is being done currently to prepare for a possible pandemic? • The Department of Health and Children continues to be in close contact with the HSE and the National Pandemic Expert Group • The Department of Health and Children and the HSE participate in regular teleconference meetings with the European Centres for Disease Control, public health officials in other European Member States and the WHO • The Department of Health and Children is the lead government department for public health emergencies and works closely with the HSE in response to pandemic influenza • The National Public Health Emergency Team (NPHET) has been meeting since the outbreak was first confirmed to coordinate the response to this threat – (This is the forum for managing responses between DOHC and the HSE during the planning and response phases of a public health emergency) • NPHET is chaired by the Secretary General of the Department of Health and Children and has been meeting frequently throughout the current situation” Slide Cited From FAQs At DOHC Daily Report 7/18/2009 116
    117. Irelands Mitigation Strategies Current Pandemic Roles • “What is being done currently to prepare for a possible pandemic? • The Government Interdepartmental Committee has been meeting to deal with health emergency planning involving transport, foreign affairs, education, security, etc. • An information leaflet has been printed and distributed to households • Posters and leaflets have been placed in air and sea ports • Ireland have accumulated anti-viral stockpiles to treat half of the population • Anti-viral medication has been distributed through public health departments to treat initial cases as they arise • Advertising will be placed on TV and other media” Slide Cited From FAQs At DOHC Daily Report 7/18/2009 117
    118. Irelands Mitigation Strategies Current Pandemic Roles • “What is being done currently to prepare for a possible pandemic? • Information is being updated on HSE and DOHC websites • HPSC have heightened surveillance – we will be seeking to pick up cases early • The National Virus Reference Laboratory (NVRL) have in place the capacity to carry out all diagnostic testing in relation to this virus • Professionals have received communications outlining their role in managing cases of influenza Slide Cited From FAQs At DOHC Daily Report 7/18/2009 118
    119. Irelands Mitigation Strategies Current Pandemic Roles for Pandemic (H1N1) 2009 WHO Phase 6 /Ireland Alert Level 2- Phase 2 “Mitigation” • Containment to Mitigation strategies: • Laboratory : • Shift from viral testing to only testing specific cases “Containment strategies” changed to • Antivirals : “mitigation strategies” for • Will be assessed on severity of case rather than Thursday, July, 16, 2009 general prophylaxis – No resistance to Tamiflu in Ireland – Tamiflu has occurred in three cases reported • Surveillance: China, Japan, Denmark – H1N1 Influenza reporting will be incorporated in normal influenza surveillance via CIDR and influenza surveillance reports • Vaccines: – Influenza H1N1 available in August September 2009 • Public Health: – Dissemination of vaccine planning and – Public health invention to general treatment implementation of the programme is a planning intervention priority – Clinically contract tracing rather than laboratory – Seasonal vaccine encouraged for all groups tracing – No contract tracing – Will be updated as more information comes available! • General Practitioners: – Will diagnose and prescribe antivirals by case by case 7/18/2009 119
    120. Surveillance System: EU Surveillance Networks • Enter-net • EuroHIV Eurosurveillance • European Surveillance System (TESSy) • EuroTB • European Antimicrobial Resistance Surveillance System (EARSS) • European Influenza Surveillance Scheme (EISS) • European Programme for Intervention Epidemiology Training (EPIET) • European Scientific Working Group on Influenza (ESWI) • European Surveillance of STIs (ESSTI) • European Working Group for Legionella Infections (EWGLI) • FluNet Global Salm-Surv (GSS) • International Network of Paediatric Surveillance Units 7/18/2009 120
    121. International Surveillance System • International • Europe • – The European Union United Kingdom – EU Public Health Eurosurveillance British Paediatric Surveillance Unit (BPSU) – Health and Consumer Protection DG • Communicable Disease Surveillance – World Health Organisation: Europe Centre, (NI) • Department of Health (UK) • Worldwide – Australia: Communicable Diseases • Department of Health, Social Services and Australia Public Safety (NI) – Australia: Immunise Australia • Faculty of Public Health Medicine (UK) Programme • Health Promotion Agency (NI) – Canada: Health Canada • Scottish Executive Health Department – New Zealand: Ministry of Health, • Welsh Assembly Government New Zealand • – USA: Centers for Disease Control – World Health Organisation: 7/18/2009 International 122 •
    122. Surveillance System: National Surveillance Institutes in Europe • Belgium: l'Institut scientifique de Santé • Netherlands: Rijksinstituut voor Publique Volksgezondheid en Milieu (RIVM) • Norway: Folkehelseinstituttet • Czech Republic: Centrum Epidemiologie a • Poland: Panstwowy Zaklad Higieny (PZH) Mikrobiologie (CEM) • Portugal: Direcção-Geral da Saúde • Denmark: Statens Serum Institut (SSI) • Slovak Republic: Úrad Verejného • Estonia: Tervisekaitseinspektsioon Zdravotnictva (UVZ) • Finland: Kansanterveyslaitos (KTL) • Slovenia: Inštitut za varovanje zdravja (IVZ) • Spain: Instituto de Salud Carlos III • France: Institut de Veille Sanitaire (InVS) • Sweden: Smittskyddsinstitutet (SMI) • Germany: Robert Koch Institut (RKI) • UK (England & Wales): Health Protection • Greece: Hellenic Center for Infectious Agency (HPA) Diseases Control (KEEL) • UK (Northern Ireland): Communicable Disease Surveillance Centre (CDSC) • Hungary: Országos Epidemiológiai Központ • UK (Scotland): Health Protection Scotland (OEK) (HPS) • Iceland: Landlæknir • U.S. Department of Health and Human • Italy: Istituto Superiore di Sanità (ISS) Services (DHHS) • Latvia: Sabiedribas veselibas agentura (SVA) • Luxembourg: Direction de la Sant 7/18/2009 123
    123. Pandemic (H1N1) 2009 Surveillance in Ireland • Reporting of clinical data by sentinel GPs • Hospital Surveillance • Enhanced surveillance • Surveillance of absenteeism rates in sentinel schools • Mortality Surveillance Pandemic Influenza A(H1N1) 09 • Regional influenza activity by Virus Infection Weekly Surveillance Report HSE area As of July, 11, 2009 • Weekly Notifications of Influenza 7/18/2009 124
    124. Pandemic (H1N1) 2009 Virus Surveillance in Ireland • Since the public health emergency was declared by WHO, HPSC and the HSE have implemented a number of surveillance initiatives to monitor the situation including: • Enhanced influenza A(H1N1) case based reporting on the Computerised Infectious Disease Reporting system (CIDR) • Contact tracing surveillance for contacts of influenza A(H1N1) cases • Expanded outbreak reporting of influenza and influenza-like illness on CIDR • An interim protocol on outbreak/cluster surveillance to detect early cases of influenza A(H1N1) • A protocol for surveillance of influenza-like illness in healthcare workers during Pandemic Phase 5. • Increased virological surveillance by the sentinel GP influenza surveillance system and recruitment of additional sentinel GPs • Expanded sentinel hospital influenza surveillance to capture information on the age breakdown of respiratory admissions Cited from Epi-insight • Sentinel paediatric hospital influenza surveillance systems have been implemented at two sites • Work is ongoing in the establishment of pilot sites for the sentinel surveillance of persons with influenza A(H1N1) who are admitted to intensive care units • Mortality surveillance has also been augmented with weekly monitoring of all cause mortality and deaths from pneumonia and influenza. HPSC will participate in a European mortality surveillance project (Euro MoMo) from early June 2009. Computerised Infectious Disease Reporting (CIDR) Adapted from Dr Jaon O'Donnell PTT From HPSC ICGP NRVL DPH/MOH Other Sentinel GP ILI consultations Hospital admissions GRO Mortality data Sentinel specimens School absenteeism HSE Influenza antiviral/vaccine uptake Non-Sentinel specimens Enhanced influenza surveillance GP Co-Ops ILI (Cluster) outbreaks Contact tracing International EISS, HPA, etc Influenza notification Health Protection Surveillance Centre (HPSC) European Influenza WHO Global Outbreak and Department of Public Health Weekly surveillance report Surveillance System (EISS) 7/18/2009 Alert Response Network and Children 125 (GOARN)
    125. Influenza Irelands Surveillance Systems • The role of HPSC as influenza surveillance co-ordinator is to: • Maintain and develop the current sentinel influenza surveillance network • Oversee enhancements as outlined e.g. year round surveillance, surveillance of hospitalised cases • Promote year round surveillance of influenza • Maintain close working relationship with the National Virus Reference Laboratory (NVRL) and the Irish College of General Practitioners (ICGP) 7/18/2009 127
    126. Pandemic (H1N1) 2009 Irelands Surveillance Systems • World Health Organization “GOARN” • European Influenza Surveillance System (EISS) • Irish • The National Influenza Surveillance System • 1. Reporting of clinical data/influenza-like illness (ILI) by sentinel GPs • 2. Virological reporting (NVRL) • 3. Hospital surveillance comprising weekly data on total admissions, total Emergency Department (A&E) admissions and total respiratory admissions (upper respiratory tract infection, lower respiratory tract infection, pneumonia, asthma, chronic bronchitis, and exacerbations of chronic obstructive pulmonary disease) from sentinel hospitals • 4. Surveillance of absenteeism rates in sentinel schools • 5. Reports on outbreaks due to influenza or ILI • 6. Mortality data (weekly review of all cause and pneumonia and influenza registered deaths (uncoded)) from the General Registrar’s Office (GRO) • 7. Weekly regional influenza indices based on clinical activity, virological activity and outbreak activity. This is defined as no report, no activity, sporadic activity, localised activity, and widespread activity – Computerised Infectious Disease Reporting (CIDR) – Hot Line: • The Flu Information Line is available 24 hours a day and is your primary source of information on Influenza A(H1N1). • Freephone: 1800 94 11 00 7/18/2009 128
    127. Computerised Infectious Disease Reporting (CIDR-2) Dissemination Pathway 7/18/2009 129
    128. The statutory requirement to notify all cases of Pandemic (H1N1) 2009 to the regional Director of Public Health/Medical Officer of Health (DPH/MOH) Under the Infectious Diseases (Amendment) (No.3) Regulations 2003 (SI No.707 of 2003) laboratory and clinical notification of swine influenza A (H1N1) is mandatory 7/18/2009 130
    129. Pandemic (H1N1) 2009 “The Pandemic!” This preliminary negative stained transmission electron micrograph depicts some of the ultrastructural morphology of the A/CA/4/09 swine flu virus. Courtesy of CDC/ C. S. Goldsmith and A. Balish. 7/18/2009 131
    130. Influenza Antigenic Changes- Drift • Antigenic Drift • Minor change, same subtype – Caused by point mutations in gene – May result in epidemic • Example of antigenic drift – In 1997, A/Wuhan/359/95 (H3N2) virus was dominant – A/Sydney/5/97 (H3N2) This colorized image, released by the U.S. Centers for Disease Control and appeared in late 1997 and Prevention April 24, 2009, depicts the influenza A H1N1 "swine flu" virus from became the dominant virus an outbreak in 1976 in 1998 7/18/2009 132
    131. Influenza Antigenic Changes - Shift • Antigenic Shift – Major change, new subtype – Caused by exchange of gene segments – May result in pandemic • Example of antigenic shift European Surveillance – H2N2 virus circulated in 1957-1967 Network for Influenza in – H3N2 virus appeared in 1968 and Pigs (ESNIP) completely replaced H2N2 virus 7/18/2009 133
    132. Categorizing Influenza Virus “Viral Nomenclature” Type of nuclear material Neuraminidase Hemagglutinin A/California/04/2009(H1N1)swl Virus Geographic Strain Year of Virus type origin number isolation subtype Try These Two! A/Brevig Mission/1/1918(H1N1) 7/18/2009 134 A/New Jersey/76 (Hsw1N1)
    133. Emergence H3N2 Viruses Antigenetic Shift 7/18/2009 135
    134. Emergence H3N2 Viruses 7/18/2009 136
    135. Pandemic (H1N1) 2009 Classic Reassortment Diamond 7/18/2009 137
    136. Pandemic (H1N1) 2009 Host Range 7/18/2009 138
    137. “Pandemic (H1N1) 2009” Antigenic Shift Pathogenesis • Antigenic Shift – The genetic change that enables a flu strain to jump from one animal species to another, including humans, is called antigenic shift. Antigenic shift can happen in three ways: • Antigenic Shift 1 – A duck or other aquatic bird passes a bird strain of influenza A to an intermediate host such as a chicken or pig. – A person passes a human strain of influenza A to the same chicken or pig. – When the viruses infect the same cell, the genes from the bird strain mix with genes from the human strain to yield a new strain. – The new strain can spread from the intermediate host to humans. • Antigenic Shift 2 – Without undergoing genetic change, a bird strain of influenza A can jump directly from a duck or other aquatic bird to humans. • Antigenic Shift 3 – Without undergoing genetic change, a bird strain of influenza A can jump directly from a duck or other aquatic bird to an intermediate animal host and then to humans. – The new strain may further evolve to spread from person to person. If so, a flu pandemic 7/18/2009 could arise. 139
    138. Genetic Relationships among Human and Swine Influenza Viruses, 1918-2009 • Red arrows indicate human influenza virus lineages, black arrows swine influenza virus lineages, and gray arrows exportation of one or more genes from the avian influenza A virus gene pool. Horizontal bars shown inside the virus represent each of the eight virus genes, abbreviated PB2, PB1, PA, HA, NP, NA, M and NS. Credit: NIAID 7/18/2009 140
    139. Viral Sequencing for Pandemic (H1N1) 2009 • Viral sequencing for BSL3 Labs A/California/04/2009(H1N1 • 1976, the novel A/New Jersey/76 (Hsw1N1) influenza • A/California/04/2009 (H1N1) A/California/06/2009 (H1N1) The fact that A/California/04/2009 and A/California/07/2009 (H1N1) related isolates are pig viruses, with little A/California/08/2009 (H1N1) or no genetic material from human A/California/10/2009 (H1N1) influenza virus strains, is fascinating. A/Texas/04/2009 (H1N1) Clearly these strains are different from A/Texas/05/2009 (H1N1) viruses that circulate in pigs because A/Kansas/03/2009 (H1N1) they can be transmitted among humans A/Ohio/07/2009 (H1N1) and cause respiratory disease. It will be A/New York/19/2009 (H1N1) very important to compare the A/New York/20/2009 (H1N1) sequences of these isolates with viruses A/Mexico/4482/2009 (H1N1) obtained from pigs in an attempt to A/Mexico/4486/2009 (H1N1) determine what changes enabled the A/Mexico/4108/2009 (H1N1) virus to adapt to humans. A/Mexico/4115/2009 (H1N1) A/Mexico/4603/2009 (H1N1) Not an exclusive list A/Mexico/4604/2009 (H1N1) 7/18/2009 141
    140. “Pandemic (H1N1) 2009” Origins Overview • Nature magazine article on 11 June, 2009, about the “Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic”. 7/18/2009 142
    141. Genetic Components of Triple-Reassortant Swine Influenza A (H1) • Triple-Reassortant Swine Influenza A (H1) Viruses Isolated from 11 Patients between December 2005 and February 2009 in the United States: Triple-Reassortment Swine Tripple-Reassorment Swine H1N1 Influenza Virus H1N2 Influenza Virus (Pts 1-6 and 8-11) (Pt 7 (2007)) Note Pt 7visited a Pig Fair (genetic ressortment H1N2) PB2 PB2 Swine PB1 PB1 Avian PA PA Human HA HA NP NP NA NA M M NS NS http://content.nejm.org/cgi /reprint/NEJMoa0903812.p df (For personal use only) Tripple Reassortment Classical swine, North American Lineage Avian, North American Lineage Human (Seasonal )H3N2 7/18/2009 Human (Seasonal )H1N1 143
    142. Pandemic (H1N1) 2009 “The Pandemic!” Human H1N1 Cases From Human H1N1 Cases From California Triple -Reassortment Swine 1998 Quadruple Reassortment 2009 PB2 PB2 PB1 PB1 PA PA HA HA NP NP NA NA M M NS NS “Quadruple Reassortment” Classical swine, North American Lineage Avian, North American Lineage http://content.nejm.org/cgi/ Seasonal H3N2 reprint/NEJMoa0903812.pdf (For personal use only) Eurasian swine Lineage 7/18/2009 144
    143. H1N1 H3N2 H1N1 (Swine) (Human) (Avian) Pandemic (H1N1) 2009 PB2 PB2 PB2 PB1 PB1 PB1 Virus Lineage Summary PA PA PA HA HA HA NP NP NP Classical swine, North American Lineage NA NA NA Avian, North American Lineage M M M NS NS NS Seasonal H3N2 Eurasian swine Lineage http://www.who.int/csr/resour ces/publications/swineflu/WHO _OFFLU2009_05_15.pdf First Detected in 1998 H3N2 Double Reassortant (Swine/Human) H3N2 Triple Ressortant (Swine/Avian/Human) H1N1 (Swine) ? PB2 PB2 PB2 PB2 PB1 PB1 PB1 PB1 “Large gaps in the historical global animal PA PA PA PA influenza surveillance data. “ HA HA HA HA NP NP NP NP NA NA NA NA M M M M NS NS NS NS Pandemic Influenza A(H1N1) 09 H1N2 Triple Ressortant H1N1 Triple Reassortant Virus Quadruple Reassortant (Swine/Avian/Human) (Swine/Avian/Human) (North American and Eurasian Swine/Avian/Human) PB2 PB2 PB1 PB1 PB2 PA PA PB1 HA HA PA NP NP HA NA NA NP M M NA NS NS M 7/18/2009 NS 145
    144. 7/18/2009 146
    145. Phylogenetic Analysis of Sequences of all Genes Identified in A/California/04/2009 • Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team 10.1056/NEJMoa0903810, May 7, 2009 NML Winnipeg, Canada 7/18/2009 147 Has Breakthrough!
    146. Emergence of a Pandemic (H1N1) 2009 Virus in Humans Using “BLAST” Supplement to: Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine origin influenza A (H1N1) virus in humans. N Engl J Med 2009;361. DOI: 10.1056/NEJMoa0903810 (BLAST) Basic Local Alignment Search Tool 7/18/2009 148
    147. “Molecular Clock” Method in Estimation of the Origins of Pandemic (H1N1) 2009 • Britons Andrew Rambaut of the University of Edinburgh and Oliver Pybus of Oxford University, and Yi Guan of the University of Hong Kong examined the genetic sequence of the Pandemic Influenza A(H1N1) 09 Virus The international team used a "molecular clock" method to compare the current virus to its relatives and estimate its age based on the mutations. – This gives a rough idea of when the new virus is likely to have emerged! "We found that the common ancestor of the (new H1N1) outbreak and the closest related swine viruses existed between 9.2 and 17.2 years ago, depending on the genomic segment, hence the ancestors of the epidemic have been circulating undetected for about a decade," 7/18/2009 149
    148. “Pandemic (H1N1) 2009” CDC Influenza Laboratory Images • Images below of the newly identified H1N1 influenza virus were taken in the CDC Influenza Laboratory. 7/18/2009 150
    149. “Pandemic (H1N1) 2009” Laboratory Images • This preliminary negative stained transmission electron micrograph depicts some of the ultrastructural morphology of the A/CA/4/09 swine flu virus. Courtesy of CDC/ C. S. Goldsmith and A. Balish. • This preliminary negative stained transmission electron micrograph depicts some of the ultrastructural morphology of the A/CA/4/09 swine flu virus. Courtesy of CDC/ C. S. Goldsmith and A. Balish. • Comparison to; • Swine influenza virus. Colorized transmission electron micrograph (37,800X) of the A/New Jersey/76 (Hsw1N1) virus under plate magnification. Image taken during the virus' first developmental passage through a chicken egg. Courtesy of the CDC/Dr. E. Palmer; R.E. Bates. • Negative stained transmission electron micrograph of recreated 1918 influenza virions. Courtesy of CDC/ Dr. Terrence Tumpey E-medicine resource 7/18/2009 151
    150. “Pandemic (H1N1) 2009” Epidemiological Risk Factors • Epidemiological risk factors that should raise suspicion of include: • Close contact to a confirmed case of pandemic (H1N1) 2009 virus virus infection while the case was ill • Recent travel to an area where there are confirmed cases of pandemic (H1N1) 2009 virus • Close contact: having cared for, lived with, or had direct contact with respiratory secretions or body fluids of a probable or confirmed case of pandemic (H1N1) 2009 virus 7/18/2009 152
    151. Pandemic Influenza A(H1N1) 09 Virus Specific Investigational Triggers • The primary focus of early investigation is to trigger the initial investigation include: • Clusters of cases of unexplained ILI or AFI acute lower respiratory disease • Severe, unexplained respiratory illness occurring in one or more health care worker(s) who provide care for patients with respiratory disease • Changes in the epidemiology of mortality associated with the occurrence of ILI or lower respiratory tract illness, an increase in deaths observed from respiratory illness or an increase in the occurrence of severe respiratory disease in previously healthy adults or adolescents • Persistent changes noted in the treatment response or outcome of severe lower respiratory illness 7/18/2009 153
    152. http://www. “Pandemic (H1N1) 2009” Infectious Period: • The infectious period for a confirmed case of swine influenza A (H1N1) virus infection is defined as 1 day prior to the case’s illness onset to 7 days after onset. • The swine flu in humans is most contagious during the first five days of the illness although some people, most commonly children, can remain contagious for up to ten days ,immunocompromised up to 0-3 months has been documented • Remember: if signs and symptoms of influenza persist past this incubation period consider yourself contagious • May 20 2009 : WHO Technical Consultation on the severity of disease Report 20,05 May Teleconferencex • Ranging between – 1–5 days (Spain) – 4–6 days (UK) – 2–7 days (US ) 7/18/2009 154
    153. Pandemic Influenza A(H1N1) 09 Virus Transmission: • Direct and indirect contact – Pig to human • asymptomatic carrier pigs – Human to human – Human to Pig • Droplet transmission • Aerosol generating procedures (AGPs) • Not transmissible by consumption of pork 7/18/2009 155
    154. Pandemic Influenza A(H1N1) 09 Virus Human Signs and Symptoms: Pandemic (H1N1) 2009 Virus Exacerbation of underlying chronic medical conditions Includes: • Upper respiratory tract disease (sinusitis, otitis media, croup) lower respiratory tract disease (pneumonia, Fever (greater bronchiolitis, status asthmaticus) than 100°F or  Cardiac (myocarditis, 37.8°C) pericarditis)  Musculoskeletal (myositis, EU > 38 °C rhabdomyolysis) *NOTE: Some people,  Neurologic (acute and post- such as the elderly, infectious encephalopathy, and people who are encephalitis, febrile seizures, immunocompromised, status epilepticus) may not develop a  Toxic shock syndrome fever.  Secondary bacterial - Diarrhoea pneumonia with or without sepsis 7/18/2009 156
    155. Pandemic (H1N1) 2009 ECDC Report of Specific Clinical Signs and Symptoms by Systems Update June 17 2009 Frequency of Number of cases % Percentage symptoms (n=879) Generalised Fever or history of fever 653 74% Headache 364 41% Muscle pain 336 38% Joint pain 195 22% Respiratory Dry cough 465 53% Productive cough 157 18% Sore throat 354 40% Runny nose 295 34% Sneezing 165 19% Shortness of breath 103 12% Gastro-intestinal Diarrhoea 101 11% Vomiting 84 10% Nausea 114 13% Other Conjunctivitis 45 5% Nose bleed 25 3% Altered consciousness 12 1% Other (various) 386 44% 7/18/2009 157
    156. Pandemic (H1N1) 2009 High Risk Groups: • There are insufficient data available at this point to determine who is at higher risk for complications of Pandemic (H1N1) 2009 virus infection • Therefore considerer higher risk for pandemic (H1N1) 09 virus complications if: 7/18/2009 158
    157. Groups at High Risk for Complications From Pandemic (H1N1) 2009 Virus • High Risk groups include: • Children <5 (children <2 are at particular risk of influenza) • HIV-infected persons • Adults aged >65 years • Residents of any age of nursing homes or other long- term care institutions • Asthmatics or other chronic pulmonary diseases, such as cystic fibrosis in children or Five-year-old Edgar Hernandez, • Chronic obstructive pulmonary disease in adults known as "patient zero" survived the earliest documented case of • Hemodynamically significant cardiac disease swine flu. “April 2 2009” • Immunosuppressive disorders or who are receiving immunosuppressive drugs • Sickle cell amenia and other hemoglobinopathies • Diseases that requiring long-term aspirin therapy • Bariatric (severely obese) BMI <40 7/18/2009 159 7/18/2009
    158. Stage 2: Algorithm for the Management of Persons with Acute Febrile Respiratory Illness who may have influenza A(H1N1)v • As of July, 16, 2009 1. The patient/contact pre-existing condition is defined in the high risk category or 2. The patient/contact is on treatment for asthma, is pregnant or is bariatric (obese) (BMI>40) or 3. Patient/contact has severe symptoms 4. Test: Take nose and throat viral swabs 5. Treat: Begin antivirals as soon as possible 6. Chemoprophylaxis for close household contacts who are on treatment for asthma, is pregnant or is severely obese (BMI >40), where the index case is lab confirmed 7. If result is positive for influenza A(H1N1)v or seasonal influenza A, antiviral treatment should be continued for 5 days 8. Treatment should be started as early as possible, while awaiting laboratory confirmation. Antiviral treatment may be started at any time if the patient is symptomatic –not just within 48 hours of onset of symptoms 9. If result is negative for influenza A, discontinue antiviral treatment 10. If result is positive for influenza A(H1N1)v or seasonal influenza A, antiviral treatment should be continued for 5 days http://www.hpsc.ie/hpsc/A- 11. Contacts who become symptomatic should be managed as Z/EmergencyPlanning/AvianPandemicInfluenza/Sw a case, i.e. tested and treated as above ineInfluenza/AdviceforHealthProfessionals/PublicH ealth/Guidance/File,3585,en.pdf 7/18/2009 160
    159. Post-Exposure Prophylaxis (PEP) for Close Contacts • As of July, 16, 2009 • Post exposure prophylaxis is indicated for close contacts that fulfil all 3 criteria: 1. The contact is on treatment for asthma, is pregnant or is bariatric (obese) (BMI>40) 2. The contact was exposed to a probable or confirmed case during the period when the case was infectious i.e. 24 hours before onset of symptoms to 7 days after onset of symptoms contact’s last exposure occurred no more than 7 days previously 3. The contact’s last exposure was no more than 7 days ago http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/SwineInfluenza/AdviceforHeal thProfessionals/PublicHealth/Guidance/File,3809,en.pdf 7/18/2009 161
    160. “Pandemic (H1N1) 2009” Outbreak In Ireland By Age, Gender and Transmission Mode Update as of July ,11 ,2009 from Weekly Surveillance Report Age Male Female Total Antiviral In-Country Out-of-Country Homecare Hospitalizations Treatment Transmission Transmission 0-4 6 3 9 9 3 2 3 0 5-9 2 2 4 4 0 4 2 0 10-14 2 3 5 5 1 2 1 0 15-19 5 6 11 11 0 7 7 0 20-24 15 8 23 23 1 19 20 0 25-29 4 13 17 17 1 15 17 0 30-34 5 4 9 9 0 8 8 0 35-39 5 4 9 9 0 8 5 0 40-44 5 3 8 4 0 4 4 0 45-49 2 3 5 5 0 4 3 0 50-54 2 4 6 6 0 6 6 0 55-59 2 2 4 4 0 5 2 1 60-64 0 2 2 2 0 1 1 0 65+ 2 3 5 5 0 2 2 0 School 28+ 28 0 Outbreak Total 57 60 117 117+ 9 need updating 97 81 1 (Update 5) 7/18/2009 162
    161. Pandemic (H1N1) 2009 According to ECDC Surveillance Report • Reported number of cases of influenza A(H1N1)v infection, travel association and hospital admission, 29 EU/EEA countries, as of 6 July 2009 7/18/2009 163
    162. Pandemic (H1N1) 2009 According to ECDC Surveillance Report • Distribution of confirmed cases of A(H1N1)v infection by date of onset (n=5191) and date of reporting (n=10,328), EU/EEA countries, as of 6 July 2009. 7/18/2009 164
    163. Pandemic (H1N1) 2009 According to ECDC Surveillance Report • Distribution of travel-related and domestic individual case reports of influenza A(H1N1)v infection, by date of onset and country of travel, 28 EU/EEA countries, 16 April – 6 July 2009 (n=5119) 7/18/2009 165
    164. Pandemic (H1N1) 2009 According to ECDC Surveillance Report • By age and gender of individual case reports of influenza A(H1N1)v infection, 28 EU/EEA countries, as of 6 July (n=6560) • Distribution by age and gender of individual case reports of influenza A(H1N1)v infection, 28 EU/EEA countries, as of 6 July 2009 (n=6560) 7/18/2009 166
    165. Pandemic (H1N1) 2009 High Risk Group Age According to ECDC • Distribution by age and travel status of individual case reports of influenza A(H1N1)v infection, 28 EU/EEA countries, as of 6 July 2009 (n=7,681) • Distribution by age and travel status of individual case reports of influenza A(H1N1)v infection, 28 EU/EEA countries, as of 6 July 2009 (n=7,681) 7/18/2009 167
    166. Pandemic (H1N1) 2009 Predefined Underlying conditions According to ECDC • Number of influenza A(H1N1)v cases reported with predefined underlying conditions, 28 EU/EEA countries, as of 6 July (n=7681) 7/18/2009 168
    167. “Pandemic (H1N1) 2009” United Kingdom Age-group and Gender Report • Confirmed cases with “Pandemic (H1N1) 2009” by age group and sex (01 July 2009), England. The 5-14 year olds remain the age group predominantly affected 7/18/2009 170
    168. Pandemic (H1N1) 2009 México, United Sates, Canada Gender and Age Summary • The Mexican Ministry of Health published an epidemiological update on May 7, 2009, on their website: • Out of the 1204 confirmed cases studied, 49.5% are females and 72% are in persons under the age of 29 years of age. • The Public Health Agency of Canada reported epidemiological information of the confirmed cases on May 20, 2009 – The majority of the cases (97%) are under the age of 50 – The median age of Canadian cases is 22 years – As of May 20, 2009, half the cases are 21 years of age or younger (median: 21 years; range: <1 – 86 years) – The majority of cases are linked to travel to Mexico 7/18/2009 171
    169. Pandemic (H1N1) 2009 Mexico, United Sates, Canada Age Summary: In Mexico In United States: As of 20 May 2009, 16:30 AM ET, 48 states of the United States have reported a total of 5,764confirmed cases including 247 hospitalizations and 8 deaths. Median age: 17 years, range 1 month- 87 years Gender: 51% female, 49% male Underlying medical conditions (n=44): 63% (median age: 18 years) Median time from illness onset to hospital admission (n=32): 4 days (range: 1-13 days) Median length of hospital stay (n=32): 5 days (range 2-31) In Canada: As of May 28, 2009, the average age reported is 22 years or younger (median: 17 years; range: <1 – 86 years). In Europe: Median age 33 7/18/2009 172
    170. Pandemic (H1N1) 2009 México Age Specific Attack Rate May 20 7/18/2009 173
    171. Pandemic (H1N1) 2009 General Diagnosis • A Confirmed case of Pandemic Influenza A(H1N1) 09 Virus infection is defined as an individual with laboratory confirmed Pandemic (H1N1) 2009 virus infection by one or more of the following tests: • Real‐time RT‐PCR ICycler® from • Viral culture BioRad • Four‐fold rise in Pandemic Influenza A(H1N1) 09 Virus specific neutralizing antibodies 7/18/2009 175
    172. WHO Case Definitions to be Used For Investigations of Pandemic (H1N1) 2009 Virus Cases • Clinical case description • Acute febrile respiratory illness (fever >38°C ) with the spectrum of disease from influenza‐like illness to pneumonia. • 1. A Confirmed case of swine influenza A(H1N1) virus infection is defined as an individual with laboratory confirmed swine influenza A(H1N1) virus infection by one or more of the following tests*: – real‐time RT‐PCR – viral culture – four‐fold rise in swine influenza A(H1N1) virus specific neutralizing antibodies. • 2. A Probable case of swine influenza A(H1N1) virus infection is defined as an individual with an influenza test that is positive for influenza A, but is unsubtypable by reagents used to detect seasonal influenza virus infection OR • A individual with a clinically compatible illness or who died of an unexplained acute respiratory illness who is considered to be epidemiologically linked to a probable or confirmed case. 7/18/2009 176
    173. CDC Case Definitions to be Used For Investigations of Pandemic (H1N1) 2009 Virus Cases • Case Definitions for Infection with Swine Influenza A (H1N1) Virus – A Confirmed case of swine influenza A (H1N1) virus infection is defined as a person with an acute respiratory illness with laboratory confirmed swine influenza A (H1N1) virus infection at CDC by one or more of the following tests: • real-time RT-PCR • viral culture • four-fold rise in swine influenza A (H1N1) virus specific neutralizing antibodies – A Probable case of swine influenza A (H1N1) virus infection is defined as a person with an acute respiratory illness with an influenza test that is positive for influenza A, but H1 and H3 negative by RT-PCR – A Suspected case of swine influenza A (H1N1) virus infection is defined as: • A person with an acute respiratory illness who was a close contact to a confirmed case of swine influenza A (H1N1) virus infection while the case was ill OR • A person with an acute respiratory illness with a recent history of contact with an animal with confirmed or suspected swine influenza A (H1N1) virus infection OR • A person with an acute respiratory illness who has travelled to an area where there are confirmed cases of swine influenza A (H1N1) within 7 days of suspect case's illness onset. • Infectious period for confirmed cases = 1 day before onset to 7 days after onset of illness • Day before onset = Day -1 • Onset day = Day 0 • Days after onset = Days 1-7 7/18/2009 177
    174. CDC Case Definitions to be Used For Investigations of Pandemic (H1N1) 2009 Cases Update • A confirmed case of S-OIV infection is defined as a person with an acute febrile respiratory illness with laboratory confirmed S-OIV infection at CDC by one or more of the following tests: – real-time RT-PCR – viral culture • A probable case of S-OIV infection is defined as a person with an acute febrile respiratory illness who is positive for influenza A, but negative for H1 and H3 by influenza RT-PCR • A suspected case of S-OIV infection is defined as a person with acute febrile respiratory illness with onset – within 7 days of close contact with a person who is a confirmed case of S-OIV infection, or – within 7 days of travel to community either within the United States or internationally where there are one or more confirmed cases of S-OIV infection, or – resides in a community where there are one or more confirmed cases of S-OIV infection. 7/18/2009 178
    175. CDC Influenza A (H1N1) Case definition of Close Contacts • The definition of close contacts is: Household members of confirmed or probable cases • Close workplace contacts of a confirmed or probable case, including sharing an office or cubicle area (sitting within one metre for at least 15 minutes) • Members of a confirmed or probable case’s class or child care group and their teacher/child care supervisor, where the case is a child aged between 0-12 years old • Others identified by a confirmed or probable case, household members or workplace contacts as having been in close physical contact (hugging, kissing, sitting within one metre for at least 15 minutes) with the confirmed case • Passengers and crew travelling on aircraft with a confirmed or probable case as defined below: – Passengers seated in the same row, and within two (2) rows in front of and behind the case; – Any passengers who moved from elsewhere in the aircraft to spend more than 15 minutes near the case – Airline staff (unless they did not visit the section of the plane in which the case was seated) 7/18/2009 179
    176. NDSC Case Definition Influenza (Influenza A and B virus) (EU) • Clinical description • Clinical picture compatible with influenza i.e. sudden onset of disease, cough, fever > 38 °C, muscular pain and/or headache. • Laboratory criteria for diagnosis • One of the following: – Detection of influenza antigen, or influenza virus specific RNA – Isolation of influenza virus – Demonstration of a specific serum antibody response to influenza A or B (four fold or greater rise).** • Case classification • Possible: Clinically compatible case with epidemiological link* • Probable: N/A Case Definitions for Notifiable Diseases Infectious Diseases (Amendment) • Confirmed: Clinical case that is laboratory confirmed. (No. 3) Regulations 2003 (SI No. 707 of 2003) • Note: Influenza of a new or re-emergent subtype is defined as influenza caused by a novel or re-emerging influenza virus which is capable of infecting humans and causing human illness, and to which a large 7/18/2009 180 proportion of the human population has little or no immunity.
    177. EU Case Definition Pandemic (H1N1) 2009 Virus April,30,2009 • Clinical criteria • At least one of the • Any person with one of the following three: following three in the • — fever > 38 °C AND signs and symptoms seven days before disease of acute respiratory infection, • — pneumonia (severe respiratory illness), onset: • — death from an unexplained acute • — a person who was a close contact to a confirmed case of novel influenza A(H1N1) virus infection while the case was ill, respiratory illness. • — a person who has travelled to an area where sustained human- • Laboratory criteria to-human transmission of novel influenza A(H1N1) is documented, • At least one of the • — a person working in a laboratory where samples of the novel influenza A(H1N1) virus are tested. following tests: • — RT-PCR, • Case classification • — viral culture (requiring BSL 3 facilities), • A. Case under investigation Any person meeting the clinical and epidemiological criteria. • — four-fold rise in novel influenza virus A(H1N1) specific neutralising antibodies • B. Probable case (implies the need for paired sera, from • Any person meeting the clinical AND epidemiological criteria AND acute phase illness and then at with a laboratory result showing positive influenza A infection of an convalescent stage 10-14 days later unsubtypable type. minimum). • C. Confirmed case • Epidemiological criteria • Any person meeting the laboratory criteria for confirmation. 7/18/2009 181
    178. Influenza Activity Index Irish Influenza Activity Code, Name and Description Index Index Name Index Description* Code Map of influenza activity 0 No Report No reports received. by HSE area during week 20 2009 1 No Activity No ILI or laboratory confirmed influenza cases and no influenza/ILI outbreaks in a HSE-Health Area. 2 Sporadic Activity Isolated case(s) of ILI or laboratory confirmed influenza case(s) in a HSE-Health Area, or an influenza/ILI outbreak in a single nstitution. 3 Localised Activity Increases in ILI in local areas (such as a city, county, or district) within a HSE-Health Area, or outbreaks in two or more institutions within an area, with laboratory confirmed cases of influenza infection. Levels of activity in the remainder of the HSE-Health Area would be sporadic or have no activity 4 Regional Activity Increases in ILI in one or more regions with a population comprising less than 50% of the HSE-Health Area’s total http://www.hpsc.ie/hpsc/A- population, with laboratory confirmed influenza cases in the ffected Z/Respiratory/Influenza/SeasonalInfl region(s). Levels of activity in the remainder of the HSE-Health Area would be sporadic or have no activity. uenza/InfluenzaSurveillanceReports/I nterseason2009/File,3737,en.pdf 5 Widespread activity Increases in ILI in one or more regions with a population comprising 50% or more of the HSE-Health Area’s total population, with laboratory confirmed influenza infections 7/18/2009 182
    179. Influenza-like illness (ILI) –Definition Community Surveillance of Clusters/Outbreaks • Influenza-like illness (ILI) -definition for interim surveillance of clusters/outbreaks • Three or more cases of ILI arising within the same 72 hour period which meet the same clinical case definition and where an epidemiological link can be established • ILI symptoms include: – Acute onset of fever (temperature≥38oC) – OR history of fever – AND flu-like illness (two or more of the Influenza-like following symptoms: cough, sore throat, Illness/Influenza/Influenza A myalgia, headache, rhinorrhea or (H1N1) Outbreak Reporting Form vomiting/diarrhoea) 7/18/2009 183
    180. National Algorithm Phase 6- Stage 2 “Mitigation” • As of July, 16, 2009 this Algorithm for the Management of Persons with Acute Febrile Respiratory Illness who may have influenza A(H1N1)v will be used during WHO phase 6 -stage 2 of Irelands mitigation strategy ! 7/18/2009 184
    181. Pandemic (H1N1) 2009 National “Acute Febrile Respiratory Illness” Algorithm • Algorithm for the management of persons with acute febrile respiratory illness who may have Influenza A(H1N1)v • Update June,26,2009 7/18/2009 185
    182. Reporting Suspect Influenza A (H1N1) Virus Infection • Clinicians must contact their state public health department to report suspected cases of Pandemic Influenza A(H1N1) 09 Virus infection and to obtain information on what clinical and epidemiological data to collect and specimen shipment protocols in their region. 1.Health and Safety regulations on biological hazards (Safety, Health and Welfare at Work Act 2005 (No. 10 of 2005) 2.European Agreement concerning the International Carriage of Dangerous Goods by road (ADR) Regulations (2007 edition). 3.S.I. No 29 of 2004 - Carriage of Dangerous Goods by Road Regulations, 2004. 7/18/2009 186
    183. Public Health Management of Pandemic (H1N1) 2009 Virus Contacts (Containment Phase) • Management of Contacts • Household contacts: request to go into home quarantine until test result • If positive, remain in voluntary home quarantine for 7 days. • All other actions wait until the test result comes back as Influenza A unsubtypable (probable). • If A unsubtypable: • Chemoprophylaxis for close contacts as defined above (1 course = 10 days) • Surveillance: Active - contacts to self-monitor for symptoms for 7 days, check temp twice daily. – Staff from local office of Director of Public Health will make contact daily to ensure asymptomatic. • No ongoing quarantine for non household contacts of a positive case • Health care workers who have worn appropriate PPE don’t need chemoprophylaxis; they should self monitor for symptoms and will be followed daily by Public Health • Taking serology may be relevant in certain circumstances in order to better understand transmission. In these circumstances paired samples should be taken (first sample when identified as a contact and second sample 14 days later). • Contacts who are workers on pig farms should not work for 7 days following contact with a case to reduce the risk of human-to-pig transmission. 7/18/2009 187
    184. Public Health Management of Pandemic (H1N1) 2009 Virus Contacts (Containment Phase) Update • Close Contacts Definition • Household members of a case • Roommates of cases in hospitals or institutions such as nursing homes, • People occupying the same room with a case (<1metre) for at least 4 hours • People who have contact with fomites contaminated with respiratory secretions (e.g. those handling tissues recently used by others or touching the hands of infectious persons who have handled tissues or touched their nose) • Travellers by plane sitting in the same row or in the 2 rows ahead or behind on a long haul flight (at least four hours duration) of a case that was symptomatic either on the flight or within 24 hours of the flight (only symptoms generating droplets such as sneezing and coughing count here) • Persons caring for a sick traveller, as described above • Health or social care workers who provided direct clinical or personal care or who examined a symptomatic patient without wearing appropriate Personal Protective Equipment (PPE) for Standard, Droplet and Contact Precautions: – Surgical mask, Plastic Apron, Gloves (and goggles if risk of splashing or spraying) for staff for all routine care (including taking nasal and throat swabs for viral testing) – 7/18/2009 Additionally, FFP2 or FFP3 mask, goggles, gloves and long sleeved gown for aerosol generating 188 procedure
    185. Public Health Management of Pandemic (H1N1) 2009 Virus Contacts (Containment Phase) June 5 2009 • Management of Contacts • · The following actions commence on receipt of test result of a probable or confirmed case: – Chemoprophylaxis for close contacts as defined above (1 course = 10 days) – Surveillance: Active - contacts to self-monitor for symptoms for 7 days, check temp twice daily. Staff from local office of Director of Public Health will make contact daily to ensure asymptomatic • Health or social care workers who provided direct clinical or personal care or who examined a symptomatic patient and who WERE wearing appropriate Personal Protective Equipment (as above) are not considered to be close contacts. However, given the potential for nosocomial transmission (e.g. inadvertent exposure to aerosols, or lack of formal fit testing of respirators, or failure to implement hand hygiene following contact with contaminated surfaces or after removing PPE), such workers – Do not need chemoprophylaxis but – Should self-monitor for symptoms and report immediately to their Occupational Health Department (or local Public Health if no Occupational Health Department is available) any symptoms suggestive of influenza • Taking serology may be relevant in certain circumstances in order to better understand transmission. In these circumstances paired samples should be taken (first sample when identified as a contact and second sample 14 days later) • Contacts who are workers on pig farms should not work for 7 days following contact with a case to reduce the risk of human-to-pig transmission • If there are school contacts, these should be urgently discussed with HPSC 7/18/2009 189
    186. Public Health Management of Pandemic (H1N1) 2009 Virus (Mitigation Phase) • Public Health: – Mandatory reporting to DPH/MOH of influenza-like illnesses and acute febrile respiratory illnesses – Clinically contract tracing rather than laboratory tracing – Public health intervention to general treatment intervention – No contract tracing – Contract tracing for the defined high risk groups with routine GP homecare referrals and follow up by Public Health Nurse – Promotion of Influenza education on vaccinations, hygiene etc – Encourage assessment, planning, implementation and evaluation of Influenza Care Centres (ICC) within the Republic of Ireland for upcoming vaccination season to decrease surge capacity at hospitals and GP offices 7/18/2009 190
    187. Pandemic (H1N1) 2009 Public Health Management for Phase 6 (Containment Phase) HPSC Form Update June 22 2009 http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/ SwineInfluenza/AdviceforHealthProfessionals/G eneral/File,3617,en.pdf 7/18/2009 191
    188. Post-exposure Prophylaxis (PEP) for close contacts of probable or confirmed human case(s) of Pandemic Influenza A(H1N1) 09 Virus in WHO Pandemic Alert Phase 6 Containment Phase: • Post exposure prophylaxis is indicated for close contacts that were exposed to a probable or confirmed case during the period when the case was symptomatic and for 24 hours before onset of symptoms AND the contact’s last exposure occurred no more than 7 days previously. • Any probable or confirmed human case of influenza A(H1N1)should be notified to the local DPH as soon as possible. Update PEP June 22 2009 7/18/2009 192
    189. Influenza A(H1N1)v Mitigation Case Surveillance Form • Health Protection Surveillance Centre 25-27 Middle Gardiner St Dublin 1, Ireland. t: +353 1 8765300 f: +353 1 8561299 e: hpsc@hse.ie • See Website for download for clinicians http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza /SwineInfluenza/AdviceforHealthProfessionals/ PublicHealth/Surveillance/File,3606,en.pdf July 15 2009 1-3 pages 7/18/2009 193
    190. Mitigation Surveillance Form for High Risk Contacts of the Influenza A(H1N1)v • Health Protection Surveillance Centre 25-27 Middle Gardiner St Dublin 1, Ireland. t: +353 1 8765300 f: +353 1 8561299 e: hpsc@hse.ie • See Website for download for clinicians • http://www.ndsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/SwineInflue nza/AdviceforHealthProfessionals/PublicHealth/File,3607,e n.pdf 1-7pages 7/18/2009 194
    191. Pandemic (H1N1) 2009 Dispatchers Guide (Update July, 16, 2009) Infection Prevention and Control Guidance for the Emergency Dispatcher • Recommendations for 999 • It is important for the Emergency Operators to question callers to ascertain if there is anyone at the incident location who is possibly afflicted by the Pandemic (H1N1) 2009,to communicate the possible risk to EMS personnel prior to arrival, and to assign the appropriate EMS resources • Emergency Operators should review existing medical dispatch procedures and coordinate any modifications with their EMS medical director and in coordination with their local department of public health 7/18/2009 195
    192. Pandemic (H1N1) 2009 Dispatchers Guide Infection Prevention and Control Guidance for the Emergency Dispatchers Interim recommendations: • Call takers should screen all callers for any symptoms of acute febrile respiratory illness. – Callers should be asked if they, or someone at the incident location, has had nasal congestion, cough, fever or other flu-like symptoms – If the emergency operator call taker suspects a caller is noting symptoms of acute febrile respiratory febrile illness, they should make sure any first responders and EMS personnel are aware of the potential for “acute febrile respiratory illness” before the responders arrive on scene 7/18/2009 196 Adapted from “Dispatchers Guide to CBRNE”
    193. Confirmed Pandemic (H1N1) 2009 Virus in The Geographic Area • Step 1: Address scene safety: – If emergency operator advises potential for acute febrile respiratory illness symptoms on scene, EMS personnel should don PPE for suspected cases of swine-origin influenza prior to entering scene. – If emergency operator has not identified individuals with symptoms of acute febrile respiratory illness on scene, EMS personnel should stay more than 6 feet away from patient and bystanders with symptoms and exercise appropriate routine respiratory droplet precautions while assessing all patients for suspected cases of swine-origin influenza. • Step 2: • Assess all patients for symptoms of acute febrile respiratory illness (fever plus one or more of the following: nasal congestion/ rhinorrhea, sore throat, or cough). – If no symptoms of acute febrile respiratory illness, provide routine EMS care. – If symptoms of acute febrile respiratory illness, don appropriate PPE for suspected case of swine-origin influenza if not already on. 7/18/2009 197
    194. Pandemic (H1N1) 2009 Virus Infection Prevention and Control Guidance for the Ambulance Service • If the ambulance service is informed that a patient is suspected or confirmed to have Pandemic Influenza A(H1N1) 09 Virus the following precautions should be taken: • 1.On arrival to the house/healthcare facility – Ambulance staff to decontaminate hands (alcohol gel) – Routine care (Infection control precautions for caring for a patient with suspected or confirmed influenza A (H1N1)v) – Wear surgical mask, plastic apron/gown, gloves (& goggles if splash/spray risk) – Aerosol generating procedures (refer to Aerosol Generating Procedure Document) – FFP2 or FFP3 mask (fit check to ensure a good seal), goggles, long sleeved disposable gown and gloves • Inform the hospital of admission of potentially infectious person Before leaving the house/healthcare facility • Request patient to wear a surgical mask and advise of respiratory An ambulance driver hygiene and cough etiquette wearing a face mask – (education leaflet if possible) drives in Hospital La Fe in • A patient with suspected or confirmed flu should not travel with any Valencia, Spain other patients 7/18/2009 198
    195. Pandemic (H1N1) 2009 Virus Infection Prevention and Control Guidance for the Ambulance Service In ambulance: • Change gloves and decontaminate hands after every patient procedure • Use single use or single patient use medical equipment where possible • Use disposal linen if available 7/18/2009 199
    196. Pandemic (H1N1) 2009 Virus Infection Prevention and Control Guidance for the Ambulance Service • Arrival to hospital • Ensure arrangements in place for receipt of the patient before the patient leaves the ambulance • Transfer patient to the care of hospital staff • Remove PPE in the following order 1. Gloves 2. Apron/gown 3. Decontaminate hands 4. Eye wear (if applicable) 5. Mask (do not touch front of mask when removing) 6. Decontaminate hands 7/18/2009 200
    197. Pandemic Influenza A(H1N1) 09 Virus Infection Prevention and Control Guidance for the Ambulance Service • Before ambulance is used again • Cleaning and disinfecting(wear appropriate PPE while cleaning) – Surfaces (stretcher, chair, door handles etc) should be cleaned with a detergent and a hypochlorite solution 1000pmm • Laundry – Place reusable blankets in an alginate bag, then into a red laundry bag and sent for laundry • Medical equipment – Follow manufacturer’s instructions for cleaning/disinfecting reusable equipment • Management of waste – All masks and any waste contaminated with blood or body fluid (including respiratory secretions) should be disposed of as Healthcare Risk waste – Management of sharps – as per Standard Precautions – Management of spillages – as per Standard Precautions 7/18/2009 201
    198. Pandemic (H1N1) 2009 Triage Initial Patient Management • Should be managed as follows: • Physical barrier (i.e. window or plexiglass barrier) or the receptionist should maintain a 2 metre (6 foot) distance from all patients whenever possible • In settings where such a separation is not possible, healthcare workers are advised to maintain whatever separation is feasible. • If there is no barrier, and a 2 metre (6 foot) distance cannot be achieved, a fit tested FFP 2-3 respirator and eye protection should be worn by the receptionist • Alcohol-based hand rub (ABHR) should be readily available for both staff and patients • Patient should be asked to perform hand hygiene using an ABHR and given a surgical mask to put on covering their nose and mouth • Patient should be placed in a separate area of the office (i.e. examination room). If an examination room or separate room is not available, the patient should remain masked • Provide hands-free garbage and laundry receptacles. • Remove magazines and toys from the waiting rooms to reduce potential contact exposures 7/18/2009 202
    199. Pandemic (H1N1) 2009 Triage Health Care Setting Screening • All patients who present to a health care setting should be screened for fever and respiratory symptoms. • This should include: • Passive screening: visual alerts posted at the entrances to all health care settings asking patients to report whether they have fever and any new or worsening respiratory symptoms, and • Active screening: At first contact, staff asks about fever and respiratory symptoms • Respiratory symptoms include cough, sore throat, coryza (runny nose), and myalgias (general body aches) • Routine practices ,contact and droplet precautions for clinicians • Additional precautions Influenza-like Illness/Influenza/Influenza A (H1N1) Outbreak Reporting Form 7/18/2009 203
    200. Pandemic (H1N1) 2009 Triage Health Care Setting Guidelines • The following infection control practices are indicated when assessing patients with fever and respiratory symptoms: • Before a clinical assessment: • Ensure patient is still wearing a surgical mask • Perform hand hygiene (alcohol based hand rub or soap and water) before and after patient assessment • Put on gloves • A gown is needed only when there is a risk of clothing or skin contamination (such as when examining young children who may have difficulty controlling their secretions) • Consider most appropriate respiratory protection 7/18/2009 204
    201. Pandemic (H1N1) 2009 Triage Health Care Setting Guidelines • Wear a surgical mask: • If the patient is compliant with respiratory hygiene practices (e.g. wearing a surgical mask) or If the patient has a weak or no cough. • Wear an FFP2-3 respirator: – If conducting an aerosol-generating medical procedure (e.g, obtaining a nasopharyngeal swab) on a suspect ILI case – All individuals in the room should wear an FFP2-3 respirator – When the patient is coughing forcefully and is unable or unwilling to comply with respiratory hygiene (e.g., coughing patient who is unable or unwilling to wear a surgical mask) 7/18/2009 205
    202. Influenza A (H1N1) Triage Health Care Setting Guidelines • After a clinical assessment: • Eye or face protection should be removed after leaving the case’s room and disposed of in either a hands-free waste receptacle (if disposable) or in a separate receptacle to go for reprocessing (if reusable) • The surgical mask or FFP2-3 respirator should be removed by the straps, being careful not to touch the mask or respirator itself, after leaving the case’s room and disposed of in a hands-free waste receptacle • HCWs should perform hand hygiene after removing the respiratory protection and after leaving the case’s room • Affected surfaces that may have been contaminated with droplets need to be cleaned. Routine office cleaning products are effective for respiratory viruses including influenza; no special cleaning products are needed. • There is no indication for use of personal air-purifying respirators (PAPRs) in the care of a suspect Pandemic (H1N1) 2009 case 7/18/2009 206
    203. HPSC Adaptation from WHO- “Patient Care Checklist” Pandemic (H1N1) 2009 June, 16, 2009 HPSC being proactive and showing continuous improvement through innovation ! 7/18/2009 207
    204. “Pandemic (H1N1) 2009” Virus Triage Health Care Setting Guidelines Resource 7/18/2009 208
    205. Pandemic Influenza A(H1N1) 09 Virus Advice to General Practitioners on Management in context to “Mitigation” July, 15,2009 Letter from DOHC http://www.dohc.ie/issues/swine_influenza /letter_med_pract_140709.pdf?direct=1 7/18/2009 209
    206. Pandemic Influenza A(H1N1) 09 Virus Advice to General Practitioners on Management of a Possible Case Resources • Update July, 16, 2009 • Health Protection Surveillance Centre 25-27 Middle Gardiner St Dublin 1, Ireland. t: +353 1 8765300 f: +353 1 8561299 e: hpsc@hse.ie • See Website for download for clinicians or hit hyperlink during slide show! http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInflu enza/SwineInfluenza/AdviceforHealthProfe ssionals/GPs/File,3636,en.pdf 7/18/2009 210
    207. Pandemic Influenza A(H1N1) 09 Virus General Practitioners Algorithm and Infection Control Resources Update July, 16, 2009 http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInf luenza/SwineInfluenza/AdviceforHealthP rofessionals/GPs/File,3636,en.pdf 7/18/2009 211
    208. National Algorithm Phase 6- Stage 2 “Mitigation” • As of July, 16, 2009 this Algorithm for the Management of Persons with Acute Febrile Respiratory Illness who may have influenza A(H1N1)v will be used during WHO phase 6 -stage 2 of Irelands mitigation strategy ! 7/18/2009 212
    209. Patient Resource for GPs Guidance For Caring For Persons At Home With Pandemic Influenza A(H1N1) 09 Virus Update :July, 16, 2009 7/18/2009 213
    210. “Pandemic (H1N1) 2009” Who's Summary of Clinical Guidelines Modalities Strategies Antibiotics In case of pneumonia, empiric treatment for community acquired pneumonia (CAP) per published guidelines pending microbiologic results (e.g. 2-3 days); tailored therapy thereafter if pathogen(s) identified. Antiviral therapy If treatment needed, oseltamivir or zanamivir. The new influenza A (H1N1) virus is currently resistant to amantadine and rimantadine. Corticosteroids Moderate to high dose steroids are NOT recommended. They are of unproven benefit and potentially harmful. Infection control Standard plus Droplet Precautions. For aerosol-generating procedures use particular respirator (N95, FFP2 or equivalent), eye protection, gowns, gloves, and an airborne precaution room, that can be naturally or mechanically ventilated, per WHO guidance NSAIDS, Paracetamol or acetaminophen given orally or by suppository. Avoid antipyretics administration of salicylates (aspirin and aspirin containing products) in children and young adults (< 18 years old) due to risk of Reye’s syndrome. Oxygen therapy Monitor oxygen saturation and maintain SaO2 over 90% (95% for pregnant women) with nasal cannulae or face mask. 7/18/2009 214
    211. “Pandemic (H1N1) 2009” Summary of Clinical Guidelines Resources • These pathways can adapted, modified and integrated into any institutional protocol – Excellent starting point for Pandemic Influenza A(H1N1) innovation • HPA: Swine flu clinical package Introduction • Adult – Swine flu adult community assessment tool – Swine flu adult hospital pathways –Emergency Department management • Paediatric – Swine flu paediatric community assessment tool – Swine flu paediatric hospital pathways – Emergency Department management 7/18/2009 215
    212. “Pandemic (H1N1) 2009” HPA: Adult and Paediatric Community Assessment Tools 7/18/2009 216
    213. “Pandemic (H1N1) 2009” HPA Adult ED and In-Patient Clinical Pathways 7/18/2009 217
    214. “Pandemic (H1N1) 2009” HPA Paediatric ED and In-Patient Clinical Pathways 7/18/2009 218
    215. Pandemic (H1N1) 2009 July, 16, 2009 “Patient Care Checklist” 7/18/2009 219
    216. Pandemic (H1N1) 2009 Diagnostics Summary • The following investigations are recommended “pandemic influenza expert group” in patients referred to hospital: Test Who this applies to Full blood count All patients Urea and electrolytes All patients Liver function tests All patients C-reactive protein If influenza-related pneumonia is suspected* Chest x-ray All patients Pulse oximetry All patients. If <92% on air, then arterial blood gases. ECG Patients with cardiac and respiratory complications or co-morbid illnesses. Patients with influenza-related pneumonia should also have the following bacteriological tests: Blood culture (Gold standard) (preferably before antibiotic treatment is commenced) Pneumococcal urine antigen (20 mls urine sample) Legionella urinary antigen 20 mls urine sample) Sputum Gram stain, culture Antimicrobial susceptibility tests on samples obtained from patients who: i.are able to expectorate purulent samples, and ii. ave not received prior antibiotic treatment. Paired serological examination for influenza/other agents Acute serum should be collected and a ‘convalescent’ sample obtained after an interval 10-14 days (both 5-10mLs clotted blood) 7/18/2009 220
    217. Clinical Management of Adults In The Hospital Setting • Severity assessment when presenting to hospital • Patients with uncomplicated influenza A(H1N1) infection would be expected to make a full recovery and do not require hospital care – Voluntary isolation with antivirals at home with self surveillance and follow up from PHD • Patients with worsening of pre-existing co-morbid medical conditions should be managed according to best practice for that condition with reference to published disease-specific guidelines (High risk groups) – Influenza-related Pneumonia assessment : • CURB-65 score* Bilateral pulmonary 7/18/2009 infiltrates 221
    218. Clinical Management of an Adults In The Hospital Setting Management of Influenza-related Pneumonia • *Score 1 point for each feature present: • Confusion (Mental Test Score of ≤ 8, or new disorientation in person, place or time.) • Urea > 7mmol/L • Respiratory rate ≥ 30/min • Blood pressure (SBP < 90mmHg or DBP ≤ 60mmHg) Patient admitted to ICU with severe bilateral pneumonia • New bilateral lung shadowing on CXR consistent with primary viral pneumonia should be taken as a feature of severe pneumonia regardless of CURB-65 score! • Assessment of those with Influenza-related pneumonia: • Severity assessment: (CURB-65 score) – *Score 1 point for each feature present CURB-65 score* Recommended action 0 Likely suitable for home treatment 1 or 2 Consider elective hospital stay, particularly with score 2, or hospital supervised outpatient stay 3 or more Manage in acute hospital as severe pneumonia 7/18/2009 222
    219. Clinical Management of Adults In The Hospital Setting • High Dependency or Intensive Care Unit referral: • Patients with primary viral pneumonia or a CURB-65 score of 4 or 5 should be considered for HDU/ICU referral • General indications for HDU/ICU referral include: 1. Persisting hypoxia with PaO2 <8Kpa despite maximal oxygen administration 2. Progressive hypercapnia 3. Severe acidosis (pH<7.26) 4. Septic shock 7/18/2009 223
    220. Paediatric Respiratory Distress Severity Assessment Paediatric Respiratory Distress Mild Severe Severity Assessment Infants Temperature > 38.5 °C Temperature > 38.5 °C Respiratory rate <50 breaths per min Respiratory rate >70 breaths per min Mild recession Moderate to severe recession Taking full feeds Nasal flaring Infants Cyanosis Intermittent apnoea Grunting respiration Not feeding Older children Temperature > 38.5 °C Temperature > 38.5 °C Resp rate < 50 breaths per min Resp rate > 50 breaths per min Mild breathlessness Severe difficulty in breathing No vomiting Nasal flaring Cyanosis Grunting respiration Signs of dehydration 7/18/2009 224
    221. Clinical management of Children Presenting To Hospital • Coughs and mild fevers: – Treat at home by parents with antipyretics and fluids – (Note: aspirin should not be used in children < 16 years) • High fever (> 38.5 °C /101.3°F) and cough or influenza like symptoms : – Seek medical advice • If there are no features which put them at high risk of complications they should be treated with oseltamivir, and given advice on antipyretics and fluids • Children at risk of complications, and all children aged less than 3 years should be seen by a GP • High fever (> 38.5 °C /101.3°F) and cough or influenza like symptoms PLUS at-risk group. These children should be seen by their GP or in an Emergency Department • Children may be considered at increased risk of complications if they have cough and fever (or influenza like illness) and temperature >38.0°C/101.3°F AND either chronic disease or one of following features: – Breathing difficulties – Severe earache – Vomiting > 24 hours – Drowsiness 7/18/2009 225
    222. Clinical management of Children Presenting To Hospital • Criteria for hospital referral for admission are any of the following: 1. Signs of persistent respiratory distress – markedly raised respiratory rate – grunting – intercostal recession – breathlessness with chest signs 2. Cyanosis 3. Severe dehydration 4. Altered conscious level 5. Complicated or prolonged seizure 6. Signs of septicaemia – extreme pallor, hypotension, floppy infant 7. Most children admitted to hospital are likely to need oxygen therapy and/or intravenous support as well as antibiotics and oseltamivir 7/18/2009 226
    223. Clinical management of Children Presenting To Hospital • Indications for referral to High Dependency or Intensive Care are: 1. The child is failing to maintain a SaO2 of >92% in FiO2 of >60% 2. The child is in shock 3. There is severe respiratory distress and a raised PaCO2 ( > 6.5 Kpa) 4. There is a rising respiratory rate and pulse rate with clinical evidence of severe respiratory distress with or without a raised PaCO2 5. There is recurrent apnoea or slow irregular breathing 6. There is evidence of encephalopathy 7/18/2009 227
    224. Clinical management of Children Presenting To Hospital • Microbiological/virological investigations in hospital: – WHO Phase 6, Irish Alert levels 2 and 3) • A. Virology – all children – Nasopharyngeal aspirate or nose and throat swabs – If presentation is more than 7 days after onset of illness, an ‘acute’ serum (2-5 ml clotted blood) should be collected and a ‘convalescent’ sample (2- 5 ml clotted blood) obtained after an interval of not less than 7 days. • B. Bacteriology – children with influenza related pneumonia – Blood culture (before antibiotic treatment is commenced) – Sputum samples obtained from older children – Paired serological examination for influenza/other agents 7/18/2009 228
    225. Pandemic (H1N1) 2009 Virus Clinical Management : Discharge Check list • Discharge and follow up Children can be safely discharged – Patients should be reviewed 24 from hospital when they: hours prior to discharge home – Are clearly improving – Are physiologically stable • Those with 2 or more of the – Can tolerate oral feeds following unstable clinical factors – Have a respiratory rate < 40/min ( should be considered for <50/min in infants) continuing care in hospital: – Have an awake oxygen saturation of >92% in air – Temperature > 37.8oC – Heart rate > 100/min – Respiratory rate > 24/min Follow up clinical review should be considered – Systolic blood pressure <90mmHg for all patients who suffered significant – Oxygen saturation < 92% on room complications or who had significant worsening air of their underlying disease, either with their – Inability to maintain oral intake general practitioner or in a hospital clinic. – Abnormal mental status or mental status not returned to baseline. 7/18/2009 229
    226. Pandemic Influenza A(H1N1) 09 Virus Clinical Management :Hospital and Community Setting Resource Extensive clinical Practice Guidelines are available at this Hyperlink (Click during Slide show!) • http://www.ndsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInflu enza/Guidance/PandemicInfluenzaPrepar ednessforIreland/File,3261,en.pdf 7/18/2009 230
    227. Summary of HPSC Management of Contacts, National Algorithm, and PEP for Containment of the Pandemic (H1N1) 2009 Virus 7/18/2009 231
    228. National Algorithm Phase 6- Stage 2 “Mitigation” • As of July, 16, 2009 this Algorithm for the Management of Persons with Acute Febrile Respiratory Illness who may have influenza A(H1N1)v will be used during WHO phase 6 -stage 2 of Irelands mitigation strategy ! 7/18/2009 232
    229. Pandemic (H1N1) 2009 Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic (H1N1) 2009 Virus http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/SwineInfluenza/ AdviceforHealthProfessionals/InfectionControl/File,3628,en.pdf 7/18/2009 234
    230. Pandemic (H1N1) 2009 Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic (H1N1) 2009 Virus • Standard Precautions require all HCWs to: • Standard Precautions must be applied by all HCWs to the care of all patients/clients in all healthcare settings regardless of the suspected or confirmed presence of an infectious agent. – Occupational health programme – Appropriate patient placement – Hand hygiene – Patient movement and transfer – Respiratory hygiene and cough etiquette – Use of personal protective equipment (PPE) – Decontamination of the environment – Decontamination of reusable medical equipment – Management of linen and laundry – Management of needle stick injuries – Management of waste – Management of spillages of blood and body fluids – Safe injection practices – Management of sharps 7/18/2009 235
    231. Pandemic (H1N1) 2009 Virus Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic (H1N1) 2009 Key Components PRECAUTIONS Key Elements of Clinical Practices and Measures 2.2 Occupational Health Programme Standard Precautions  HCWs should self monitor their own health for influenza like symptoms  HCWs with symptoms should not attend work and should immediately report symptoms to their line manager 2.3 Patient Placement Standard Precautions Home  Assess the patient with suspected or confirmed influenza A(H1N1) by phone at home if possible  GP/Primary care/Community Droplet Precautions  Place in a single room and avoid communal areas if possible. Otherwise do not place within approximately 1 metre of other patients Contact Precautions Hospital  Place patient with suspected or confirmed influenza A(H1N1) in a single room preferably with ante room and en-suite facilities  Emergency departments without single rooms must have interim arrangements in place to prioritise transfer to an appropriate single room  Avoid communal areas and placing patient within approximately 1 metre of other patients Ambulance Refer to ambulance advice document 2.4 Hand Hygiene Standard Precautions Hand hygiene using liquid soap or alcohol hand gel/rub must be performed before and after all patient care procedures 2.5 Patient Movement and Transfer Standard Precautions External transfer Patient should wear a surgical mask outside their room It is the responsibility of the transferring facility to inform staff of the precautions required Droplet Precautions  Refer to ambulance advice document Contact Precautions Internal transfer  Minimise movement of patient from single room  Patient should wear a surgical mask outside their room  Staff should be informed of the precautions required in the receiving departments (e.g. diagnostic departments)  Avoid holding patients in communal areas (radiology etc)  HCW PPE: Wear a surgical mask and observe hand hygiene 7/18/2009 236
    232. Pandemic (H1N1) 2009 Virus Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic (H1N1) 2009 Virus Key Components PRECAUTIONS Key Elements of Clinical Practices and Measures 2.6 Respiratory Hygiene & Standard Precautions As per Standard Precautions patients presenting with signs and symptoms of undiagnosed respiratory Cough Etiquette infections should be  Identified promptly in primary care and emergency departments  Offered masks (and other symptomatic persons e.g., persons who accompany ill patients should also be offered masks)  Encouraged to maintain spatial separation, ideally a distance of approximately 1 meter, from others in common waiting areas Emergency departments and primary care facilities should:  Ensure that supplies of tissues, foot operating waste bins and hand hygiene facilities are available in all departments including waiting areas throughout the facility  Educate patients/visitors/carers on Respiratory Etiquette and Cough Hygiene using some or all of the following:  Patient information leaflets  Posters in all departments especially waiting areas Droplet Precautions  If influenza A(H1N1) is suspected place patient & persons who accompany ill patients in a single room  See Appendix A for respiratory hygiene and cough etiquette poster. The poster can be downloaded from the following website •http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/SwineInfluenza/AdvicefortheGeneralPublic /RespiratoryHygiene/ 7/18/2009 237
    233. Pandemic (H1N1) 2009 Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic (H1N1) 2009 Virus Key Components PRECAUTIONS Key Elements of Clinical Practices and Measures 2.7 Personal Standard Precautions The following applies to all settings: Protective Droplet Precautions GP/Primary care/Ambulance transfer/Hospital Equipment Contact Precautions Patient should wear: (PPE)  A surgical mask when outside their single room HCWs must wear the following for: 1. Routine care  Surgical mask, Plastic Apron/Gown, Gloves (& Goggles if splashing/spraying risk) 2. Aerosol Generating Procedures  FFP2 or FFP3 mask (correctly fitted), Goggles, Long sleeved disposable gown, Gloves Refer to Aerosol Generating Procedures document and to PPE poster Masks  Change mask if it becomes damp, wet or torn  Change and discard mask when leaving the room or patient care area HCW’s when putting on and removing PPE must :  Put on and remove in the correct sequence (refer to PPE poster)  Remove gloves & apron/gown inside the single room  Remove mask in the ante room or immediately outside the single room if there is no ante room. Ensure door is closed.  Decontaminate hands immediately after removing PPE 7/18/2009 238
    234. Swine influenza A (H1N1) Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed swine influenza A (H1N1) Key Components PRECAUTIONS Key Elements of Clinical Practices and Measures 2.8 Environmental Decontamination Standard Precautions In addition to Standard Precautions: Only take essential equipment and supplies into the room. Droplet Precautions  Do not stockpile as unused stock will have to be discarded on cessation of additional precautions  Patient charts/records should not be taken into the single room Contact Precautions  The frequency and intensity of cleaning may need to be increased based on the patients level of hygiene and the level of environmental contamination  HCW’s must wear surgical mask, gloves, apron for cleaning the patients room  Thoroughly clean the environment and furniture and all patient care equipment daily with a neutral detergent and disinfectant (hypochlorite solution 1000 ppm) paying special attention to frequently touched sites and equipment close to the patient  On patient discharge/transfer cleaning and disinfection of the environment  Prior to initiating environmental cleaning and disinfection, all privacy, shower and window curtains must be removed and sent for laundering All disposable items including paper towels and toilet paper should be discarded All sterile and non-sterile supplies in the patient room to be discarded on patient transfer/discharge Dishes and Eating Utensils  Treatment rooms (e.g., x-ray etc)  Clean and disinfect the environment and furniture after use with a neutral detergent and disinfectant (hypochlorite solution 1000 ppm) paying special attention to frequently touched sites (door handles, bed rails etc)  Medical equipment (refer to 2.9)  Cutlery and crockery - No additional measures are required for cutlery and crockery washed in a dishwasher or wash with liquid detergent and water 2.9 Patient Care Equipment & Standard Precautions In addition to Standard Precautions: Decontamination of Medical Devices  Dedicate patient care medical devices (e.g., thermometers, sphygmomanometers, stethoscopes, glucometers) to single Droplet Precautions patient use  Use disposable equipment whenever possible Contact Precautions  Manufacturer’s instructions should be followed for cleaning and disinfecting of reusable medical equipment after use  Single use items should be disposed of after use  Bedpan/Commodes  Use a working washer disinfector at 80°C for one minute  Dedicate a commode to single patient use if no en suite available  Decontaminate commode surface after each patient use with a hypochlorite solution 1000 ppm 7/18/2009 239
    235. Swine influenza A (H1N1) Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed swine influenza A (H1N1) Key Components STANDARD Key Elements of Clinical Practices and Measures PRECAUTIONS 2.10 Linen/Laundry Standard Precautions  No additional precautions necessary  As per Standard Precautions all contaminated laundry should be carefully placed in an alginate stitched or water soluble bag and then placed into a laundry bag clearly identified with labels, colour-coding or other methods prior to transport to an approved laundry capable of dealing with contaminated linen 2.11 Management of needle stick injuries (NSI) and Standard Precautions  No additional precautions necessary blood and body fluid exposure 2.12 Management Standard Precautions  No additional precautions necessary for Non Healthcare Risk and Healthcare Risk Waste of Waste  Dispose of all PPE as Healthcare Risk Waste (e.g. used masks) 2.13 Management spillages of blood and body fluids Standard Precautions  No additional precautions necessary 2.14 Safe Injection Practices Standard Precautions  No additional precautions necessary 2.15 Management of sharps Standard Precautions  No additional precautions necessary 7/18/2009 240
    236. Pandemic (H1N1) 2009 Clinical Diagnostics 7/18/2009 241
    237. Guidance on Laboratory procedures when pandemic influenza is present outside Ireland (Irish Alert Level 2) • Containment stage: Samples should be collected for influenza investigation (including viral culture when advised by GP ) from all patients who: 7/18/2009 242
    238. Guidance on Laboratory procedures when pandemic influenza is present outside Ireland (Irish Alert Level 1) • WHO Phase 6- Containment phase (Stage 1) • 1. Samples should be collected for influenza investigation (including viral culture when advised by WHO) from all patients who: • Have been hospitalised with viral pneumonia; – Have travelled to areas of known or potential influenza activity in the week preceding onset of illness and have symptoms associated with the pandemic influenza strain – Have a flu-like illness and are family members or other close contacts of either of the above • 2. All samples from “highly suspicious cases” must be promptly referred to NVRL for investigation, as per agreed procedures. Any influenza strains detected should be provisionally characterised at the NVRL urgently and referred with available phylogenetic data urgently to the WHO Collaborating Centre in London for confirmation and sub typing • 3. NVRL should validate any novel diagnostic tests to ensure that “best practice” methodologies are utilised and can be introduced immediately • 4. NVRL should monitor the developments regarding the laboratory diagnosis and “bedside” diagnosis of the new influenza strain 7/18/2009 243
    239. Guidance on Laboratory procedures when pandemic influenza is present outside Ireland (Irish Alert Level 2) • WHO Phase 6- HPSC- Mitigation (Stage 2) Update July ,16, 2009. – Patient is in a Defined Risk Group – Patient has a close household contact who is on treatment for asthma, is pregnant or is bariatric (severely obese) (BMI ≥40) – Patient has severe symptoms Defined risk groups are: Chronic respiratory, heart, kidney, liver, neurological disease; immunosuppression (whether caused by disease or treatment); diabetes mellitus; people aged 65 years and older; children <5 (children <2 are at particular risk of influenza); people on medication for asthma, bariatric people (BMI ≥40) and pregnant women 7/18/2009 244
    240. Taking Specimens for Influenza Virus Testing From Patients with Suspected Pandemic Influenza A(H1N1) 09 Virus • Health Protection Surveillance Centre 25-27 Middle Gardiner St Dublin 1, Ireland. t: +353 1 8765300 f: +353 1 8561299 e: hpsc@hse.ie • See Website for download for clinicians or hyperlink during slideshow http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPand emicInfluenza/SwineInfluenza/Ad viceforHealthProfessionals/Hospit alClinicians/File,3604,en.pdf 7/18/2009 245
    241. Pandemic Influenza A(H1N1) 09 Virus Irelands Laboratories Overview • Approximately 34 (BL3) laboratories distributed among the universities an biotechnology companies in Ireland • These predominantly handle up to Category 3 pathogens or conduct genetic manipulations under regulation of the Environmental Protection Agency • High containment Class 3 (+) laboratory has been commissioned at the University College Dublin National Virus Reference Laboratory (UCD NVRL) • Environmental and clinical specimens are investigated in a Class 3 containment laboratory at Cherry Orchard Hospital, Dublin • Novel Influenza A H1N1 in BSL-3 practices (enhanced BSL-2 conditions) 7/18/2009 246
    242. Pandemic Influenza A(H1N1) 09 Virus National Virus Reference Laboratory • Postal address: Medical Microbiology, CRID Building, University College Dublin, Belfield, Dublin 4, Ireland. Telephone Number: +353-1-716 1325/1236 Fax Number: +353-1-716 1239 Email: margaret.brindley@ucd.ie 7/18/2009 247
    243. Pandemic Influenza A(H1N1) 09 Virus Specimen Collection • Clinicians should obtain a respiratory swab for swine influenza testing and place it in a refrigerator (not a freezer). – A diagnosis of confirmed swine flu requires laboratory testing of a respiratory sample (a simple nose and throat swab) – Collected during the first five days • Once collected, the clinician should contact their state or local health department to facilitate transport and timely diagnosis at a public health laboratory • Laboratories should send all unsubtypable influenza A specimens as soon as possible to NRVL • Spill containment measures should be in place! 7/18/2009 248
    244. Pandemic Influenza A(H1N1) 09 Virus Laboratory Precautions • Viral isolation on clinical specimens from patients who are suspected cases of swine influenza A (H1N1) virus infection should be performed in a BSL2 laboratory with BSL3 practices (enhanced BSL2 conditions) • Additional precautions include: Recommended Personal Protective Equipment (based on site specific risk assessment ) – Respiratory protection – fit-tested FFP 2-3 respirator or higher level of protection – Shoe covers – Closed-front gown – Double gloves – Eye protection (goggles or face shields) 7/18/2009 249
    245. Pandemic Influenza A(H1N1) 09 Virus Laboratory Precautions • Routine laboratory procedures, including diagnostic work and PCR analysis: • Biosafety Level 2 (BSL2), as detailed in the WHO Laboratory biosafety manual, 3rd edition. • Examples of routine laboratory procedures that require BSL2 include: • Diagnostic testing of serum, blood (including haematology and clinical chemistry), respiratory tract specimens, or other specimens • Manipulations involving neutralized or inactivated (lysed, fixed, or otherwise treated) virus particles and/or incomplete, non-infectious portions of the viral genome • Routine examination of mycotic and 7/18/2009 250 bacterial cultures
    246. Pandemic Influenza A(H1N1) 09 Virus Laboratory Precautions • Viral isolation on clinical specimens from patients who are suspected or confirmed cases of Pandemic Influenza A(H1N1) 09 Virus infection should only be performed in laboratories capable of meeting the following additional essential (minimal) Bio containment :BL3(+) Two microbiological safety cabinets containment requirements: (msc ) class I and class I/ III) at • Practices recommended for NVRL containment laboratories — Biosafety Level 3 in the WHO Laboratory biosafety manual, 3rd edition 7/18/2009 251
    247. Pandemic Influenza A(H1N1) 09 Virus Laboratory Precautions • A controlled ventilation system maintains directional airflow into the laboratory room • Exhaust air from the laboratory room is not recirculated to other areas within the building – Air should be HEPA filtered, if reconditioned NRVL BL3(+) Has and recirculated within the laboratory. two microbiological – When exhaust air from the laboratory is safety cabinets (class discharged to the outdoors, it must be I and class I/ III) dispersed away from occupied buildings and air intakes. – This air may be discharged through HEPA filters • All manipulations of infectious or potentially infectious materials must be performed in appropriately maintained and validated BSCs. (Ireland: NRVL Uses msc class I and class I/ III) • Access to the laboratory is restricted when work is in progress 7/18/2009 252
    248. Pandemic Influenza A(H1N1) 09 Virus Laboratory Precautions • Viral isolation on clinical specimens : • Biosafety Level Three plus (BL3+) containment laboratory • PPE • Laboratory workers should wear protective equipment, including: – Disposable gloves NRVL Layout of Bio – Solid front or wrap-around gowns Containment :BL3(+) – Scrub suits – Coveralls with sleeves that fully cover the forearms – Head coverings – Shoe covers or dedicated shoes – Eye protection (goggles or face shield) – Respiratory protection (fit-tested particulate respirator, e.g. EU FFP2, US NIOSH-certified N95 or equivalent, or higher protection), because of the risk of aerosol or droplet exposure 7/18/2009 253
    249. Pandemic Influenza A(H1N1) 09 Virus Laboratory Precautions Summary • Clinical laboratory testing • Viral isolation (laboratory diagnostic work) • Diagnostic laboratory work on • Growth of the virus in cell culture clinical samples from patients or embryonated eggs should be who are suspected cases of novel performed in a BSL-2 laboratory influenza A H1N1 virus infection with BSL-3 practices. should be conducted in a • All viral manipulations should be biosafety level 2 (BSL-2) done inside a microbiological laboratory. safety cabinets (msc ) class I and • All sample manipulations with class I/ III) that is certified the potential for creating an annually. aerosol should be done inside a microbiological safety cabinets (MSC) that is certified annually. Bio containment :BL3(+) Two microbiological safety cabinets (msc ) class I and class I/ III) at NVRL 7/18/2009 254
    250. Pandemic Influenza A(H1N1) 09 Virus Laboratory Precautions • Animal work • The following activities require animal facility — Biosafety Level 3 facilities and work practices, as detailed in the WHO Laboratory biosafety manual, 3rd edition. – Inoculation of animals for potential recovery of the agent from influenza A (H1N1) specimens – Any protocol involving animal inoculation for confirmation and/or characterization of putative influenza A (H1N1) agents – Bio containment :BL3(+) At NRVL/Cherry Orchard 7/18/2009 255
    251. Pandemic Influenza A(H1N1) 09 Virus Laboratory Precautions • Waste • All waste disposal procedures should be followed as outlined in your facility standard laboratory operating procedures • Appropriate disinfectants • 70% Ethanol • 5% Lysol • 10% Bleach • Influenza viruses can survive on environmental surfaces and can infect a person for up to 2 to 8 hours after being deposited on an environmental surface • Commonly used surfaces such as door handles, handrails, table surfaces etc. should be cleaned first and then disinfected with a chlorine releasing disinfectant (1000 ppm) twice daily Detailed information on • Disinfectants with proven activity against enveloped viruses disinfectants and their recommended use can be include chlorine, alcohol, peroxygen, quaternary ammonium found in Laboratory biosafety manual, 3rd compounds and phenolic compounds and should be adequate if ed., Geneva, World Health Organization, 2004 used according to manufacturer’s recommendations 7/18/2009 256
    252. Pandemic Influenza A(H1N1) 09 Virus Laboratory Precautions • Personnel should self monitor for fever and any symptoms Never place knee on • Accidental exposure: floor – Antiviral chemoprophylaxis with zanamivir or oseltamivir for 7 days( See PEP slide) Center for Disease Control and Prevention, shows a negative-stained image of the swine flu virus. 7/18/2009 257
    253. NRVL Testing for Pandemic Influenza A(H1N1) 09 Virus • Preferred Respiratory Specimens • Swabs – Nasopharyngeal Aspirates • Storing Clinical Specimens • Shipping Clinical Specimens • Recommended Tests HSE :Taking • Other Influenza Tests specimens for influenza virus testing – Rapid Influenza Antigen Test from patients with – Immunofluorescence (DFA or IFA) suspected Pandemic Influenza A(H1N1) 09 – Viral Culture Virus 7/18/2009 258
    254. NRVL Testing for Pandemic Influenza A(H1N1) 09 Virus • Taking specimens for influenza virus testing from patients with suspected influenza A (H1N1): • As with all respiratory viruses, diagnosis of influenza virus depends on the collection of high-quality specimens, their rapid transport to the virology laboratory and appropriate storage before laboratory testing • Virus is best detected in specimens containing infected cells and secretions • Specimens should ideally be taken preferably during the first 5 days after onset of clinical symptoms 7/18/2009 259
    255. NRVL Testing for Pandemic Influenza A(H1N1) 09 Virus • Before taking specimens: • Before a specimen is taken, it should first be discussed with the Director or Public Health as outlined in the national algorithm for the management of persons with possible influenza A (H1N1) • Infection prevention and control precautions • While not strictly an aerosol generating procedure it is recommended that the same National Algorithm precautions are followed when taking Update June, 26, 2009 nasal and throat viral swabs to out rule influenza A (H1N1) 7/18/2009 260
    256. NRVL Testing for Pandemic Influenza A(H1N1) 09 Virus • Infection prevention and control precautions: • While not strictly an aerosol generating procedure it is recommended that the following PPE is used when taking nasal and throat viral swabs to out rule influenza A (H1N1) • The following personal protective equipment (PPE) should be taken: – Hand hygiene – Standard Precautions – Surgical – Eye protection (i.e. goggles) – Plastic apron (single use only) – Gloves (some of these procedures require sterile gloves) – Hand hygiene post procedure • Refer to donning and removal of PPE document 7/18/2009 261
    257. Aerosol Generating Procedures (AGP) According to WHO And HPSC • Aerosol generating procedures: • Nebulisation • Intubation and related • Non-invasive positive procedures, e.g. manual pressure ventilation(NIV) ventilation • Bi-level positive airway • Respiratory and airway suctioning pressure (BiPAP) ,CPAP, (including tracheostomy care) • High frequency oscillating • Nasopharyngeal aspiration ventilation • Cardiopulmonary resuscitation • Bronchoscopy • Nasopharyngeal aspirate • Transtracheal aspirate • Bronchoalveolar lavage • Biopsy of lung or tracheal tissues • Autopsy procedures – i.e.. (Oscillating saws) 7/18/2009 262
    258. Influenza A(H1N1) Infection Prevention and Control Precautions Personal Protective Equipment (PPE) Summary • Nasal and throat viral swabs: • Nasopharyngeal aspirate, transtracheal aspirate, • The following precautions should be bronchoalveolar lavage and biopsy taken: of lung or tracheal tissues at post- mortem, nebulizers , • Hand hygiene BIPAP/CPAP/NIV are all considered • Surgical mask aerosol generating procedures: • Goggles (if risk of splashing or spraying) • The following precautions should be • Plastic apron taken: • Gloves • Hand hygiene • Hand hygiene post procedure • FFP2 or FFP3 respiratory mask • Goggles • Long sleeved disposable gown • Gloves (some of these procedures require sterile gloves) • Hand hygiene post procedure Update June 9 2009 7/18/2009 263
    259. NRVL Testing for Pandemic Influenza A(H1N1) 09 Virus • Respiratory specimens to take: • A. Upper respiratory tract – Nasopharyngeal (NP) and oropharyngeal (OP) swab – Nasopharyngeal aspirate – Sputum (if ordered) • B. Lower respiratory tract – Where clinically indicated, invasive procedures can be performed for the diagnosis of viral lower respiratory tract infections: – Transtracheal aspirate (TA) – Bronchoalveolar lavage (BAL) – Post-mortem lung or tracheal tissue 7/18/2009 264
    260. NRVL Testing for Pandemic Influenza A(H1N1) 09 Virus • Swabs to use: – Specific viral swab (contains viral transport medium in the container of the swab) – Regular swab – after taking the specimen the swab should be broken off into a bottle containing virus transport medium – Nasopharyngeal secretions should be aspirated into a sterile plastic mucous extractor. Transport the mucous extractor with the secretions – A transtracheal aspirate/ broncho-alveolar lavage should be transported in a sterile container 7/18/2009 265
    261. Influenza A (H1N1) Nasopharyngeal Swabs • According to PHAC And CDC : Nasopharyngeal Swabs • Ideally, swab specimens should be collected using (COPAN flocked swab) swabs with a synthetic tip (eg, polyester or Dacron) and a plastic shaft • Optimal specimens continue to be Nasopharyngeal Swabs (COPAN flocked swab) but Starplex non- flocked swabs are also acceptable for nasopharyngeal and nasal samples • Do not use wired shaft pertussis swab as it interferes with the test and give a false negative result • Swabs with cotton tips and wooden shafts are not recommended • Specimens collected with swabs made of calcium alginate are not acceptable • The swab specimen collection vials should contain 3 mL of VTM (eg, containing protein stabilizer, antibiotics to discourage bacterial and fungal growth, and buffer solution), such as M4RT or the BD Universal Viral Transport System 7/18/2009 266
    262. Pandemic Influenza A(H1N1) 09 Virus Flocked Swabs and Copan-Manufactured VTM for Pandemic Influenza A(H1N1) 09 Virus • CDC Recommends Flocked Swabs and Copan-Manufactured VTM for H1N1 Pandemic Influenza A(H1N1) 09 Virus : Optimal specimens continue to be Nasopharyngeal Swabs (COPAN flocked swab) 7/18/2009 267
    263. Pandemic Influenza A(H1N1) 09 Virus Nasopharyngeal Flocked Swabs Procedure • “Specimens for the laboratory diagnosis of Novel A (H1N1)Influenza should be collected in the following order of priority: 1. Nasopharyngeal aspirates 2. Acute serum 3. Convalescent serum 7/18/2009 268
    264. Pandemic Influenza A(H1N1) 09 Virus Nasopharyngeal (NP) , Oropharyngeal (OP) Swab • Nasopharyngeal (NP) and oropharyngeal (OP) swab collection: • Collect specimen with a sterile Dacron/nylon swab with a non-wooden shaft (do NOT use calcium alginate swabs or swabs with wooden sticks) • For NP swab, insert swab into each nostril parallel to the palate and leave in place for a few seconds to absorb secretions. Swab both nostrils • For OP swab, swab the posterior pharynx and tonsillar areas, avoiding the tongue • Place swab immediately into sterile vials containing 2 ml of viral transport media • Label each specimen container with patient’s FIRST AND LAST NAME, date of birth, medical record number, date of collection, specimen type • Place specimen vial onto ice or in refrigerator prior to and during transport at 4°C (but not frozen) • Should not be kept un-refrigerated for more than 12 hours 7/18/2009 269
    265. Pandemic Influenza A(H1N1) 09 Virus Nasopharyngeal Aspirates Overview • Ideally, swab specimens should be collected using swabs with a synthetic tip (eg, polyester or Dacron) and an aluminium or plastic shaft • Swabs with cotton tips and wooden shafts are not recommended • Specimens collected with swabs made of calcium alginate are not acceptable • The swab specimen collection vials should contain 3 ml of VTM (eg, containing protein stabilizer, antibiotics to discourage bacterial and fungal growth, and buffer solution), such as M4RT or the BD Universal Viral Transport System 7/18/2009 270
    266. Pandemic Influenza A(H1N1) 09 Virus Nasopharyngeal Aspirates Procedure • Hierarchy “Specimens for the laboratory diagnosis of Novel A (H1N1)Influenza should be collected in the following order of priority: 1. Nasopharyngeal aspirates 2. Acute serum 3. Convalescent serum 7/18/2009 271
    267. Pandemic Influenza A(H1N1) 09 Virus Nasopharyngeal Aspirates Collection • Nasopharyngeal wash/aspirates collecion: • Have the patient sit with head tilted slightly backward • Instill 1ml-1.5ml of nonbacteriostatic saline (pH 7.0) into one nostril • Insert the tubing into the nostril parallel to the palate • Aspirate nasopharyngeal secretions. Repeat this procedure for the other nostril • Rinse the catheter into viral transport medium (syringe or bulb) or aspirate viral transport media through catheter into collection trap • Label specimen container with patient’s FIRST AND LAST NAME, date of birth, medical record number, date of collection, specimen type • Place specimen vial onto ice or in refrigerator prior to and during transport • Do not freeze 7/18/2009 272
    268. Pandemic Influenza A(H1N1) 09 Virus Bronchoalveolar Lavage (BAL) Collection • Bronchoalveolar lavage or tracheal aspirate: • During bronchoalveolar lavage or tracheal aspirate, use a double-tube system to maximize shielding from oropharyngeal secretions • Centrifuge half of the specimen, and fix the cell pellet in formalin • Place the remaining unspun fluid in sterile vials with external caps and internal O-ring seals • If there is no internal O-ring seal, then seal tightly with the available cap and secure with Parafilm® • HPSC ; broncheoalveolar lavage should be transported in a sterile container 7/18/2009 273
    269. Pandemic Influenza A(H1N1) 09 Virus Sputum Collection • Sputum collection: • Educate the patient about the difference between sputum and oral secretions • Have the patient rinse the mouth with water and then expectorate deep cough sputum directly into a sterile screw-cap sputum collection cup or sterile dry container • Label specimen container with patient’s FIRST AND LAST NAME, date of birth, medical record number, date of collection, specimen type • Place specimen vial onto ice or in refrigerator prior to and during transport • Do not freeze 7/18/2009 274
    270. Pandemic Influenza A(H1N1) 09 Virus Stool Collection • In the USA, gastrointestinal symptoms (nausea, vomiting and/or diarrhoea) have occurred in up to 38% of outpatients with confirmed influenza A(H1N1) • Diarrhoea has been uncommon in hospitalised cases • SOP (Standard operating procedure) on collection • Full PPE (in case of splashes) • Place in Biological Bag • Do not freeze! • For all specimens Contact DPH/MOH/NVRL for shipping instructions accordance to national and international standards 7/18/2009 275
    271. Pandemic Influenza A(H1N1) 09 Virus Serology Suites • Acute Serum Suites • Convalescent Serum Suites • Immediate • 14 days after • Specimens: • Specimens: – Blood in clotted tube (red top) – Blood in clotted tube (red top) – Blood in EDTA (purple top) – Blood in EDTA (purple top) • {Full blood count) – {Full blood count) • Additional routine blood work according to physicians orders or follow pre ordered Influenza-like illness ,Influenza A(H1H1) suites as institutional protocols 7/18/2009 276
    272. Pandemic Influenza A(H1N1) 09 Virus Serology Acute and Convalescent Serum Samples • Acute and Convalescent serum samples: • Collect 5-10 ml whole blood in a serum separator or red top tube Allow the blood to clot, centrifuge briefly, and collect all resulting sera in vial with external caps and internal O-ring seals • Refrigerate at 4°C • The minimum amount of serum needed for testing is 200 ml, which can easily be obtained from 5 ml of whole blood • A minimum of 1 cc of whole blood is needed for testing of paediatric patients • If possible, collect 1 cc in an EDTA tube and in a clotting tube • If only 1 cc can be obtained, use a clotting tube • Label specimen container with patient’s FIRST AND LAST NAME, date of birth, medical record number, date of collection, specimen type 7/18/2009 277
    273. Pandemic Influenza A(H1N1) 09 Virus and Blood Safety • 2009 H1N1 Influenza Virus and Blood Safety: • Bld cultures Aerobic No case of transfusion transmitted seasonal influenza has ever then anaerobic been reported in the United States or elsewhere, and, to date, no cases of transfusion transmitted H1N1 flu have been reported! • Safety of Plasma Derivatives • The newly emerging 2009 H1N1 Influenza Virus is a large lipid- enveloped virus. Validation studies performed by the product manufacturers have shown that viruses with similar characteristics to this agent are effectively inactivated and/or removed by the manufacturing processes in place for these products • Individuals who are not in good health are not suitable to donate blood and blood establishments must defer these potential donors therefore…. • Blood donor screening procedures currently in place at blood establishments should identify persons with symptoms of H1N1 flu infection 7/18/2009 278
    274. Pandemic Influenza A(H1N1) 09 Virus and Blood Safety • Irish Blood Transfusion Service advisory • Swine Flu Important Information • “We are asking all donors who have returned from Mexico or the United States of America in the last 14 days NOT to attend any blood donor clinic at this time. This situation is under review on a daily basis and further updates will be available here. Please note that this precaution is in the interest of donor and recipient safety. Your patience and cooperation is greatly appreciated” 7/18/2009 279
    275. Pandemic Influenza A(H1N1) 09 Virus Diagnostics - Chest X-ray • Approximately 2-5% of confirmed cases in the US and Canada as well as 6% in Mexico have been hospitalised • In Mexico – One-third of those hospitalised required mechanical ventilation • Of those hospitalised in California – 15 of 25 (60%) tested had radiographic changes suggestive of pneumonia including ten with multilobar infiltrates – Four (13%) required mechanical ventilation 7/18/2009 280
    276. Pandemic Influenza A(H1N1) 09 Virus Diagnostics Summary • The following investigations are recommended in patients referred to hospital: Test Who this applies to Full blood count All patients Urea and electrolytes All patients Liver function tests All patients C-reactive protein If influenza-related pneumonia is suspected* Chest x-ray All patients Pulse oximetry All patients. If <92% on air, then arterial blood gases. ECG Patients with cardiac and respiratory complications or co-morbid illnesses. Patients with influenza-related pneumonia should also have the following bacteriological tests: Blood culture (preferably before antibiotic treatment is commenced) Pneumococcal urine antigen (20 mls urine sample) Legionella urinary antigen 20 mls urine sample) Sputum Gram stain, culture Antimicrobial susceptibility tests on samples obtained from patients who: i.are able to expectorate purulent samples, and ii. ave not received prior antibiotic treatment. Paired serological examination for influenza/other agents Acute serum should be collected and a ‘convalescent’ sample obtained after an interval not less than 7days (both 5-10mLs clotted blood) 7/18/2009 281
    277. “Pandemic (H1N1) 2009” Virus Real-time RT-PCR Detection Panel (Swine Flu Test Kit) • Countries with the PCR Capacity in Place to Diagnose Pandemic Influenza A(H1N1) 09 virus Infection in Humans Doc Available at WHO • 23 EU and EFTA countries are currently able to perform PCR to diagnose Pandemic Influenza A(H1N1) 09 virus infection in humans 7/18/2009 282
    278. Pandemic Influenza A(H1N1) 09 Virus Laboratory Tests Molecular Diagnostics: • Molecular diagnostics: • S-OIV assay The swine-origin influenza virus (S-OIV) assay (National Virus Reference Laboratory, NVRL, Dublin) is a real-time one-step RT-PCR assay containing primers and a dual-labelled hydrolysis probe targeting the M gene of influenza A viruses other than seasonal A(H1N1) and A(H3N2) viruses • HPA (H1)v assay The influenza A(H1)v specific assay of the Health Protection Agency (HPA) contains primers and a dual-labelled TaqMan MGB probe (Applied Biosystems) targeting conserved sequences in the HA gene of A(H1N1)v viruses, and the positive control swine A(H1N1) virus A/Aragon/3218/2009, in a 1-step TaqMan PCR assay [3]. The advantage of using a genetically distinct positive control virus (A/Aragon/3218/2008) is that false positives can be differentiated by sequence from true positives • CDC (H1)v assay The Centers for Disease Control and Prevention (CDC) real-time RT-PCR kit designed for the detection and characterisation of influenza A(H1N1)v viruses contains a panel of oligonucleotide primers and dual-labelled hydrolysis probes [4]. The CDC (H1)v primer and probe set evaluated in this study has been designed to specifically detect A(H1)v influenza in a one-step RT-PCR assay. • HPA (N1)v assay The influenza A(N1)v real-time assay (HPA) is a two-step TaqMan PCR assay incorporating oligonucleotide primers and a dual-labelled MGB TaqMan probe for the detection of the NA gene of influenza A(H1N1)v viruses and the positive control virus A/Aragon/3218/2008 [5]. The assay has been designed to be performed in conjunction with the influenza A(H1)v specific assay, to provide confirmation of diagnosis of influenza A(H1N1)v virus infection 7/18/2009 283
    279. Swine Influenza Virus Real-time RT-PCR Detection Panel (Swine Flu Test Kit) • Instructions how to obtain CDC real time RT-PCR Kits for detection of Influenza A( H1 N1) • Thr rRT-PCR kits includes the following primers /probes: – Universal Influenza A(Infa) – Swine Influenza A(swIfa) – SwineH1 (swH1) – RNaseP (Control)( RP) • The rRT-PCR kits can also include detailed procedures CDC-developed PCR as well as positive control materials diagnostic test to detect novel H1N1 virus • Send the following e-mail to flouder@cdc.gov • I would like to request a rRT-PCR primers/probe kit for Swine A/H1 Flu • Contact name: • Institution Name: • Contact phone #: • 7/18/2009 Institution Shipping Address(No PO Box): 284 • Preferred Shipping carrier:
    280. Pandemic Influenza A(H1N1) 09 Virus Virus Real-time RT-PCR Detection Panel • INTENDED USE: The Influenza A(H1N1) Virus Real-time RT-PCR Detection Panel is intended for use in real- time RTPCR assays on an ABI 7500 Fast Dx Real-Time PCR instrument in conjunction with clinical and epidemiological information • Test from nasopharyngeal or nasal swab BinaxNOW® Real-time PCR Biosystems 7500 Influenza A & B detection of Mexican Real-Time PCR Test Swine Flu Kit A C B 7/18/2009 285
    281. Pandemic Influenza A(H1N1) 09 Virus Laboratory Tests • Real-time RT-PCR for influenza A, B, H1, H3 – swine-origin influenza A (H1N1) virus will test positive for influenza A and negative for H1 and H3 by real-time RT-PCR • Rapid influenza antigen test • Immunofluorescence (DFA or IFA): • Viral culture: • Please Read below in narration! • Emergency Use Authorization of Swine Flu Test Kit : NML Winnipeg • Centers for Disease Control and Prevention (CDC) has developed the Swine Influenza Virus Real-time RT-PCR Detection Panel (Swine Flu Test Kit) for the presumptive presence of swine influenza A (H1N1) virus from the nasal or nasopharyngeal swab. • Swine Influenza Test Kit will be made available on the CDC Swine Flu website. 7/18/2009 286
    282. Pandemic Influenza A(H1N1) 09 Virus Recommended Tests • Real-time RT-PCR for influenza A, B, H1, H3 at a state health department laboratory is recommended • Currently, Pandemic Influenza A(H1N1) 09 Virus will test positive for influenza A and negative for H1 and H3 by real-time RT-PCR • If reactivity of real-time RT-PCR for influenza A is strong (eg, Ct <30), it is more suggestive of a novel influenza A virus • Confirmation of Novel Influenza is performed at the NRVL currently, but may be available in public health laboratories 7/18/2009 287
    283. CDC Rt-PCR Testing Algorithm and Results Interpretation The overall approach to influenza virus detection by RT-PCR should be considered in the context of the national situation, e.g., how many swl = swine like specimens can be handled (throughput), what gene sequence to target for RT-PCR, and whether to use concurrent or sequential testing for RT-PCR of PCR Assays AIV = Avian Influenza virus M, NP and HA genes. PCR = Polymerase chain reaction Influenza A-swl subtype specific Influenza type A (universal) PCR (H1 gene) Matrix gene PCR (other genes targets are optional) Test for Seasonal influenza H1-and N3 using specific Confirmed Positive Positive Positive PCR H1N1 swl And tested negative Positive Negative for seasonal influenza H1 or H3 specific PCR Check for lab Negative Positive confirmation by Influenza A Negative retesting from original Other than H1N1 swl sample Negative for influenza A viruses (check for Positive Check for lab other pathogens confirmation by Positive retesting from original Negative Confirmed Positive sample Test for H5N1 or other AIV or H1 or H3 Influenza B 7/18/2009 288
    284. Submission of Tissue Specimens for the Pathologic Evaluation of Pandemic Influenza A(H1N1) 09 Virus • Central (hilar) lung with segmental bronchi, right and left primary bronchi, trachea (proximal and distal) • Representative pulmonary parenchyma from right and left lung • For patients with suspected myocarditis, encephalitis, or rhabdomyalysis, myocardium (right and left ventricle), central nervous system (cerebral cortex, basal ganglia, pons, medulla, and cerebellum), and skeletal muscle, respectively • Any other organ showing significant gross or microscopic pathology 7/18/2009 289
    285. Pandemic Influenza A(H1N1) 09 Virus Submission of Specimens • General Guidelines for Shipping Pathology Specimens: • Packaging and Shipping Guidelines Layout of Bio Containment :BL3(+) – Formalin-fixed wet tissues OL: Outer lobby S: Shower – Formalin-fixed paraffin- IL: Inner Lobby LAB: Laboratory embedded blocks – Glass slides with sections from paraffin-embedded blocks – Fresh frozen tissue 7/18/2009 290
    286. “Pandemic (H1N1) 2009” NRVL Submission of Specimens • Postal address: Medical Microbiology, CRID Building, University College Dublin, Belfield, Dublin 4, Bio containment :BL3(+) Two microbiological safety cabinets Ireland. (msc ) class I and class I/ III) at NVRL Telephone Number: +353-1-716 1325/1236 Fax Number: +353-1-716 1239 Email: margaret.brindley@ucd.ie 7/18/2009 291
    287. Pandemic Influenza A(H1N1) 09 Virus Who Submission of Specimens • All samples from “highly suspicious cases” must be promptly referred to NVRL for investigation, as per agreed procedures • Any influenza strains detected should be provisionally characterised at the NVRL urgently and referred with available phylogenetic data urgently to the WHO Collaborating Centre in London for confirmation and sub typing • Dr A. Hay • WHO Collaborating Centre for Reference and Research on Influenza • National Institute for Medical Research • Mill Hill, London NW7 1AA, United Kingdom • Fax: +44 208 906 44 77 • Email: whocc@nimr.mrc.ac.uk • http://www.nimr.mrc.ac.uk/wic/ 7/18/2009 292
    288. NRVL Testing for Pandemic Influenza A(H1N1) 09 Virus • 1. Health and Safety regulations on biological hazards (Safety, Health and Welfare at Work Act 2005 (No. 10 of 2005) • 2. European Agreement concerning the International Carriage of Dangerous Goods by road (ADR) Regulations (2007 edition) • 3. S.I. No 29 of 2004 - Carriage of Dangerous Goods by Road Regulations, 2004 • Biosafety: “Directive 90/679/EEC in S.I. No. 248/1998 — Safety, Health and Welfare At Work (Biological Agents) (Amendment) Regulations, 1998.” 7/18/2009 293
    289. Pandemic Influenza A(H1N1) 09 Virus Shipping Clinical Specimens • Clinical specimens should be shipped on dry ice in appropriate packaging • All specimens should be labelled clearly and include information requested by the appropriate public health laboratory or NRVL • Suspect case specimens shipped from the public health laboratory to the NRVL should include all information required for seasonal influenza surveillance isolate or specimen submission 7/18/2009 294
    290. Pandemic Influenza A(H1N1) 09 Virus International Shipment Protocol As with all clinical specimens, respiratory specimens should be packaged and transported to the virology laboratory in accordance with national and international guidelines. Contact the National Virus Reference Laboratory or local laboratory for advice if concerned! 7/18/2009 295
    291. Pandemic Influenza A(H1N1) 09 Virus Who Shipment Protocol Adapted from WHO E-tool-Intro Shipping requirements for Pandemic Influenza A(H1N1) 09 Virus specimens are described under: http://www.who.int/csr/resources/publications/swineflu/in structions-shipments/en/index.html All Shippers Must take the E-tool-intro coarse to be able to ship Infectious Substances “Category A” 7/18/2009 296
    292. Pandemic Influenza A(H1N1) 09 Virus Who Shipment Protocol • If the shipment also includes other dangerous goods (such as liquid nitrogen or dry ice), shippers must be trained appropriately in the transport of those goods • Additional information can be found in the WHO document “Guidance on regulations for the transport of infectious substances”, available at: • http://www.who.int/csr/resources/publications/ biosafety/WHO_HSE_EPR_2008_10/en/index.ht ml 7/18/2009 297
    293. Pandemic Influenza A(H1N1) 09 Virus Who Submission of Specimens • Shippers should note: • Specimens collected directly from humans or animals that are suspected or confirmed to be infected with the Pandemic Influenza A(H1N1) 09 Virus , including specimens from the respiratory tract (swabs) and blood specimens, should be shipped as: • "BIOLOGICAL SUBSTANCE, CATEGORY B" and assigned to UN 3373 • Pandemic Influenza A(H1N1) 09 Virus cultures (i.e. virus isolates) must be shipped as: • Category A "INFECTIOUS SUBSTANCE; AFFECTING HUMANS" and assigned to UN 2814 7/18/2009 298
    294. Pandemic Influenza A(H1N1) 09 Virus Who Shipment of Specimens • Category A , Category B, Or Exempt • Packaging Samples • All samples must be packaged using triple packaging. • Triple packaging provides three layers of containment to protect the substances being shipped • These layers are primary, secondary, and outer containers. • The following diagram shows the basic concept of triple packages Must be packaged using triple packaging 7/18/2009 299
    295. This Packaging is Used For Category A Infectious Substances 7/18/2009 300
    296. Category A: Markings and Labels MARKINGS • All shippers must properly mark and label Category A packages. The following is a list of markings and labels for Category A packages: Markings • Shipper’s name, address, and telephone number u 4G/CLASS 6.2/02 • Receiver’s name, address, and telephone number n F/BVT 312103 • Name and telephone number of responsible person (who is available 24 hours a day until shipment arrives) INFECTIOUS SUBSTANCE, AFFECTING HUMANS • UN Specification Marking UN2814 • Proper Shipping Name and UN Number LABELS Labels • Infectious substance label • Package orientation label (only used when primary container exceeds 50ml) 7/18/2009 301
    297. Pandemic Influenza A(H1N1) 09 Virus Category A Packing Requirements • Primary container is leakproof • Secondary container is leakproof • Outer container is rigid Triple Packaging Example • Pressure tested at 95kPa • Drop tested from 9m • Puncture tested at 7kg • UN specification marking • Shipper must be trained 7/18/2009 302
    298. Steps For Packaging Category A Samples Swine influenza A(H1N1) 1. Open secondary container. virus cultures (i.e. virus isolates ) must be shipped 2. Insert absorbent material. as: 3. Don gloves. Category A "INFECTIOUS SUBSTANCE; AFFECTING 4. Cushion primary container. HUMANS" and assigned to UN 2814. 5. Place primary container in secondary container. Needs 6. Doff gloves. Dangerous Goods Declaration 7. Close secondary container. 8. Place secondary container in outer container. 9. Insert laboratory test instructions and description of materials. 10.Close outer container. 7/18/2009 303
    299. Dangerous Goods Declaration • All shipments of Category A pathogens require a properly completed Dangerous Goods Declaration. This declaration must be signed by the shipper and serves as a legal contract between the shipper and operator • Samples classified as Category B or Exempt do not require this form Completed Form 7/18/2009 304
    300. Air Waybill • All goods being shipped by air must have a completed Air Waybill 7/18/2009 305
    301. This Packaging is Used For Category B Infectious Substances 7/18/2009 306
    302. Category B Packaging Requirements • Primary container is leakproof • Secondary container is leakproof • Outer container: Either secondary or outer container is rigid – If the shipment is transported by air, the outer container must be rigid • Pressure tested at 95kPa • Drop tested from 1.2m 7/18/2009 307
    303. Category B: Markings and Labels • All shippers must properly mark and label MARKINGS Category B packages. The following is a list of markings and labels for Category B packages: Markings • Shipper’s name, address, and telephone number UN 3373 BIOLOGICAL SUBSTANCE, CATEGORY B • Receiver’s name, address, and telephone number • UN Number • Proper Shipping Name Labels • None are required (unless shipping with dry ice) 7/18/2009 308
    304. Steps For Packaging Category B Sample Specimens collected directly 1. Open secondary container. from humans or animals that are suspected or confirmed to 2. Insert absorbent material. be infected with the swine influenza A(H1N1) virus, 3. Don gloves. including specimens from the respiratory tract (swabs) and 4. Cushion primary container. blood specimens, should be shipped as : 5. Place primary container in secondary container. "BIOLOGICAL 6. Doff gloves. SUBSTANCE, CATEGORY B" 7. Close secondary container. and assigned to UN 3373. 8. Place secondary container in outer container. Does Not Need Dangerous Goods 9. Insert laboratory test instructions and description of Declaration materials. 10. Close outer container. 7/18/2009 309
    305. Exempt Packaging Requirements • Primary container is leakproof • Secondary container is leakproof • Outer packaging must be of adequate strength 7/18/2009 310
    306. Exempt Packaging Requirements Primary container (leakproof) Secondary container (leakproof) Absorbent and cushioning material Outer packaging 7/18/2009 311
    307. Exempt Marking Labels • All shippers must properly mark and label MARKINGS Exempt packages. The following is a list of markings and labels for Exempt packages: • Markings • Shipper’s name, address, and telephone number EXEMPT HUMAN SPECIMEN • Receiver’s name, address, and telephone number • Proper Shipping Name EXEMPT ANIMAL SPECIMEN Labels • None are required (unless shipping with dry ice) 7/18/2009 312
    308. Steps For Packaging Exempt Sample 1. Open secondary container. 2. Insert absorbent material. 3. Cushion primary container. 4. Place primary container in secondary container. 5. Close secondary container. 6. Place secondary container in outer container. 7. Insert laboratory test instructions and description of materials. 8. Close outer container. 7/18/2009 313
    309. Health Protection Agency (HPA) Cat B Packaging Poster 7/18/2009 314
    310. Biosaftey : Spill Clean-up Procedure 1. Wear gloves and protecting clothing, including face and eye protection if indicated 2. Cover the spill with a cloth or paper towels to contain it 3. Pour an appropriate disinfectant over the cloth or paper towels and the immediately surrounding area (5% bleach solutions are generally appropriate, but for spills on aircraft, quaternary ammonium disinfectants should be used) 4. Apply the disinfectant concentrically beginning at the outer margin of the spill area, working towards the centre 5. After about 30 min, clear away the materials. If there is broken glass or other sharps are involved, use a dustpan or a piece of stiff cardboard to collect the materials and deposit them into a puncture-resistant container for disposal 6. Clean and disinfect the area of the spillage (if necessary, repeat steps 2–5) 7. Dispose of contaminated materials into a leak-proof, puncture- resistant waste disposal container 8. After successful disinfection, report the incident to the competent authority and inform them that the site has been 7/18/2009 315 decontaminated
    311. Post-exposure Prophylaxis (PEP) for close contacts of probable or confirmed human case(s) of Pandemic Influenza A(H1N1) 09 Virus in WHO Pandemic Alert Phase 6 (Update June 22 2009) 7/18/2009 316
    312. Pandemic Influenza A(H1N1) 09 Virus Vaccine For Ireland In Ireland advance purchase agreements with two manufacturers for the procurement of 7.7 million doses of pandemic vaccine have been negotiated! 1. Novartis 2. ? 7/18/2009 317
    313. Canadian Lab Working on Pandemic Influenza A(H1N1) 09 Virus Vaccine • No Vaccine available at this time! NML Winnipeg • Late on May 6, Canada's National Microbiology Laboratory first completed the sequencing of the virus, publishing the result to GenBank • Samples from Mexico, Nova Scotia and Influenza A H1N1 virus is seen in an image taken using an electron Ontario had the same sequence, ruling microscope, at PHAC's National Microbiology Laboratory. (Public out genetic explanations for the greater Health Agency of Canada, National Microbiology Laboratory) severity of the Mexican cases 7/18/2009 318
    314. Pandemic Influenza A(H1N1) 09 Virus Vaccine Resource Update • For more Information: • Recommendations of the Strategic Advisory Group of Experts (SAGE) on Influenza A (H1N1) vaccines 19 May 2009 • http://www.who.int/csr/resources/publications/swineflu/SAGEH1N1vaccinere commendation2009_05_19.pdf • Influenza vaccines have been available for over 50 years. Generally, they are trivalent, i.e. they contain three different, inactivated virus strains, either whole viruses or parts or subunits of them – Because the flu virus is changing its antigenic shape constantly (either in minor drifts or in major shifts), the composition of the flu vaccine needs to be adapted to these changes regularly • The monitoring of these changes is done by the Global Influenza Surveillance Network of the World Health Organization (WHO) – At the beginning of each year the WHO makes a recommendation for the strains to be included into the vaccine for the coming influenza season 7/18/2009 319
    315. Vaccine Technology Overview • Traditional Egg-based Process (last 50 years) • Cell Culture Process (1990’s) – Grown in eggs – Mammalian (Kidney) cell culture – Moderate specific to original strain (growth of epidemic – Vaccine are not grown on the tissue but in the single cells of viruses in eggs result in variants that are antigenically distinct the tissue from the original viruses – Highly specific to original strain (strains grown in cell cultures – Low Yield (approx 1-3 eggs per dose) equal the original clinical isolates) – Allergies to egg albumin? – High Yield – Potential impurities in eggs (antibiotics, other viruses) may – Virus grown in mammalian cell culture is therefore more cause sterility problems representative of the circulating wild type virus than that – Long Process (6-12 months) grown in eggs – A flu pandemic could probably not be contained and defeated – Cell culture based systems, however, could be rapidly on egg-based procuction, because the production takes too expanded and scaled up in times of emergency long and eggs don’t grow on demand – Up -front costs for operational readiness of such plants (with – Emerging endemic viruses sometimes do not grow at all in its huge fermenters) are much higher than the costs for egg – eggs based systems – Egg-based production of flu vaccines is well established and – Ie. Polio Vaccine cost-effective – Example: Pharmaceutical company - Novarits – Example:Pharmaceutical company- Glaxo-Smith-Kline (GSK) • Transient Expression of haemagulltinin – Insect cell culture – Very High Yield – Not very well established but is cost effective – Low production time 7/18/2009 320
    316. Classical Reassortment • The goal of reassortment is to combine the desired HA and NA antigens from the target strain (flu strain 1) with genes from a harmless strain that grows well in an egg (flu strain 2) • The illustration details the following steps in creating the vaccine: – Flu strains 1 and 2 are injected into a fertilized chicken egg – The genes from flu strain 1 multiply and mix with the genes from flu strain 2, forming as many as 256 possible gene combinations – Researchers search the many combinations for the flu strain that contains the HA and NA genes from flu strain 1 and remaining genes from flu strain 2 that ensures that it is able to grow efficiently in eggs. – This new reassortant flu strain and two other flu strains will make up next year’s vaccine. • This image is in the public domain. Please credit the National Institute of Allergy and Infectious Diseases (NIAID). 7/18/2009 321
    317. Reverse Genetics • Reverse Genetics • A flu virus contains eight gene segments. One of the gene segments codes for the surface antigen hemagglutinin (HA) and another codes for the surface antigen neuraminidase (NA) • Scientists can custom-make a flu strain by assembling genes that code for the desired features. Two genes representing the HA and NA antigens are selected from the target strain (flu strain 1), while the remaining six genes come from a virus that's time-tested for its ability to grow inside an egg (flu strain 2). (Although the influenza virus actually uses RNA as its genetic material, the researchers make complementary pieces of DNA because DNA is easier to work with.) • The illustration details the following steps in creating the vaccine: – After removing the dangerous part of the HA gene, scientists splice the HA and NA genes from flu strain 1 into circular pieces of DNA called plasmids. – Additional plasmids are created using the remaining six genes found in flu strain 2. – Scientists insert the HA and NA plasmids from flu strain 1 and the six plasmids carrying genes from flu strain 2 into animal cells growing in the laboratory. – The genes in the plasmids instruct the animal cells to make the desired new flu strain • This image is in the public domain. Please credit the National Institute of Allergy and Infectious Diseases (NIAID). 7/18/2009 322
    318. Pandemic Influenza A(H1N1) 09 Virus Vaccine Development Process Seasonal 1. Collection of specimens and disease/epidemiology data (All year round) A(H1N1) 09 2. Diagnosis and virus isolation ,preliminary analysis (Hrs to 3 wks) 2a. Virus Isolation in eggs (1-3 wks) 3. Ferret antisera production Vaccine development (3-5 weeks) Approx 6 -12 months 4. Thorough antigenic and genetic analysis (1-3 wks) 4a. Serological Studies (3-16 wks) 5.Review and selection of candidate viruses for vaccine use (1-3 wks) 6a. Classical Reassortment of 6b. Reassortment of high high growth viruses growth using reverse genetics (3-4wks) and full safety testing (8 wks) 7a. Antigenic and genetic 9a. Development of 9b. Development of 7b. Antigenic and genetic characterizations of 8. Evaluation of growth standardized reagents standardized reagents characterizations of reassortments property fir inactivated vaccines for inactivated ressortment (3 wks) (4wks) (6wks) vaccines (3 wks) (4wks) 7/18/2009 Availability of vaccine virus and standardised reagents Adapted from WHO H5N1 vaccine development
    319. Pandemic Influenza A(H1N1) 09 Virus Vaccine Development Process Glossary • Novel (new) subtype of human influenza A virus. This term refers to human influenza viruses that have haemagglutinin and neuraminidase antigens that are distinct from seasonal influenza viruses and have the potential to cause a pandemic. • Clinical specimens (original). These are materials collected from humans, generally in order to confirm a diagnosis. For influenza, most commonly, clinical specimens are taken from the respiratory tract (for example, swabs and aspirated fluid) but they can be from other locations. Clinical specimens can be frozen and stored for later use • Influenza reference viruses. These are wild-type influenza viruses that WHO has selected as representative of important groups of influenza viruses on the basis of extensive antigenic and genetic studies and comparisons with viruses from many countries. As the influenza viruses evolve in nature, new reference viruses are selected. • Wild-type influenza viruses (synonym: virus isolates). These are influenza viruses that have been cultured either in eggs or cells (i.e. isolated) directly from clinical specimens and have not been modified. • “Classical” reassortment. This is a non-patented laboratory technique that is often used to make (seasonal) candidate vaccine viruses • Genetic reassortment. In this process genes from two or more influenza viruses are mixed in different combinations, resulting in hybrid viruses with genetic characteristics of each parent virus. This process occurs in nature but can also be done in a laboratory using “classical” reassortment or reverse genetics • High-growth reassortant viruses. These are influenza viruses that have been genetically modified to grow better in eggs for optimal vaccine production. • Reverse genetics. This is a laboratory technique that is used to construct or modify influenza viruses and is protected by patents in several countries. It is used to render highly pathogenic H5N1 viruses less dangerous. • Reagents for influenza vaccine standardization. These reagents are used to standardize the amount of haemagglutinin protein in influenza vaccines as required by regulatory agencies. The reagents have to be produced in large quantities so that all vaccine batches can be tested. • Seed viruses. These are influenza viruses prepared from candidate influenza vaccine viruses by individual manufacturers for the manufacturer’s specific vaccine-production process. 7/18/2009 324
    320. Results of Haemagglutination Inhibition Tests of Influenza A(H1N1) Viruses With Post‐infection Ferret SeraA 7/18/2009 325
    321. Viral Gene Sequences to Assist Update Diagnostics for Pandemic Influenza A(H1N1) 09 Virus - GenBank Accession Numbers Pandemic Influenza A(H1N1) 09 Virus The WHO Collaborating Centre for influenza in CDC Quadruple Reassortant Lineage Atlanta USA has posted the full genome sequences of swine influenza (North American and Eurasian A/California/04/2009 (H1N1) influenza virus on the Swine/Avian/Human) GenBank sequence database. To access, go to: http://www.ncbi.nlm.nih.gov/sites/entrez?db=nuccore PB2 &itool=toolbar, then enter the accession number as shown below: PB1 • PB2 gene accession number is: FJ966079 PA • PB1 gene accession number is: FJ966080 HA • PA gene accession number is: FJ966081 NP • HA gene accession number is: FJ966082 • NP gene accession number is: FJ966083 NA • NA gene accession number is: FJ966084 M •M gene accession number is: FJ966085 NS • NS gene accession number is: FJ966086 Tip: to access all the gene sequence records at once, copy the following line of text and paste Classical swine, North American Lineage it into the search bar in the above GenBank web link. FJ966079,FJ966080,FJ966081,FJ966082,FJ966083,FJ9660 Avian, North American Lineage 84,FJ966085,FJ966086 Seasonal H3N2 Eurasian swine Lineage 7/18/2009 326
    322. Pandemic Influenza A(H1N1) 09 Virus Gene sequences of the currently available reassortant candidate vaccine viruses: • X-179A – The accession numbers of the HA and NA gene sequences of X-179A in GenBank is: • HA: GQ214335 • http://www.ncbi.nlm.nih.gov/nuccore/238623303 • NA: GQ214336 • http://www.ncbi.nlm.nih.gov/nuccore/238623305 • IDCDC-RG15 – The accession numbers of the HA and NA gene sequences of IDCDC-RG15 in GenBank is: • HA: GQ219781 • http://www.ncbi.nlm.nih.gov/nuccore/238623307 • NA: GQ219782 • http://www.ncbi.nlm.nih.gov/nuccore/238623309 • IVR-153 – The accession numbers of the HA and NA gene sequences of IVR-153 in GISAID is: • HA: EPI181843 • http://platform.gisaid.org/dante-cms/live/struktur.jdante?aid=1131 • NA: EPI181844 • http://platform.gisaid.org/dante-cms/live/struktur.jdante?aid=1131 7/18/2009 327
    323. Pandemic Influenza A(H1N1) 09 Virus International Vaccine Candidates • Wild type influenza virus: • Traditional reassortant viruses are derived only from wild type viruses isolated and grown in hens’ eggs, or in a validated clean cell culture system. • A/California/7/2009 (egg isolate) – classical reassortment and reverse genetics • A/England/195/2009 (MDCK cell isolate) – reverse genetics • A/California/4/2009 (MDCK isolate) – reverse genetics • A/Texas/5/2009 (MDCK isolate) - reverse genetics • A/Ohio/7/2009 (MDCK isolate) - reverse genetics • A/New York/20/2009 (MDCK isolate) - reverse genetics 7/18/2009 328
    324. ) Pandemic Influenza A(H1N1)09Vaccine Virus Development Summary Candidate vaccine viruses using reverse Candidate vaccine viruses using classical Development of vaccine potency reagents Wild type viruses have been/ are being sent genetics technology are being developed by: reassortment technology are being for inactivated vaccines against Influenza to vaccine manufacturers on request developed by: A(H1N1) is planned in: including: Centers for Disease Control and Prevention NIBSC, UK, from NIBSC, UK Baxter (CDC), Atlanta USA A/California/7/2009(H1N1)swl, an egg virus enquiries@nibsc.ac.uk rdonis@cdc.gov isolate enquiries@nibsc.ac.uk National Institute for Biological Standards New York Medical College, USA, from CBER FDA, USA CSL Limited and Control (NIBSC) A/California/7/2009(H1N1)swl zhiping.ye@fda.hhs.gov enquiries@nibsc.ac.uk zhiping.ye@fda.hhs.gov Centre for Biologics Evaluation and Research CSL Limited, Australia, from Therapeutic Goods Administration GlaxoSmithKline Biologicals (CBER) A/California/7/2009(H1N1)swl gary.grohmann@health.gov.au zhiping.ye@fda.hhs.gov gary.grohmann@health.gov.au St. Jude Children’s Research ERL NIID, Japan MedImmune Hospital,Memphis USA mtashiro@nih.go.jp richard.webby@stjude.org National Institute of Infectious Diseases Microgen (NIID), Japan mtashiro@nih.go.jp Nobilon International Novartis June 15 2007 cell cultured vaccine ready for first stage Omninvest Vaccines Sanofi Pasteur June 17 2009 Donates 10,000,000 vaccine doses to WHO (When Ready) Adapted from WHO vaccine policy May 18 2009 Solvay and Vivaldi 7/18/2009 329
    325. Pandemic Influenza A(H1N1) 09 Virus International Vaccine Candidates Candidate influenza Parental H1N1 virus Laboratory vaccine viruses NYMCX-179A conventional A/California/7/2009 NYMC, USA reassortant virus IVR-153 conventional A/California/7/2009 CSL, Australia reassortant virus IDCDC –RG15 reverse A/Texas/5/2009 CDC, USA genetics virus CBER-RG2 reverse genetics A/California/04/2009 CBER, USA virus NIBRG-121 reverse A/California/7/2009 NIBSC, UK genetics virus 7/18/2009 330
    326. Pandemic Influenza A(H1N1) 09 Virus NIBSC Candidate Vaccine Viruses Candidate Parental H1N1 NIBSC code Availability influenza vaccine virus viruses NIBRG-121 A/California/7/2009 09/122 Now 27/05/09 NYMCX-179A A/California/7/2009 09/124 Now W/C 8/06/09 IVR-153 A/California/7/2009 09/144 Now Previously VI 1525 2/06/09 7/18/2009 331
    327. Reagents for Single Radial Diffusion Assay of Influenza A (H1N1)v Virus Vaccine Reagents for NIBSC code Availability influenza Vaccine Standardisation A/California/7/2009 NA Mid July 2009 antigen (cell derived) A/California/7/2009 NA End July 2009 antigen (egg derived) A/California/7/2009 09/142 Now antiserum 7/18/2009 332
    328. Influenza A (H1N1) Vaccine Development: NIBRG‐121 27 May 2009 • NIBRG‐121 (NIBRG‐121 reassortant virus) • A candidate reassortant vaccine virus (NIBRG‐121) has been developed, using reverse genetics technology, from an A/California/7/2009(H1N1)v virus, by the National Institute for Biological Standards and Control (NIBSC), Potters Bar, Hertfordshire, United Kingdom. • The haemagglutinin (HA) and neuraminidase (NA) sequences of the A/California/7/2009(H1N1)v virus can be found on the public web site of GenBank via the following links: • HA sequence – http://www.ncbi.nlm.nih.gov/nuccore/227977171?ordinalpos=1&itool=Ent rezSystem2.PEntrez.Sequence.Sequence_ResultsPanel.Sequence_RVDocSu m • NA sequence – http://www.ncbi.nlm.nih.gov/nuccore/229396468?ordinalpos=1&itool=Ent rezSystem2.PEntrez.Sequence.Sequence_ResultsPanel.Sequence_RVDocSu m 7/18/2009 333
    329. Pandemic Influenza A(H1N1) 09 Virus NIBRG‐121 (NIBRG‐121 Reassortant Virus) • Now Available from: • Division of Virology • National Institute for Biological Standards and Control • Blanche Lane, South Mimms, Potters Bar • Hertfordshire, EN6 3QG, United Kingdom • E‐mail: enquiries@nibsc.hpa.org.u • k or standards@nibsc.hpa.org.uk • http://www.nibsc.ac.uk/flu_site/viruses_reagents.html • The candidate reassortant vaccine virus contains infectious materials and should be handled only in appropriate containment facilities (until completion of the above‐mentioned safety tests, it is recommended to use biosafety level 2 plus *BSL‐2 plus+ facilities with biosafety level 3 *BSL‐3+ practices)3 7/18/2009 334
    330. Performance Improvement for Irelands Vaccination Targets Guidance on Allocating and Targeting Pandemic Influenza Vaccine 7/18/2009 335
    331. US Example of Vaccination Target Groups • Vaccination target groups, estimated populations, and tiers for severe, moderate and less severe pandemics as defined by the Pandemic Severity Index (PSI) 7/18/2009 336
    332. US Example of Vaccination Tiers • Vaccination tiers and target groups for a severe pandemic 7/18/2009 337
    333. Vaccination Tiers and Targets Performance Improvement Summary • Dissemination of the Novel Influenza Vaccine is imperative and tiers and targets is an excellent example of the possible breakdown or needs assessment of high risk groups! • Incorporating the Empirical Model (HPA Model) and Pandemic Severity Index with also interrelating tiers and targets Irelands pandemic groups and committees have the potential to target vaccination groups effectively and assess future needs when the Influenza A(H1N1) vaccine becomes available in the Autumn! • Allocation of funds for the vaccine for Irelands population should be based upon a needs assessment and not only on general assumptions of clinical attack rates in the HPA model! • Cost-effective planning is essential during the economic times! • ? How much vaccine do you really need to pre-order keeping pandemic severity in mind? • Ireland Pre ordered 7.7 million influenza A(H1N1) vaccine dosages! • 2nd wave could mutate with resistance! Multi-dosages/Difficult to find the balance! • Proactive better than reactrve! Finding the balance Pandemic Severity Pandemic Influenza Preparedness for Ireland: Advice of the Pandemic Influenza Expert Group; Chapter 6 Public Health Population Vaccine Response: Vaccines First Vaccine Vial from Novartis 7/18/2009 338
    334. WHO “SAGE” Recommendations For Vaccine Distribution July, 7, 2009 • The following recommendations were provided to the WHO Director- General: A. All countries should immunize their health-care workers as a first priority to protect the essential health infrastructure ! – As vaccines available initially will not be sufficient, a step-wise approach to vaccinate particular groups may be considered. B. SAGE suggested the following groups for consideration, noting that countries need to determine their order of priority based on country-specific conditions: 1. Pregnant women 2. Those aged above 6 months with one of several chronic medical conditions 3. Healthy young adults of 15 to 49 years of age 4. Healthy children 5. Healthy adults of 50 to 64 years of age 6. Healthy adults of 65 years of age and above http://www.who.int/csr/diseas e/swineflu/notes/h1n1_vaccine 7/18/2009 _20090713/en/index.html 339
    335. Pandemic Influenza A(H1N1) 09 Virus Antiviral Medications 7/18/2009 340
    336. 7/18/2009 341
    337. Pandemic Influenza A(H1N1) 09 Virus Antiviral Purpose in Pandemics 7/18/2009 342
    338. Pandemic Influenza Expert Group (PIEG) On Antivirals • According to the Pandemic Influenza Expert Group (PIEG) • Treatment with NAI (within 48 hours) for seasonal influenza leads to reduction of: • 0.4 -1 days in duration of symptoms • 25-43% of complications requiring antibiotics • 55% in Lower Respiratory Tract Infections • 34% in need for antibiotics • 59% in hospitalisations • 44% in otitis in children 7/18/2009 343
    339. Pandemic Influenza A(H1N1) 09 Virus Antiviral Medications 2 Classes of Medications Available • M2 Inhibitors :Adamantanes – Amantadine, Rimantadine – Activity only against influenza A viruses • Neuraminidase inhibitors – Oseltamivir, Zanamivir. (Primivir experimental) – Activity against influenza A and B viruses Class Effective Against Drug Name (INN) Brand Name Year Approved Manufacturer M2 inhibitors Influenza A Amantadine Symmetrel 1976 Endo (adamantane Pharmaceuticals derivatives Rimantadine Flumadine 1994 Forest Laboratories Neuraminidase Influenza A & B Zanamivir Relenza 1999 GlaxoSmithKline inhibitors Hoffmann-La Oseltamivir Tamiflu 1999 Rochene 7/18/2009 344
    340. Pandemic Influenza A(H1N1) 09 Virus Antivirals Oseltamivir, Zanamivir • Chemically related • Different routes of administration – Oseltamivir (Tamiflu): Tablet, suspension – Zanamivir (Relenza): Orally inhaled powder • Mechanism of action: – Block active site of neuraminidase – Reduce the amount of viral particles released from infected cells • Decrease shedding of influenza A and influenza B viruses 7/18/2009 345
    341. Pandemic Influenza A(H1N1) 09 Virus Neuraminidase Inhibitor Resistance • Cross-resistance • Frequency – 5.5% in oseltamivir pediatric treatment study (U.S.) The Strategy for the – 18% in oseltamivir pediatric Control of treatment study (Japan) Antimicrobial Resistance in Ireland • Global Neuraminidase Inhibitor Susceptibility Network 7/18/2009 346
    342. Pandemic Influenza A(H1N1) 09 Virus Antivirals • Director Schuchat said that the virus was resistant to Amantadine and Rimantadine • Susceptible to Oseltamivir (Tamiflu) and Zanamivir (Relenza) OSELTAMIVIR (TAMIFLU) for the prevention of Influenza A (H1N1) 7/18/2009 347
    343. Pandemic Influenza A(H1N1) 09 Virus Antiviral Resistance • This Pandemic Influenza A(H1N1) 09 Virus is sensitive (susceptible) to the neuraminidase inhibitor antiviral medications zanamivir and oseltamivir. • It is resistant to the adamantane antiviral medications amantadine and rimantadine 7/18/2009 348
    344. Pandemic Influenza A(H1N1) 09 Virus Antiviral Resistance • The World Health Organization recently announced the identification of three persons with oseltamivir-resistant Pandemic Influenza A(H1N1) 09 Virus infection; all viruses had the same mutation that confers resistance, H274Y (H275Y in N2 numbering), in the neuraminidase protein. • On July 3, The Hong Kong Department of Health reported a resistant virus isolated from a 16 year-old girl who had a fever upon arrival at the Hong Kong International airport on June 11, 2009. Her symptoms began prior to boarding the plane in San Francisco, California. The patient had not taken antiviral agents and reported no illness among close contacts. • On July 2, 2009, a person infected with an oseltamivir-resistant novel influenza A (H1N1) virus was reported from Japan from an illness on May 15, 2009. This patient also became ill while receiving oseltamivir for chemoprophylaxis. • On June 29, 2009, the National Influenza Center in Denmark reported an oseltamivir-resistant novel influenza A (H1N1) virus from an unknown date. The virus was isolated from a patient who became ill while taking a chemoprophylaxis dose of oseltamivir to prevent influenza infection after exposure to an ill person. 7/18/2009 349
    345. Pandemic Influenza A(H1N1) 09 Virus Antiviral Resistance • The presence of the resistance marker and the phenotypic (in vitro) resistance was confirmed by a WHO collaborating centre, UK. – The virus is not a re-assortant and remains susceptible to zanamivir (another neuraminidase inhibitor) • HX of Neuraminidase segment gene (position 274 in N2 numbering system) – This mutation has been described in the past, associated http://www.ecdc.europa.eu/en/fil es/pdf/Health_topics/0907_Influe with so-called secondary resistance to oseltamivir acquired nza_AH1N1v_Resistance_TA_Oselt amivir.pd during treatment of both H1N1 and H5N1 virus infections 7/18/2009 350
    346. Pandemic Influenza Expert Group (PIEG) On Antivirals “ High Risk Groups” • Group 1: Treatment of persons hospitalised for influenza (if hospitalised within 48 hours of onset of symptoms). To be consistent with the goal of reducing morbidity and mortality and considering the optimal use of antiviral drugs in relation to onset of illness, those who are hospitalised within the first 48 hours of onset of illness should be highest priority for treatment. Treatment with oseltamivir may be considered in those who are hospitalised more than 48 hours after onset of symptoms, although its effectiveness in this situation is not established • Group 2: Treatment of ill health care and emergency services workers. Considering the essential role that health care workers and emergency service workers will have in the pandemic response, influenza infection in these groups, identified within the first 48 hours of onset of illness, should be high priority for treatment • Group 3: Treatment of ill high risk persons* in the community. Persons with underlying heart and lung conditions or those who are immunocompromised, and who present for medical care within 48 hours of onset of symptoms, will also be considered high priority for treatment since they are at high risk of complications • Group 4: Treatment of high risk residents of institutions (nursing homes and other chronic care facilities) to control outbreaks. Reducing the impact of influenza outbreaks in institutions where the most vulnerable persons reside will contribute to the objectives of reducing morbidity and mortality and reduce health care demands 7/18/2009 351
    347. Post Exposure Prophylaxis for Close Contacts • As of July, 16, 2009 • Post exposure prophylaxis is indicated for close contacts that fulfil all 3 criteria: 1. The contact is on treatment for asthma, is pregnant or is bariatric (obese) (BMI>40) 2. The contact was exposed to a probable or confirmed case during the period when the case was infectious i.e. 24 hours before onset of symptoms to 7 days after onset of symptoms contact’s last exposure occurred no more than 7 days previously 3. The contact’s last exposure was no more than 7 days ago http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/SwineInfluenza/AdviceforHeal thProfessionals/PublicHealth/Guidance/File,3809,en.pdf 7/18/2009 352
    348. Pandemic Influenza A(H1N1) 09 Virus Antiviral Treatment • Only 2 antiviral medications are equally efficacious when used for early treatment – Decrease the duration and symptoms of uncomplicated influenza by approximately 1 day – Decrease viral shedding • Early treatment with neuraminidase inhibitors can reduce some complications – Otitis media, lower respiratory tract complications, antibiotic use, hospitalizations 7/18/2009 353
    349. Pandemic Influenza A(H1N1) 09 Virus Antiviral Treatment • Suspected Cases • Empiric antiviral treatment is recommended for any ill person suspected to have Pandemic Influenza A(H1N1) 09 Virus ) infection • Antiviral treatment with either oseltamivir alone or with a combination of zanamivir should be initiated as soon as possible after the onset of symptoms • Recommended duration of treatment is five days. • Recommendations for use of antivirals may change as data on antiviral susceptibilities become available • Adults Antiviral doses and schedules recommended for treatment of Pandemic Influenza A(H1N1) 09 virus infection are the same as those recommended for seasonal influenza: Except for children! 7/18/2009 354
    350. Pandemic Influenza A(H1N1) 09 Virus Antiviral Treatment • Oseltamivir: ≥1 year; Zanamivir: ≥7 years – Dosage varies by age and weight • Early treatment of Swine influenza – Ideally, begin treatment within 48 hours of illness onset • Duration: 5 days • Antiviral treatment may be started at any time if patient is symptomatic, not just within 48 hours of onset of symptoms • “In January 2009, the European Commission granted a Commission Decision to a type II variation (II/61) to update of section 4.2 of the SPC to provide instructions on the extemporaneous preparation of liquid formulations of Tamiflu using the contents of the 30mg, 45mg and 75mg capsules. The rational for this extemporaneous solution is that Tamiflu powder for oral suspension was developed and is approved and commercialised in the EU for children above 1 year of age and adults who cannot swallow capsules. This formulation has a shelf life of 24 months and it is anticipated that limited availability of this formulation may occur specifically in emergency situations such as an influenza pandemic or more simply when supplies of the oral suspension are not available. Development activities were undertaken to explore the feasibility of preparing extemporaneous formulations at home by the patient, parent or guardian using readily available sweetened food products to mask the bitter taste of the capsule content. This type II variation (II/61) was submitted to provide instructions in the SPC and the PL on how this liquid extemporaneous preparation should be made using the 30 mg, 45 mg and 75 mg capsules of Tamiflu. • The CHMP is now working in close collaboration with the MAH (Roche) to give practical guidance on how Tamiflu can be dosed from this extemporaneous solution to be given to children less than 1 year of age. This practical guidance should soon be agreed and released.” • Cited from: FOLLOW-UP RECOMMENDATIONS FROM CHMP ON Novel Influenza (H1N1) outbreak Tamiflu (oseltamivir) Relenza (zanamivir) EMEA/H/A-5.3/1172 Article 5(3) of Regulation (EC) No 726/2004 http://www.emea.europa.eu/humandocs/PDFs/EPAR/tamiflu/32609509en.pdf 7/18/2009 355
    351. EMEA Dosing recommendations for antiviral chemoprophylaxis of children younger than 1 year using oseltamivir • Age Recommended prophylaxis dose for 10 days : • <3 months – Not recommended unless situation judged critical due to limited data on use in this age group • 3-5 months 20 mg once daily • 6-11 months 25 mg once daily • During a pandemic, if Tamiflu is http://www.emea.europa.eu/h umandocs/PDFs/EPAR/tamiflu/ prescribed to children under the age 32609509en.pdf of one, the recommended dosage is 2 to 3 mg per kg body weight • 7/18/2009 (EMEA May 8 report) 356
    352. Oseltamivir Tx for Ireland Treatment Schedule: Update June, 22, 2009 • Adults - The following actions commence on receipt of test result of a probable or confirmed case: – Chemoprophylaxis for close contacts as (1 course = 10 days) • Oseltamivir 75mg every 12 hours for 10 days – (Dose to be reduced by 50% if creatinine clearance is less than 30ml/minute i.e. 75mg od) Children Dose • Children Child aged >1yr; body weight Oseltamivir 2-3mg/kg twice daily for 5 days Pandemic Influenza Preparedness for Ireland: Child aged ≥1yr; body weight 15kg or Oseltamivir 30mg 12-hourly for 5 days Advice of the Pandemic lower Influenza Expert Group Chapter 9: Health system 16-23kg (3yr-<7yrs) Oseltamivir 45mg 12-hourly for 5 days response – clinical guidelines November 2008 23-40kg Oseltamivir 60mg 12-hourly for 5 days Child 40kg or over Oseltamivir 75mg 12 hourly for 5 days 7/18/2009 357
    353. Emergency Use Authorization of Tamiflu (Oseltamivir) In US • Oseltamivir is not licensed for use in children less than 1 year of age in US • If used Oral suspension 7/18/2009 358
    354. Tamiflu (Oseltamivir) Treatment for Pandemic Influenza A(H1N1) 09 Virus for Ireland Adult dose/ pregnancy and breastfeeding mothers • Treatment for acute illness: 75 mg PO bid for 5 days • Prophylaxis: 75 mg PO qd for 10 days – Paediatric dose (possible hospital admission) • Treatment for acute illness and age <1 year – 2 to 3 mg per kg once daily for 5 days • Treatment for acute illness and age >1 year – <15 kg: 30 mg PO bid for 5 days – 15-23 kg: 45 mg PO bid for 5 days – 23-40 kg: 60 mg PO bid for 5 days – >40 kg: Administer as in adults for 5 days • Prophylaxis and age <1 year – 2 to 3 mg per kg once daily for 10 days – <3 months: Data limited; not recommended unless situation judged critical Hospital admission encouraged • Prophylaxis and age >1 year – <15 kg: 30 mg PO once daily or 10 days – 15-23 kg: 45 mg PO once daily or 10 days – 23-40 kg: 60 mg PO once daily for 10 days – >40 kg: Administer as in adults for 10 days • There currently is no paediatric suspension available in Ireland • All paediatric dosages available in oral suspension and not to exceed 10 days 7/18/2009 • A supply of 75mg, 45mg and 30mg capsules is available 359
    355. Tamiflu (Oseltamivir) Resources • Tamiflu (oseltamivir) Tamiflu is taken by mouth. The European Medicines Agency (EMEA) has reviewed the use of Tamiflu (ostelamivir) . The Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that during the pandemic: – Tamiflu can be used in children younger than one year of age – Tamiflu can be used in women who are pregnant or breastfeeding • Tamiflu 75mg Capsule Summary of Product Characteristics Tamiflu 75mg Capsule Patient Information Leaflet Tamiflu Oral Suspension Summary of Product Characteristics Tamiflu Oral Suspension Patient Information Leaflet Tamiflu 30mg Hard Capsule Summary of Product Characteristics Tamiflu 45mg Hard Capsule Summary of Product Characteristics Tamiflu 30mg/45mg Hard Capsule Patient Information Leaflet 7/18/2009 360
    356. Pandemic Influenza A(H1N1) 09 Virus Oseltamivir (Tamiflu) Adverse Effects • Metabolized by liver, excreted in • Dosage reduction: urine – Kidney disease • Adverse effects • Severe Effects • Gastrointestinal (nausea, vomiting) Other side effects may include: • 1. Hallucinations • headache 2. Delusional behaviour 3. Loss of contact with reality • diarrhoea 4. Convulsions • nausea 5. Nausea and vomiting • vomiting 6. Psychosis • nasal irritation 7. Suicidal behaviour 8. Death of both adults and • bronchitis children • cough • sinus inflammation • ear, nose and throat infections • dizziness 7/18/2009 361
    357. Oseltamivir (Tamiflu) Children Dosing Fact Sheets 7/18/2009 362
    358. Oseltamivir (Tamiflu) Children Fact Sheets 7/18/2009 363
    359. Relenza (Zanamivir) Treatment for Pandemic Influenza A(H1N1) 09 Virus for Ireland – Adult dose , pregnancy and breastfeeding mothers • Treatment for acute illness: – 10 mg inhaled orally bid for 5 d • Prophylaxis of household contact: – 10 mg inhaled orally qd for 10 d (initiate within 48 hrs) • Prophylaxis for community outbreak: – 10 mg inhaled orally qd for 28 d (initiate within 5 d of outbreak) – Paediatric dose • Treatment for acute illness – <7 years: Not established – >7 years: Administer as in adults • Prophylaxis in household contact – <5 years: Not established – >5 years: Administer as in adults • Prophylaxis in community outbreak – Adolescents 12-16 years: Administer as in adults 7/18/2009 364
    360. Pandemic Influenza A(H1N1) 09 Virus Zanamivir (Relenza) Resources • Relenza - Summary of Product Characteristics (SmPCs) Relenza is taken by inhalation. The European Medicines Agency (EMEA) has reviewed the use of Relenza (zanamivir). The Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that during the pandemic:- - Relenza can be used in women who are pregnant or breastfeeding - Relenza inhalation powder Summary of Product Characteristics Relenza inhalation powder Patient Information Leaflet 7/18/2009 365
    361. Pandemic Influenza A(H1N1) 09 Virus Zanamivir (Relenza) Adverse Effects • Not metabolized, excreted – headache unchanged – diarrhea • Adverse effects – nausea – Gastrointestinal (nausea, – vomiting diarrhea) – nasal irritation – Headache – bronchitis – Cough (bronchospasm in – cough persons with pulmonary – sinus inflammation disease: not recommended – ear, nose and throat infections for persons with underlying pulmonary disease) • dizziness 7/18/2009 366
    362. Pandemic Influenza A(H1N1) 09 Virus Zanamivir (Relenza) 10 Steps • The Diskhaler has three parts: • Don’t take it apart until you have looked at the step-by-step guide • The Rotadisk fits into the Diskhaler • The Rotadisk fits onto the wheel of the Diskhaler • Each of the four blisters on the Rotadisk contains a single dose of Relenza 7/18/2009 367
    363. Pandemic Influenza A(H1N1) 09 Virus Zanamivir (Relenza) Application Steps 1 Remove the blue cover – Check that the mouthpiece is clean, inside and outside 2 Hold the white sliding tray as shown and pull it out until it stops 3 Gently squeeze the finger grips on the sides of the white tray. Remove the tray from the main body – The white tray should come out easily 4 Place a new Relenza Rotadisk on the wheel – Make sure the printed side is up, with the blisters facing downwards. The blisters fit into the holes in the wheel. 5. Push the white tray back into the main body If your not ready replace the blue cover 368 7/18/2009
    364. Pandemic Influenza A(H1N1) 09 Virus Zanamivir (Relenza) Application Steps 6. Hold the Diskhaler horizontally • To get your dose ready to inhale: • Do this just before you inhale a dose a) Flip the lid up as far as it will go b) The lid must be fully vertical, to make sure that the blister is pierced completely c) Push the lid back down. • Your Diskhaler is now ready for use. Keep it horizontal until you have inhaled your dose • Use diskhaler immediately after set up! 7/18/2009 369
    365. Pandemic Influenza A(H1N1) 09 Virus Zanamivir (Relenza) Application Steps 7. Don’t put the Diskhaler into your mouth yet Breathe out as far as is comfortable, keeping the Diskhaler away from your mouth – Don’t blow into the Diskhaler. If you do,you’ll blow the powder out of the Rotadisk • To prepare the next blister (the second part of your dose): 8. Pull the white tray out as far as it will go (don’t remove it completely), then push it back in again • This will turn the wheel so the next blister will appear – Repeat if necessary until a full blister is positioned under the piercing needle. – Repeat steps 6 and 7 to inhale the medicine. 9. After you’ve inhaled the full dose (normally two blisters): • Wipe the mouthpiece with a tissue and replace the blue cover. It’s important to keep the Diskhaler clean. • To replace the Rotadisk: 10. When all four blisters are empty, remove the Rotadisk from the Diskhaler and insert a new one, using steps 1 to 5. 7/18/2009 370
    366. Zanamivir (Relenza) Fact Sheets 7/18/2009 371
    367. Summary for Oseltamivir and Relenza Treatment for Pandemic Influenza A(H1N1) 09 Virus Final Draft for Ireland Oseltamivir Relenza – Adult dose/ pregnancy and breastfeeding mothers – Adult dose , pregnancy and breastfeeding mothers • Treatment for acute illness: 75 mg PO bid for 5 days • Prophylaxis: 75 mg PO once daily for 10 days • Treatment for acute illness: – Paediatric dose (possible hospital admission) – 10 mg inhaled orally bid for 5 d • Treatment for acute illness and age <1 year • Prophylaxis of household contact: – 2 to 3 mg per kg once daily for 5 days – 10 mg inhaled orally qd for 10 d (initiate within 48 hrs) • Treatment for acute illness and age >1 year • Prophylaxis for community outbreak: – <15 kg: 30 mg PO bid for 5 days – 10 mg inhaled orally qd for 28 d (initiate within 5 d of – 15-23 kg: 45 mg PO bid for 5 days outbreak) – 23-40 kg: 60 mg PO bid for 5 days – >40 kg: Administer as in adults for 5 days – Paediatric dose • Prophylaxis and age <1 year • Treatment for acute illness – 2 to 3 mg per kg once daily for 10 days – <3 months: Data limited; not recommended unless – <7 years: Not established situation judged critical Hospital admission – >7 years: Administer as in adults encouraged • Prophylaxis and age >1 year • Prophylaxis in household contact – <15 kg: 30 mg PO once daily or 10 days – <5 years: Not established – 15-23 kg: 45 mg PO once daily or 10 days – 23-40 kg: 60 mg PO once daily for 10 days – >5 years: Administer as in adults – >40 kg: Administer as in adults for 10 days • Prophylaxis in community outbreak – Adolescents 12-16 years: Administer as in • There currently is no paediatric suspension available in adults Ireland • All paediatric dosages not to exceed 10 days • A supply of 75mg, 45mg and 30mg capsules is available EMEA and Roche have reviewed regimes for children, pregnancy, and breastfeeding mothers! 7/18/2009 372
    368. Tamiflu (Oseltamivir) Liquid Extemporaneous Preparation • Extemporaneous Preparation: • When Tamiflu solution is not available capsules can be opened and placed in bowl with additives • Roche has provided guidelines for the extemporaneous preparation and consumption of 7/18/2009 373
    369. Guidelines for Reporting Suspected Adverse Reactions to Antiviral Medicines an Influenza Pandemic “Pharmacovigilance” • How to report? The most efficient way to report adverse reactions to the IMB in a pandemic situation is via our online reporting system at www.imb.ie 1. On-line at www.imb.ie and follow the links to ‘On-line Reporting’ to complete a Human Medicines Adverse Reaction Report 2. ‘Freepost system’ – Adverse Reaction Report Forms (yellow cards) can be obtained directly from the Pharmacovigilance Unit of the IMB or downloaded from the website under the ‘Publications section’. A supply of yellow cards/Adverse Reaction Report Forms may be requested by telephoning the Pharmacovigilance Unit of the IMB at 01-676 4971 7/18/2009 374
    370. Guidelines for Reporting Suspected Adverse Reactions to Antiviral Medicines during Influenza Pandemic “Pharmacovigilance” Yellow card Pharmacovigilance Section, Irish Medicines Board, ) Kevin O'Malley House, Earlsfort Centre, Filled out by Public Health Earlsfort Terrace, Dublin 2, Ireland. Tel :353-1-676 4971 Fax: 353-1-634 3514 Email: 375 imbpharmacovigilance@imb.ie 7/18/2009
    371. Pandemic Influenza A(H1N1) 09 Virus Special Considerations for Children • Aspirin or aspirin-containing products (e.g. bismuth subsalicylate – Pepto Bismol) should not be administered to any confirmed or suspected ill case of Pandemic Influenza A(H1N1) 09 Virus infection aged 18 years old and younger due to the risk of Reye syndrome • For relief of fever, other anti-pyretic medications are recommended such as acetaminophen or non steroidal anti- inflammatory drugs • Long term aspirin use in children >14 years old are considered in the high risk category for antivirals 7/18/2009 376
    372. Pandemic Influenza A(H1N1) 09 Virus Antivirals “Pregnant Women” • Oseltamivir, zanamivir, amantadine, and rimantadine are all “Pregnancy Category C" medications, indicating that no clinical studies have been conducted to assess the safety of these medications for pregnant women • EU: Following a review of the available data for Tamiflu and Relenza, the CHMP concluded that the benefits of using these medicines in pregnant or breastfeeding women outweigh the risks in case of an Pandemic Influenza A(H1N1) 09 Virus pandemic • At present, the groups identified at higher risk of influenza- related complications from seasonal influenza and the H1N1 2009 include pregnant women in their second and especially the third trimester and women within four weeks post- partum. • Experience with past pandemics demonstrates they can be affected disproportionately compared to non-pregnant women • Currently, little is known about whether influenza viruses are transmitted to the foetus through the placenta, although this class of viruses is not considered to be teratogenic in humans 7/18/2009 377
    373. Pandemic Influenza A(H1N1) 09 Virus Irelands National Antiviral Stockpile (INAS) • Mobilization plans to be Irish Alert Level Description tested for National Stock Pile Irish Alert Level 1 Cases only outside Ireland (in during this Pandemic a country or Influenza A(H1N1) 09 Virus countries with or outbreak if the Irish Alert without extensive Irish travel/trade Level Hits 2 links • Surveillance and monitoring Irish Alert Level 2 New virus isolated must be In place for future in Ireland exercise improvements for Irish Alert Level 3 Outbreak(s) in Ireland mobilizations of Irelands Irish Alert Level 4 Widespread National Antiviral Stockpile activity in Ireland Alert levels will increase in Phase 6 declaration by WHO 7/18/2009 378
    374. Pandemic Influenza Expert Group (PIEG) On Antivirals Irelands National Antiviral Stockpile • One million treatment packs of Oseltamivir (Tamiflu) are stockpiled • This quantity is sufficient to treat 47% of the population and is over international trends • 63kg of the API has also been purchased – Active Pharmaceutical Ingredient (API), oseltamivir phosphate powder, should be purchased to treat young children between the ages of one and five years – Arrangements have been put in place so that API powder will be converted to paediatric capsules, which will be used for all children aged one to 11 years of age • 706,000 packs of zanamivir (Relenza) have now been ordered • This is sufficient to cover 20% of the population over the age of seven • 500,000 surgical masks, five million pairs of disposable gloves and 150,000 surgical gowns for health care providers 7/18/2009 379
    375. Pandemic Influenza A(H1N1) 09 Virus WHO Country Antiviral Distribution Plan 6 May 2009 • WHO headquarters stocks distributed to – – Honduras Indonesia countries. Regional stock distribution is – Kenya not included here so this is not the full list of – – Kiribati Kyrgyzstan countries receiving antivirals from WHO – Lao People's Democratic Republic globally – – Lesotho Liberia – Afghanistan – Madagascar – Angola – Malawi – Armenia – Mali – Azerbaijan – Mauritania – Bangladesh – Benin – Mexico – Bhutan – Mongolia – Bolivia – Mozambique – Burkina Faso – Myanmar – Burundi – Nepal – Cambodia – Nicaragua – Cameroon – Niger – Central African Republic – Nigeria WHO/Tom Moran – Chad – Pakistan – Comoros – Papua New Guinea WHO staff prepare boxes of – Congo – Republic of Moldova antiviral drugs for countries – Cote d´Ivoire – Rwanda – Cuba – Sao Tome and Principe May 8 2009 – Democratic People's Republic of Korea – Senegal – Democratic Republic of the Congo – Sierra Leone – Democratic Republic of Timor-Leste – Solomon Islands – Djibouti – Somalia – Eritrea – Sri Lanka – Ethiopia – Sudan – Gambia – Georgia – Tajikistan – Ghana – Togo – Guinea – Uganda – Guinea-Bissau – Ukraine – Guyana – United Republic of Tanzania – Haiti – Uzbekistan – Viet Nam 380 7/18/2009 – Yemen – Zambia – Zimbabwe
    376. Typical Antiviral Clinic Process Flow Chart Queue Medical Assessment (screeners) Antivirals/ Contraindication Require Antiviral Triage Vaccination (to EXIT) Med Consult Home, hosp, MD Antiviral/Vaccination Area Medical Orientation Post Antiviral/Vaccination Evaluation and Education Education Form collection EXIT Registration 381 7/18/2009
    377. Performance Improvement for Irelands Antiviral Tiers and Targets • According to ECDC : An important general principle is that having stockpiles is of limited use without the agreed objectives, protocols, administration and delivery systems to accompany them. Good resource! Finding the balance Delaying the Pandemic Population Antiviral Stockpiling (Clinical Attack Rate) Interim guidance: Public health use of influenza antivirals during influenza pandemics 7/18/2009 382
    378. Guidance for Pharmacy Staff Pandemic Influenza A(H1N1) 09 Virus • Full Tamiflu info @ http://www.emea.europa.eu/humandocs/PDFs/EPAR/tamiflu/H-402-PI-en.pdf 7/18/2009 384
    379. Pandemic Influenza A(H1N1) 09 Virus Standard Precautions • Health Protection Surveillance Centre 25-27 Middle Gardiner St Dublin 1, Ireland. t: +353 1 8765300 f: +353 1 8561299 e: hpsc@hse.ie • See Website for download for clinicians 7/18/2009 385
    380. Pandemic Influenza A(H1N1) 09 Virus Irish Universal Respiratory Hygiene • Pandemic Influenza Preparedness for Ireland: Advice of the Pandemic Influenza Expert Group • The following are components of a universal respiratory hygiene strategy to be adopted in all health care facilities • Read in Narration! Breaking the Chain of Infection 7/18/2009 386
    381. Pandemic Influenza A(H1N1) 09 Virus Transmission-Based Precautions • Contact Precautions • Contact precautions should be applied in addition to Standard Precautions to prevent transmission of highly transmissible organisms that are transmitted from person to person via the contact route (e.g. Methicillin resistant Staphylococcus aureus) • Airborne Precautions • Airborne Precautions should be applied, in addition to Standard Precautions, to prevent transmission of highly transmissible organisms that are transmitted via the air from one person to another (e.g. Tuberculosis) • Droplet Precautions • Droplet Precautions should be applied, in addition to Standard Precautions, to prevent transmission of highly transmissible organisms that are transmitted via respiratory secretions from one person to another (e.g. Influenza) 7/18/2009 387
    382. Pandemic Influenza A(H1N1) 09 Virus YOUR 4 MOMENTS FOR HAND HYGIENE 1. Clean your hands when(Canadian) 2, Clean your hands entering before touching the patient or any object or immediately before any furniture in the patient’s aseptic procedure. environment. To protect the patient To protect the patient/ patient against harmful organisms, environment from harmful including the patient’s own organisms carried on your organisms, entering his or hands her body. 4. Clean your hands when 3. Clean your hands leaving after touching immediately after an patient or any object or exposure risk to body fluids furniture in the patient’s (and after glove removal). environment. To protect yourself and the To protect yourself and the health care environment from health care environment harmful patient organisms. from harmful patient See WHO Hygiene Protocol organisms witch has 5 Steps Irish has 6 Steps 7/18/2009 388
    383. The “My 5 Moments for Hand Hygiene” Approach (WHO) 7/18/2009 389
    384. 6 Step Irish Hygiene Protocol • Ireland In 2006-7, Ireland organised a national campaign called ‘Clean Hands Save Lives’. • Same as the following! • All have 6 Steps in essence! A doctor checks patients presenting symptoms of the swine flu virus, now named influenza A(H1N1), kept in isolation at the National Institute of Respiratory Diseases (INER) in Mexico City on May 5, 2009. (LUIS ACOSTA/AFP/Getty Images) 7/18/2009 390
    385. Guidelines for Hand Hygiene in Irish Health Care Settings • Audit: In 2008 (Q1-3) the median rate of alcohol hand rub consumption increased to 17.9 litres per 1,000 bed-days used, from 10.5 and 15.0 in 2006 and 2007 respectively This represents a 19.3% increase since 2007 Good Resource 7/18/2009 391
    386. Performance Improvement Pandemic Planning “Hand Washing” • Author promotes this hand wash technique with incorporating times/wash • 20-30 seconds for non-soiled hands • 60 seconds for visibly soiled hands 7/18/2009 392
    387. Pandemic Influenza A(H1N1) 09 Virus “Protocol for Surveillance of Influenza-like Illness in Healthcare Workers during Pandemic Influenza A(H1N1)v “Mitigation Phase” • Health Protection Surveillance Centre 25-27 Middle Gardiner St Dublin 1, Ireland. t: +353 1 8765300 f: +353 1 8561299 e: hpsc@hse.ie • See Website for download for clinicians or this hyperlink http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/SwineInfluenza/A dviceforHealthProfessionals/OccupationalHealthProfessionals/File ,3638,en.pdf According to HPSC these two protocols are to be read in conjunction so the following slides have been compared and contrasted accordingly! 7/18/2009 393
    388. Pandemic Influenza A(H1N1) 09 Virus Protocol for Surveillance of Influenza-like Illness in Healthcare Workers during Pandemic Phase 5 or Greater Containment Phase • Health Protection Surveillance Centre 25-27 Middle Gardiner St Dublin 1, Ireland. t: +353 1 8765300 f: +353 1 8561299 e: hpsc@hse.ie • See Website for download for clinicians or this hyperlink http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/SwineInflue nza/AdviceforHealthProfessionals/HospitalClinicians/ According to HPSC these two protocols are to be read in conjunction so the following slides have been compared and contrasted accordingly! 7/18/2009 394
    389. Pandemic Influenza A(H1N1) 09 Virus Surveillance of Healthcare Workers • Healthcare worker (HCW) • Porters includes: • Domestic staff • Hospital clinician teams • Receptionists • General practitioners • Administration staff • Nurses • Ambulance staff • Laboratory scientists • Mortuary workers • Physiotherapists and other allied health professional • Healthcare students • Health volunteers and community health workers Safety, Health and Welfare at Work Act 2005 7/18/2009 395
    390. Healthcare Workers with Probable Pandemic Influenza A(H1N1) 09 Virus • Unusual clusters or syndromes • If there are unusual clusters of disease or syndromes among HCWs – The DPH/MOH will immediately inform HPSC of any unusual clusters of disease or syndromes among Healthcare workers July ,16 , 2009 update “WHO” Definition of a healthcare cluster: A cluster is defined as two or more healthcare workers in the same healthcare facility/unit with unexplained acute respiratory illness and with fever ≥38°C, or with severe lower respiratory tract infection or pneumonia, and with onset of illness within a period of 14 days of each other. 7/18/2009 396
    391. Pandemic Influenza A(H1N1) 09 Virus Surveillance of Healthcare Workers Clinical criteria • Acute onset of fever (temperature > 38 °C or history of fever and two or more of the following: Containment Phase Mitigation Phase • Cough • Sore throat • Myalgia • Headache • Rhinorrhea • Vomiting/Diarrhoea • Pneumonia • Influenza-like Illness (ILI) HPSC June ,26, 2009 HPSC July ,16, 2009 • Acute Febrile respiratory illness (AFRI) • Acute respiratory illness with suspected/probable pneumonia (ARI) 7/18/2009 397
    392. Comparison of Community and Healthcare Cluster Definitions Definition Community Surveillance Definition of a healthcare cluster of Clusters/Outbreaks (World Health Organization) • Influenza-like illness (ILI) - • A cluster is defined as two or definition for interim surveillance more healthcare workers in the of clusters/outbreaks same healthcare facility/unit with • Three or more cases of ILI arising within the same 72 hour period unexplained acute respiratory which meet the same clinical case illness and with fever ≥38°C, or definition and where an with severe lower respiratory epidemiological link can be tract infection or pneumonia, and established with onset of illness within a • ILI symptoms include: – Acute onset of fever (temperature period of 14 days of each other ≥38°C) – OR history of fever – AND flu-like illness (two or more of the following symptoms: cough, sore throat, myalgia, headache, rhinorrhea or vomiting/diarrhoea) 7/18/2009 398
    393. Pandemic Influenza A(H1N1) 09 Virus Stage 2: Algorithm for the Management of Persons with Acute Febrile Respiratory Illness who may have influenza A(H1N1)v 1. Patient with sudden onset (developing in <6 hours) influenza‐like illness: • Fever *pyrexia ≥38°C] or a history of fever, AND • TWO OR MORE of the following: – cough; sore throat; rhinorrhoea; limb or joint pain; headache; vomiting or diarrhoea OR • Severe/ life‐threatening illness likely to have a infectious cause (pre-exsisting co-morbid conditions) 2. “Patient has a close household contact who is on treatment for asthma, is pregnant or is severely obese (BMI >40) 3. Test: Take nose and throat viral swabs • Treat: Begin antivirals as soon as possible • Chemoprophylaxis for close household contacts who are on treatment for asthma, is pregnant or is severely obese (BMI >40), where the index case is lab confirmed 7/18/2009 399
    394. Healthcare Workers with Probable Pandemic Influenza A(H1N1) 09 Virus • Report to occupational health department • The relevant line manager should notify the occupational health department: • If there is an apparent increase in absenteeism rates among a particular group of HCWs or in a particular area • If there is an apparent cluster of acute respiratory illness among a particular group of HCWs or in a particular area • If a HCW becomes ill with a severe lower respiratory tract infection or pneumonia • In institutions where there is no Occupational Health Physician, the General Manager will consult with the Chair of the Medical Executive to assign this role to a suitable doctor. See also Supplement 10, Guidance for Pandemic Influenza: Infection Control in Hospitals, Community and Primary Care Settings available at: • http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/Guidance/PandemicInfluenzaPrepared nessforIreland/ 7/18/2009 400
    395. Healthcare Workers with Probable Pandemic Influenza A(H1N1) 09 Virus • Single cases • If a HCW is admitted to hospital with respiratory symptoms of ILI (Influenza-like-Illness), AFRI (acute febrile respiratory illness) or severe lower respiratory illness/pneumonia and they have at least one of the following in the seven days before disease onset: – Been a close contact of a confirmed case of Pandemic Influenza A(H1N1) 09 Virus infection while the case was ill – Have travelled to an area where sustained human-to- human transmission of Pandemic Influenza A(H1N1) 09 Virus is documented – Worked in a laboratory – Are within the defined risk groups that includes pregnant women, people on medication for asthma, and bariatric (obese) individuals with a BMI ≥40 Update June 11 2009 http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianP andemicInfluenza/SwineInflu enza/AdviceforHealthProfessi onals/GPs/File,3724,en.pdf 7/18/2009 401
    396. Healthcare Workers with Probable Pandemic Influenza A(H1N1) 09 Virus Occupational Health Role • If a HCW has been involved in caring for or examining a symptomatic patient with Pandemic Influenza A(H1N1) 09 Virus infection the following actions should be taken: • 1.Inform the regional DPH/MOH if the HCW provided direct clinical or personal care or examined the symptomatic patient without appropriate Personal Protective Equipment (PPE). Discuss contact management with DPH/MOH • 2.For HCWs who are defined in the high risk category or and did not wear PPE* while caring for symptomatic patient: – Institute post-exposure prophylaxis with oseltamivir (Tamiflu) as soon as possible unless more than 7 days have elapsed since the last exposure. The dose of oseltamivir is 75mg daily for 10 days following last exposure • 3.Provide all HCW contacts with clear public health recommendations and information on Pandemic Influenza A(H1N1) 09 Virus (available at www.hpsc.ie/hpsc/) 7/18/2009 402
    397. Healthcare Workers with Probable Pandemic Influenza A(H1N1) 09 Virus Occupational Health Role • 4. Request that any febrile respiratory or other unexplained illness within 7 days of last contact be reported • 5. If the HCW contact becomes unwell they should be investigated and treated by there GP and occupational health (liaise with DPH/MOH) • They should also be advised to discontinue work immediately and upon return be medically cleared • 6. Advise all contacts to strictly adhere to all infection control and prevention precautions as follows: – Avoid touching their faces, including their eyes and nose and mouth with their hands – Wash hands frequently. This means washing with soap and running water for a minimum of 15-30 seconds or the use of an alcohol-based hand sanitiser (minimum 60% alcohol) if the hands are not visibly soiled – If visible soiled use WHO guidance for visible soiled hand wash technique (60 seconds/hand wash) – Cover their mouth with a tissue when they cough and/sneeze, and dispose carefully in a bin afterwards 7/18/2009 403
    398. Pandemic Influenza A(H1N1) 09 Virus Infection Control In Health Care Setting • For visible soiled hands WHO recommends the following technique 7/18/2009 404
    399. Healthcare Workers with Probable Pandemic Influenza A(H1N1) 09 Virus Occupational Health Role Update June, 11, 2009 • “Close contacts in the health care setting are defined as: health or social care workers who provided direct clinical or personal care or who examined a symptomatic patient (including taking nasal and throat swabs for viral testing) without wearing appropriate personal protective equipment (PPE) for Standard, Droplet and Contact Precautions: – Routine care (including taking nasal and throat viral swabs): surgical mask, gloves, plastic apron (and goggles if risk of splashing or spraying) – Aerosol generating procedures: FFP2 or FFP3 masks, goggles, long-sleeved gown and gloves. – Failure to implement hand hygiene following contact with contaminated surfaces or after removing PPE is also considered to pose risk of infection. – Casual contact with the ill person for example, passing them in the corridor at work or waving to them etc. does not mean you are a contact and does not require any further action. • The following groups of healthcare workers caring for patients with probable/confirmed Pandemic Influenza A(H1N1) 09 Virus ) will require a risk assessment and consideration of chemoprophylaxis: – Healthcare workers who have not worn appropriate PPE – Healthcare workers who have worn PPE without formal fit testing – Healthcare workers who have worn surgical masks but who have been unwittingly exposed to patient generated aerosols” 7/18/2009 Cited from HPSC 405
    400. Healthcare Workers with Probable Pandemic Influenza A(H1N1) 09 Virus Surveillance • The Occupational Health team (or as per local arrangements) will inform Public Health about details of contacts • A Public Health Doctor will contact you to ask you a number of questions about your health and the amount / type of contact which you had with the sick person, and will advise on what precautions you need to take • In hospitals, where there is an Occupational Health Department, this will be carried out by Occupational Health staff 7/18/2009 406
    401. Healthcare Workers with Probable Pandemic Influenza A(H1N1) 09 Virus Surveillance • Health or social care workers who provided direct clinical/personal care or who or who examined a symptomatic patient without wearing appropriate PPE** – Those who were wearing appropriate PPE should self monitor for one week and report symptoms as explained in Public Health Management of Contacts PEP Phase 6 Update June, 22, 2009 7/18/2009 407
    402. Healthcare Workers with Probable Pandemic Influenza A(H1N1) 09 Virus Surveillance • All healthcare workers at this time should be self monitoring for flu- like symptoms and should report the development of same to their line manager promptly • HCW contacts of suspected or Pandemic Influenza A(H1N1) 09 Virus should check their temperature twice a day and look out for flu-like symptoms for a period of 7 days: – Fever (38.0°C or 100.4 °F or higher) – Flu like symptoms (cough, runny nose, sore throat, headache or aches and pains) – Diarrhoea, vomiting • Please report the development of any flu like symptoms to public health staff and to your line manager promptly • You will also be asked to contact Occupational Health and referred to your GP or emergency department physician 7/18/2009 408
    403. Healthcare Workers “Fitness for Work” Occupational Health Role • Fitness for Work • Occupational health advice on fitness for work (or on the need for work restrictions at a given time) should be sought by: • Healthcare workers who develop symptoms of ILI (Influenza Like Illness), who should report to their line manager in the first instance • Healthcare workers recovering from ILI • Healthcare workers who have been in unprotected contact with suspect or confirmed cases of ILI (either in the community or at work) • Healthcare workers who have been prescribed antiviral therapy by their GP or a Public Health Doctor • Healthcare workers who have pre-existing medical conditions which might increase their risk of severe influenza complications • Pregnant healthcare workers • Healthcare workers who cannot achieve an adequate ‘seal’ with the PPE provided by their employer 7/18/2009 409
    404. Pandemic (H1N1) 2009 Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic (H1N1) 2009 Virus http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/SwineInfluenza/ AdviceforHealthProfessionals/InfectionControl/File,3628,en.pdf 7/18/2009 410
    405. Pandemic Influenza A(H1N1) 09 Virus Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic Influenza A(H1N1) 09 Virus • Standard Precautions require all HCWs to: • Standard Precautions must be applied by all HCWs to the care of all patients/clients in all healthcare settings regardless of the suspected or confirmed presence of an infectious agent. – Occupational health programme – Appropriate patient placement – Hand hygiene – Patient movement and transfer – Respiratory hygiene and cough etiquette – Use of personal protective equipment (PPE) – Decontamination of the environment – Decontamination of reusable medical equipment – Management of linen and laundry – Management of needle stick injuries – Management of waste – Management of spillages of blood and body fluids – Safe injection practices – Management of sharps 7/18/2009 411
    406. Pandemic Influenza A(H1N1) 09 Virus Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic Influenza A(H1N1) 09 Virus Key Components PRECAUTIONS Key Elements of Clinical Practices and Measures 2.2 Occupational Health Programme Standard Precautions  HCWs should self monitor their own health for influenza like symptoms  HCWs with symptoms should not attend work and should immediately report symptoms to their line manager 2.3 Patient Placement Standard Precautions Home  Assess the patient with suspected or confirmed influenza A(H1N1) by phone at home if possible  GP/Primary care/Community Droplet Precautions  Place in a single room and avoid communal areas if possible. Otherwise do not place within approximately 1 metre of other patients Contact Precautions Hospital  Place patient with suspected or confirmed influenza A(H1N1) in a single room preferably with ante room and en-suite facilities  Emergency departments without single rooms must have interim arrangements in place to prioritise transfer to an appropriate single room  Avoid communal areas and placing patient within approximately 1 metre of other patients Ambulance Refer to ambulance advice document 2.4 Hand Hygiene Standard Precautions Hand hygiene using liquid soap or alcohol hand gel/rub must be performed before and after all patient care procedures 2.5 Patient Movement and Transfer Standard Precautions External transfer Patient should wear a surgical mask outside their room It is the responsibility of the transferring facility to inform staff of the precautions required Droplet Precautions  Refer to ambulance advice document Contact Precautions Internal transfer  Minimise movement of patient from single room  Patient should wear a surgical mask outside their room  Staff should be informed of the precautions required in the receiving departments (e.g. diagnostic departments)  Avoid holding patients in communal areas (radiology etc)  HCW PPE: Wear a surgical mask and observe hand hygiene 7/18/2009 412
    407. Pandemic Influenza A(H1N1) 09 Virus Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic Influenza A(H1N1) 09 Virus Key Components PRECAUTIONS Key Elements of Clinical Practices and Measures 2.6 Respiratory Hygiene & Cough Standard Precautions As per Standard Precautions patients presenting with signs and symptoms of undiagnosed respiratory infections should be Etiquette  Identified promptly in primary care and emergency departments  Offered masks (and other symptomatic persons e.g., persons who accompany ill patients should also be offered masks) Droplet Precautions  Encouraged to maintain spatial separation, ideally a distance of approximately 1 meter, from others in common waiting areas Emergency departments and primary care facilities should:  Ensure that supplies of tissues, foot operating waste bins and hand hygiene facilities are available in all departments including waiting areas throughout the facility  Educate patients/visitors/carers on Respiratory Etiquette and Cough Hygiene using some or all of the following:  Patient information leaflets  Posters in all departments especially waiting areas  If influenza A(H1N1) is suspected place patient & persons who accompany ill patients in a single room  See Appendix A for respiratory hygiene and cough etiquette poster. The poster can be downloaded from the following website •http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenza/SwineInfluenza/AdvicefortheGeneralPublic/RespiratoryHygiene/ 7/18/2009 413
    408. Pandemic Influenza A(H1N1) 09 Virus Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic Influenza A(H1N1) 09 Virus Key Components PRECAUTIONS Key Elements of Clinical Practices and Measures 2.7 Personal Standard Precautions The following applies to all settings: Protective Droplet Precautions GP/Primary care/Ambulance transfer/Hospital Equipment Contact Precautions Patient should wear: (PPE)  A surgical mask when outside their single room HCWs must wear the following for: 1. Routine care  Surgical mask, Plastic Apron/Gown, Gloves (& Goggles if splashing/spraying risk) 2. Aerosol Generating Procedures  FFP2 or FFP3 mask (correctly fitted), Goggles, Long sleeved disposable gown, Gloves Refer to Aerosol Generating Procedures document and to PPE poster Masks  Change mask if it becomes damp, wet or torn  Change and discard mask when leaving the room or patient care area HCW’s when putting on and removing PPE must :  Put on and remove in the correct sequence (refer to PPE poster)  Remove gloves & apron/gown inside the single room  Remove mask in the ante room or immediately outside the single room if there is no ante room. Ensure door is closed.  Decontaminate hands immediately after removing PPE 7/18/2009 414
    409. Pandemic Influenza A(H1N1) 09 Virus Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic Influenza A(H1N1) 09 Virus Key Components PRECAUTIONS Key Elements of Clinical Practices and Measures 2.8 Environmental Decontamination Standard Precautions In addition to Standard Precautions: Only take essential equipment and supplies into the room. Droplet Precautions  Do not stockpile as unused stock will have to be discarded on cessation of additional precautions  Patient charts/records should not be taken into the single room Contact Precautions  The frequency and intensity of cleaning may need to be increased based on the patients level of hygiene and the level of environmental contamination  HCW’s must wear surgical mask, gloves, apron for cleaning the patients room  Thoroughly clean the environment and furniture and all patient care equipment daily with a neutral detergent and disinfectant (hypochlorite solution 1000 ppm) paying special attention to frequently touched sites and equipment close to the patient  On patient discharge/transfer cleaning and disinfection of the environment  Prior to initiating environmental cleaning and disinfection, all privacy, shower and window curtains must be removed and sent for laundering All disposable items including paper towels and toilet paper should be discarded All sterile and non-sterile supplies in the patient room to be discarded on patient transfer/discharge Dishes and Eating Utensils  Treatment rooms (e.g., x-ray etc)  Clean and disinfect the environment and furniture after use with a neutral detergent and disinfectant (hypochlorite solution 1000 ppm) paying special attention to frequently touched sites (door handles, bed rails etc)  Medical equipment (refer to 2.9)  Cutlery and crockery - No additional measures are required for cutlery and crockery washed in a dishwasher or wash with liquid detergent and water 2.9 Patient Care Equipment & Standard Precautions In addition to Standard Precautions: Decontamination of Medical Devices  Dedicate patient care medical devices (e.g., thermometers, sphygmomanometers, stethoscopes, glucometers) to single Droplet Precautions patient use  Use disposable equipment whenever possible Contact Precautions  Manufacturer’s instructions should be followed for cleaning and disinfecting of reusable medical equipment after use  Single use items should be disposed of after use  Bedpan/Commodes  Use a working washer disinfector at 80°C for one minute  Dedicate a commode to single patient use if no en suite available  Decontaminate commode surface after each patient use with a hypochlorite solution 1000 ppm 7/18/2009 415
    410. Pandemic Influenza A(H1N1) 09 Virus Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic Influenza A(H1N1) 09 Virus Key Components STANDARD Key Elements of Clinical Practices and Measures PRECAUTIONS 2.10 Linen/Laundry Standard Precautions  No additional precautions necessary  As per Standard Precautions all contaminated laundry should be carefully placed in an alginate stitched or water soluble bag and then placed into a laundry bag clearly identified with labels, colour-coding or other methods prior to transport to an approved laundry capable of dealing with contaminated linen 2.11 Management of needle stick injuries (NSI) and Standard Precautions  No additional precautions necessary blood and body fluid exposure 2.12 Management Standard Precautions  No additional precautions necessary for Non Healthcare Risk and Healthcare Risk Waste of Waste  Dispose of all PPE as Healthcare Risk Waste (e.g. used masks) 2.13 Management spillages of blood and body fluids Standard Precautions  No additional precautions necessary 2.14 Safe Injection Practices Standard Precautions  No additional precautions necessary 2.15 Management of sharps Standard Precautions  No additional precautions necessary 7/18/2009 416
    411. Pandemic Influenza A(H1N1) 09 Virus HealthCare Environmental Waste • In aerosol generating activities (e.g., collection of clinical specimens, endotracheal intubation, nebulizer treatment, bronchoscopy, and resuscitation involving emergency intubation or cardiac pulmonary resuscitation) SOP must be in place • Appropriate disinfectants – 70% Ethanol – 5% Lysol – 10% Bleach http://www.hpsc.ie/hpsc/A- Z/EmergencyPlanning/AvianPandemicInfluenz a/SwineInfluenza/AdviceforHealthProfessiona ls/InfectionControl/File,3625,en.pdf • According to PIEG: Commonly used surfaces such as door handles, handrails, table surfaces etc. should be cleaned first and then disinfected with a chlorine releasing disinfectant (1000 ppm) twice daily. 7/18/2009 420
    412. Aerosol Generating Procedures (AGP) According to WHO • Aerosol generating procedures: • Nebulisation • Intubation and related • Non-invasive positive procedures, e.g. manual pressure ventilation ventilation • Bi-level positive airway • Respiratory and airway suctioning pressure (BiPAP) ,CPAP,NIV (including tracheostomy care) • High frequency oscillating • Nasopharyngeal aspiration ventilation • Cardiopulmonary resuscitation • Bronchoscopy • Nasopharyngeal aspirate • Transtracheal aspirate • Broncheo-alveolar lavage • Biopsy of lung or tracheal tissues • Autopsy procedures – i.e.. (Oscillating saws) Documented transmission Non- documented transmission 7/18/2009 421
    413. Recommended Initial PPE Protection Levels AGENT CATEGORY MINIMUM LEVEL OF PROTECTION UNKNOWN LEVEL A NERVE LEVEL A(1) BLISTER LEVEL A(2) BLOOD LEVEL B(3) CHOKING LEVEL B(3) BIOLOGICAL High Efficiency Particulate Air FILTER w/LEVEL C RADIOLOGICAL High Efficiency Particulate Air FILTER w/LEVEL C (1) High concentrations may result in nerve agent poisoning (2) Sufficient vapor will cause blisters (3) Level A may be required in an enclosed area 7/18/2009 422
    414. Pandemic Influenza A(H1N1) 09 Virus Personal Protective Equipment PPE • PPE = Personal Protective Equipment • PPP = Personal Protective Practices • PPE + PPP = Prevention Personal Protection is not just “personal”: It is also about preventing spread of disease to others! 7/18/2009 423
    415. Pandemic Influenza A(H1N1) 09 Virus Personal Protective Equipment PPE • Avian flu indicated that using a face mask with a rating of N99, N100 or P100 in the United States • A rating of FFP3 in Europe should be effective in protecting against transmission – 99% efficiency FFP3 Respirator Mask • N95 or FFP2 face masks provide about 94% efficiency – 94% efficiency Particle Recent work by Viscusi5 suggests that most N95 Respirator N95 (FFP2) respirators stored in warehouse and laboratory conditions are likely to maintain there filtration capacity for up to 10 years 7/18/2009 424
    416. HPA-Recommendations For Extending The Lifespan Of Masks: • Use out-of-date facemasks and respirators to the extent available • Use lower grade respirators to the extent available (where a respirator is indicated) • Out-of-date but in-grade respirators are preferred to incorrect grade but in-date stock • Layered facemasks might be considered as a last resort when no respirators (of any grade) are available for the performance of aerosol generating procedures however this will impact on the supply of facemasks for other uses • Re-use of any device is not recommended except as absolute last resort • Decontamination of facemasks is not recommended • Experimental work suggests that high efficacy respirators can be decontaminated without degradation using certain regimens, but these are unlikely to prove practical and there are insufficient data to be certain of a reliable effect. This should only be considered if practical and then as a measure of last resort • Hospitals can perform individual risk assessments to minimise all but essential non-pandemic use of facemasks and determine whether alternatives measures could be adopted • Masking patients with a facemask as an alternative to masking HCWs might be a more efficient use of limited quantities of masks in certain circumstances • Any other nose/mouth covering could be considered once facemask are exhausted, but there are no data in support of specific items other than the DIY 7/18/2009 425 cotton mask described by Dato et al
    417. Pandemic Influenza A(H1N1) 09 Virus Personal Protective Equipment PPE • Disposable particulate respirators (e.g. NIOSH N95 or European EN149: 2001 • FFP2; NIOSH N99 or European EN149: 2001 FFP3; or NIOSH N100) • Must have Fit Testing Program FFP2 9300 valved disposable respirator FFP3 valved moulded cup mask 7/18/2009 426
    418. Pandemic Influenza A(H1N1) 09 Virus Respiratory Protection Programme • Example 7/18/2009 427
    419. Pandemic Influenza A(H1N1) 09 Virus Respiratory Protection Programme • A respiratory protection programme for staff advised to wear respirators should be provided by each healthcare facility to ensure compliance with the following health and safety legislation and standards:  Safety, Health and Welfare at Work Act, 2005  Safety, Health and Welfare at Work (General Application) Regulations 2007 (S.I. No. 299 of 2007). Chapter 3 of Part 2: Personal Protective Equipment  Safety, Health and Welfare at Work (Biological Agents) Regulations 1994 (S.I. No. 146 of 1994) (as amended by S.I. 248 of 1998).  IS EN 529:2005 (Irish Standard on Respiratory Protective Devices) 7/18/2009 428
    420. Pandemic Influenza A(H1N1) 09 Virus Respiratory Protection Programme • Governance: • Identify department responsible to deliver the respiratory protection programme • Identify personnel responsible for the implementation of the respiratory protection programme • Allocation of resources to deliver the programme • Selection, purchase and supply of suitable masks to each healthcare facility • Storage and maintenance of equipment • Disposal of used equipment • Record keeping 7/18/2009 429
    421. Pandemic Influenza A(H1N1) 09 Virus Respiratory Protection Programme • Theoretical information, training and instruction including: • Types of risk • Knowledge and understanding of respiratory equipment including limitations • Personal factors including medical conditions, improper fitting • Fit testing and fit checking • Practical training including: • An initial fit test using qualitative/ quantitative methods • Ongoing fit check to confirm the seal each time the mask is donned • Donning, removing and disposing of mask 7/18/2009 430
    422. Pandemic Influenza A(H1N1) 09 Virus Respiratory Protection Programme • Persons with excessive facial hair, the following options may be considered: • HCW agrees to remove the beard / facial hair • HCW agrees to be otherwise deployed • Pre-exposure prophylaxis (with antiviral medication) be considered • Use of powered air respirator be considered • If none of these options is deemed Types of respirators that can be fit tested with this method include: appropriate or possible (and only in • Filtering facepieces FFP1, FFP2, FFP3; exceptional circumstances) a bearded HCW • Half facemask respirators fitted with a particulate or combined filter may proceed in the clinical care of such patients, only having been fully informed of the risks and in the knowledge that an FFP2 or FFP3 respirator cannot ensure adequate protection 7/18/2009 431
    423. Pandemic Influenza A(H1N1) 09 Virus Personal Protective Equipment (PPE) • Pandemic Influenza A(H1N1) 09 Virus: • Infection Prevention and Control Precautions for use when caring for patients with suspected or confirmed Pandemic Influenza A(H1N1) 09 Virus 7/18/2009 432
    424. How To Perform a Particulate Respirator Seal Check 7/18/2009 433
    425. Donning and Doffing Personal Protective Equipment (PPE) Donning PPE Doffing PPE 7/18/2009 434
    426. Pandemic Influenza A(H1N1) 09 Virus First Responders (PRAs) Personal Protective Equipment (PPE): • Interim recommendations: • When treating a patient with a suspected case of Pandemic Influenza A(H1N1) 09 Virus as defined above, the following PPE should be worn: – Fit-tested disposable FF3 respirator and eye protection (e.g., goggles; eye shield), disposable non-sterile gloves, and gown, when coming into close contact with the patient. • When treating a patient that is not a suspected case of swine-origin influenza but who has symptoms of acute febrile respiratory illness, the following precautions should be taken: – Place a standard surgical mask on the patient, if tolerated. If not tolerated, EMS personnel may wear a standard surgical mask. – Use good respiratory hygiene – use non-sterile gloves for contact with patient, patient secretions, or surfaces that may have been contaminated. Follow hand hygiene including hand washing or cleansing with alcohol based hand disinfectant after contact. • Encourage good patient compartment vehicle airflow/ ventilation to reduce the concentration of aerosol accumulation when possible. • 7/18/2009 435
    427. Secondary Responders Health Professionals (PPE) • Pending clarification of transmission patterns for this virus, personnel providing direct patient care for suspected or Pandemic Influenza A(H1N1) 09 Virus cases should wear a fit-tested FFP2 9300 valved disposable disposable FFP2-3 respirator respirator mask • Fit-tested disposable FF3 respirator and eye protection (e.g., goggles; eye shield), disposable non-sterile gloves, and gown, when coming into close contact with the swine influenza 7/18/2009 FFP3 valved moulded cup mask 436
    428. Tertiary Responders Mortuary (PPE) • However, for people who must directly handle remains, such as recovery personnel, or persons identifying remains or preparing the remains for burial or cremation, there can be a risk of exposure to Pandemic Influenza A(H1N1) 09 Virus • Fit-tested disposable FF3 respirator and eye protection (e.g., goggles; eye shield), disposable non-sterile gloves, and gown, when coming into close contact with the fatalities • Increase level of protection if needed! 7/18/2009 437
    429. Pandemic Influenza A(H1N1) 09 Virus Handling Human Remains (HHR) • Potentially contaminated human remains must be segregated from the general population of a hospital or other facility as soon as the risk is recognized • Only those wearing the appropriate level of PPE should perform segregation of contaminated human remains • Segregation involves: • Placing the human remains along with all personal effects and clothing into an impermeable body bag (double bagged if possible) • Attaching available identifying information to the body and bag • Decontaminating the outside of the body bag (HAZMAT teams may assist with determining the most appropriate agent to use), using extreme care to avoid tearing the body bag during handling, • Moving the bagged human remains to a secure holding area • Notifying the medical examiner of the circumstances of the death, and releasing the human remains to personnel designated by the medical examiner 7/18/2009 438
    430. Pandemic Influenza A(H1N1) 09 Virus Handling Human Remains Health Care setting • Pandemic Influenza A(H1N1) 09 Virus handling of Human Remains Civil Registration Act 2004. Pt.5 Provision of particulars, and registration, of deaths. 7/18/2009 439
    431. Pandemic Influenza A(H1N1) 09 Virus Handling Human Remains (HHR) • Family Contact with the Deceased in Health Care Settings • For deceased persons with confirmed, probable, or suspect Pandemic Influenza A(H1N1) 09 Virus consider limiting contact with the body in health care settings to close family members • Direct contact with the body is discouraged; however, necessary contact may occur as long as hands are washed immediately with soap and water 7/18/2009 440
    432. Pandemic Influenza A(H1N1) 09 Virus Handling Human Remains • Transport of Deceased Persons with Pandemic Influenza A(H1N1) 09 Virus • Transport of deceased persons does not require any additional precautions when bodies have been secured in a transport bag • Hand hygiene should be performed after completing transport • Standard precautions should be used when handling deceased individuals, and preparing bodies for autopsy or transfer to mortuary services • Standard Precautions apply, and appropriate use of personal protective equipment (PPE) (e.g., gowns, gloves, masks, and/or eye protection) is recommended • After PPE is removed, hand hygiene should be performed 7/18/2009 441
    433. Pandemic Influenza A(H1N1) 09 Virus Handling Human Remains Medical Examiner • Pandemic Influenza A(H1N1) 09 Virus handling of Human Remains 7/18/2009 442
    434. Pandemic Influenza A(H1N1) 09 Virus Handling Human Remains Medical Examiner • Personal protective equipment (PPE) • Standard autopsy PPE, which includes: – Scrub suit worn under an impervious gown or apron – Goggles, face shield – Double surgical gloves with an interposed layer of cut-proof synthetic mesh gloves – Surgical mask or respirator – Shoe covers • Aerosols generated procedure: use of oscillating saws – FPP 2-3 disposable particulate respirators – Powered Air Purifying Respirator (PAPR) • Autopsy personnel who cannot wear a disposable particulate respirator because of facial hair or other fit limitations should wear a loose-fitting (e.g. helmeted or hooded) PAPR • Remove PPE before leaving the autopsy suite and dispose in accordance with facility policies and procedures 7/18/2009 443
    435. Pandemic Influenza A(H1N1) 09 Virus Handling Human Remains Medical Examiner: Environmental Precautions for Autopsies • Autopsies on human remains infected Pandemic Influenza A(H1N1) 09 Virus in autopsy settings that have adequate air- handling system • Airborne infection isolation rooms (AIIRs): • Minimum of six (old construction) to twelve (new construction) air changes per hour (and direct exhaust of air to the outside or passed through a HEPA filter if air is recirculated • For autopsies, local airflow control (e.g., laminar flow systems) can be used to direct aerosols away from personnel; however, this safety feature does not eliminate the need for appropriate PPE • Use biosafety cabinets for the handling and examination of smaller specimens • Use vacuum shrouds for oscillating saws to contain aerosols and reduce the volume released into the ambient air environment 7/18/2009 444
    436. Pandemic Influenza A(H1N1) 09 Virus Handling Human Remains Funeral Service • Pandemic Influenza A(H1N1) 09 Virus handling of Human Remains 7/18/2009 445
    437. Pandemic Influenza A(H1N1) 09 Virus Handling Human Remains Funeral Service • Pandemic Influenza A(H1N1) 09 Virus) ; Cat B for HHR • There should be minimal contact/handling of the body • When there is a need to do so, the following precautions are recommended: – When handling dead bodies, do not smoke, eat or drink and avoid contact with their own mouth, eyes or nose with their hands – Avoid direct contact with blood or body fluids from the dead body – Make sure that any cuts, wounds or abrasions are covered with waterproof bandages or dressings – Put on disposable gloves and protective clothing/uniform when handling dead bodies – Hands must be washed after removing gloves and protective clothing – Embalming should not to be done, but if so Minimize environmental contamination during embalming – Viewing of the face without physical contact may be permitted – Relatives who are worried about having already been exposed to the infection should contact the physician – Cremation is recommended for the deceased’s body 7/18/2009 446
    438. Pandemic Influenza A(H1N1) 09 Virus Bioethics 1. Equity of access to antivirals and vaccines 2. Transparency, honesty and good Ethical Dilemmas in a Pandemic Proceedings of the Irish Council for communications Bioethics Conference 17th October 2006, Dublin 3. Individual autonomy v. public good  Freedom vs. Quarantine 4. Imperatives of urgency in outbreak Dr. Darina O’Flanagan situations 5. Duty of care of healthcare workers and value of reciprocity of employers 7/18/2009 447
    439. Pandemic Influenza A(H1N1) 09 Virus Global Migration and Quarantine The WHO has no free-standing international quarantine authority “Quarantine” is still a country-by-country power! QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 448
    440. Pandemic Influenza A(H1N1) 09 Virus Preventive Methods 1. Isolation Suspected swine flu patient (left) is escorted by a quarantine officer to 2. Quarantine Ambulance 3. Social Distancing 4. EU and Irish Quarantine Statue hard to find therefore US example Used! 5. In Ireland voluntary quarantine measures are presented in HPSC Post Exposure Prophylaxis “PEP” form QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 449
    441. Pandemic Influenza A(H1N1) 09 Virus Preventive Methods • Definitions: • Isolation • The separation of an individual, or individuals, infected with a communicable disease from non infected individuals either in the home or hospital • Quarantine • The separation of an individual, or individuals, exposed to a communicable disease, from non infected and non-exposed individuals • Social distancing: • Refer to a range of non quarantined measures that might serve to reduce contact between persons, such as, closing of schools or prohibiting large gathering QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 450
    442. Pandemic Influenza A(H1N1) 09 Virus New Definition of Quarantine • “Means the physical separation, including confinement or restriction of movement, of an individual or individuals who are present within an affected area, as defined herein, or who are known to have been exposed or may reasonably be suspected to have been exposed to a communicable disease of public health threat and who do not yet show signs or symptoms of infection with the communicable disease of public health threat in order to prevent or limit the transmission of the communicable disease of public health threat to other unexposed and uninfected individuals.” QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 451
    443. Rationale for Isolation & Quarantine • Isolation is a fairly common infection control measure used to prevent the spread of disease to non-infected family, healthcare professionals, patients, etc. • Quarantine in an extreme public health Hong Kong Hotel Quarantined Due measure used to prevent the spread of to Swine Flu Case disease to the community 300 people at a Hong Kong hotel have been placed under quarantine after a guest there became China's first confirmed swine flu case. QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 452
    444. When might Isolation & Quarantine be Considered? • Isolation is used primarily in health care facilities with highly infectious patients (e.g., varicella, measles, TB) • Quarantine is used in extreme circumstances when disease spread cannot be prevented by other means, such as by post-exposure prophylaxis (e.g. ,SARS)) • Quarantine is also used when exposed individuals refuse other disease prevention means, such as vaccination (e.g., smallpox) QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 453
    445. Preconditions to Imposition of Quarantine or Isolation • Any quarantine or isolation is implemented in the least restrictive environment necessary to contain the communicable disease of public health threat • Any quarantined persons shall be confined separately from any isolated persons Metropark Hotel • Upon determining that any quarantined person Wanchai after a can be reasonably believed to have become Mexican traveller infected with a communicable disease of public was determined to health threat, the infected person shall be have the virus promptly removed from quarantine and placed in isolation QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 454
    446. Preconditions to Imposition of Quarantine or Isolation • The health and disease status of any quarantined and isolated persons shall be monitored regularly to determine if such persons require continued quarantine or isolation • Any quarantined or isolated persons shall be immediately released from quarantine or isolation upon a determination that such quarantined or isolated persons pose no risk of transmitting the communicable disease of public health threat to other persons • The site of any quarantine or isolation shall be, to the extent practicable, safely and hygienically maintained with adequate food, clothing, health care, and other essential needs made available to the persons who are subject to any order of quarantine and isolation Movie media QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 455
    447. Pandemic Influenza A(H1N1) 09 Virus Preventive Methods “Order of Quarantine” US Example • Ex parte-prepared by the Commissioner: • Sets forth: • Nature of the Public Health Threat including the specific disease if practical • Reasons why quarantine is required – Voluntary Compliance has failed or would be ineffective • Sufficient information to provide notice • Means by which the quarantine to be Biohazard implemented warning: • Geographic parameters (if any) This building • Duration of quarantine Under • Penalty for non-compliance Quarantine until • Provided to those covered individually if possible, further notice otherwise by a means determined by the Commissioner QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 456
    448. Pandemic Influenza A(H1N1) 09 Virus Isolation “Order of Isolation” US Example • Order of Isolation • Ex parte-issued by the Commissioner • Sets forth: – Identity of isolated persons – Bases for the isolation – Specific communicable disease – Site of the isolation – Date and time when isolation commences – Any conditions of the isolation QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 457
    449. Pandemic Influenza A(H1N1) 09 Virus International Quarantine • BEIJING, May 6 (Xinhua) -- Passengers quarantined in the Chinese mainland who took the same flight with a Mexican national later diagnosed with influenza A/H1N1 in Hong Kong will be out of quarantine on Thursday if they display no flu-like symptoms, China's Ministry of Health said Wednesday QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 458
    450. Pandemic Influenza A(H1N1) 09 Virus Quarantine Airports • Quarantine Triage “Red” passenger could get escorted to restricted area RED (Terminal) • There will be a documentation, and a qualified medical expert about the situation and the upcoming procedures. QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 459
    451. Pandemic Influenza A(H1N1) 09 Virus International Quarantine Reporting • Potential Quarantine Database (THAD)(Canadian) • International Health Regulations • Border Health Initiatives • Security and Prosperity Partnership • Global Public Health Information Network (GPHIN) • Passive and Active Surveillance ICU of the Jinan Infectious Disease Hospital in Jinan,China QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 460
    452. Pandemic Influenza A(H1N1) 09 Virus Quarantine Ethics • Targeting versus stigmatizing • Care in all communications • Public health officials, clinicians & the community must combat fear, stigma and discrimination through health education and communication QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 461
    453. Pandemic Influenza A(H1N1) 09 Virus In-Shelter Isolation Biohazard warning: This House Has been self quarantined until further notice Please keep Clear by 20 feet QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 462
    454. Pandemic Influenza A(H1N1) 09 Virus International Quarantine Recommendations • Quarantine is a net not a shield • Enhance communication strategies • Use traveller data to inform syndromic definitions • Create port risk assessment tool • Identify essential key partners for training – Border Services – Cruise Lines and Airlines – Cargo Ships • Establish International Quarantine Working Group QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER QUARANTINE DO NOT ENTER 7/18/2009 463
    455. Public Health Management for Contacts of Probable or Confirmed Case of on a Aircraft (Update June 2 2009) 7/18/2009 464
    456. Influenza has a 72% attack rate in exposed persons in a 4.5 hour plane flight Communicability is highest 1-2 days before to 4-5 days after onset REMEMBER – SOCIAL DISTANCING IS 6 FEET! 7/18/2009 465
    457. Pandemic Influenza A(H1N1) 09 Virus Management OF Passengers Or Crew Members With Symptoms Of Influenza • Minimize the number of personnel directly exposed to the ill person Separate the ill person (6 feet) from others as much as possible without compromising flight safety • Have the ill person wear a facemask, if it can be tolerated, to reduce the number of droplets coughed or sneezed into the air • If a facemask can not be tolerated, provide tissues and ask the ill person to cover his or her mouth and nose when coughing or sneezing along with a plastic bag for proper disposal of contaminated tissues • Gloves are not intended to replace proper hand hygiene. Gloves should be carefully removed and discarded and hands should be cleaned immediately following activities involving contact with body fluids. Gloves should not be washed or reused • Personnel having close contact with an ill person should wear a facemask at a minimum or, ideally, a NIOSH-certified particulate respirator rated N- 95 or better Leaflets warning passengers of possible • Dispose of soiled material, gloves, items contaminated with body fluids, and disposable respirators in a sturdy plastic bag that is tied shut and not swine flu symptoms reopened, and disposed of according to state solid waste regulations 7/18/2009 466
    458. Pandemic Influenza A(H1N1) 09 Virus Irish Port Health Travel Alert Resources • 29 April, 2009, notices were put in place at Irish ports and airports 7/18/2009 467
    459. Pandemic Influenza A(H1N1) 09 Virus Risk Travel Advisories • Department of Health and Children and Department of Foreign Affairs travel advisory July, 16, 2009 Chinese health workers in protective outfits examine passengers onboard an AeroMexico flight AM 98 that landed at Pudong international airport in Shanghai from Mexico Thursday, April 30, 2009 7/18/2009 468
    460. Irish Embassy in México • Embassy • Ambassador His Excellency Dermot Brangan Travel Advisory • Address: First Secretary Security Status Embassy of Ireland Sarah Mangan May 18 2009 Secretary Cda. Blvd. Avila Camacho, 76-3 Myles Doherty Col. Lomas de Chapultepec Honorary Consulate 11000 Mexico D.F. • Address: Mexico Honorary Consulate of Ireland Telephone: Av. Coba 15 Mza.8 +52 55 5520 5803 SM22 Fax: Cancún Security Status 77500 Quintana Roo July , 16, 2009 + (52 55) 55 20 58 92 Telephone: Email: +52 998 112 5436 Submit your query here Fax: Website: +52 998 884 9940 www.irishembassy.com.mx Email: Exercise Caution consul@gruporoyale.com Honorary Consul: Anthony Leeman 7/18/2009 469
    461. HPSC Travel Precautions • Travelling Precautions • Do not travel or fly home if you are ill • Familiarise yourself with sources of health • If you become ill during a flight you should advice in the country of travel, and pay inform the cabin crew attention to local government and public • Cover your nose and mouth with a tissue health announcements including any when coughing, sneezing or wiping and movement restrictions and prevention dispose of tissues into a bin immediately recommendations • If you are caring for someone who is ill, try to • Avoid close contact with people who have ensure they are not in close contact with fever, sneezing or cough others. Wearing a mask may be protective, • General advice includes frequent and for those who are caring for someone with thorough hand washing with soap and water, influenza or alcohol based hand cleaners • Clean surfaces regularly to get rid of germs • If you are sick, avoid close contact with others, stay at home or in your hotel room. • If you have a mild flu-like illness seek medical advice over the phone if practical • Seek medical care if severely ill 7/18/2009 470
    462. Pandemic Influenza A(H1N1) 09 Virus Advice for Travellers to Ireland Update 7/18/2009 471
    463. Pandemic Influenza A(H1N1) 09 Virus Passenger Health Questionnaire 7/18/2009 472
    464. Pandemic Influenza A(H1N1) 09 Virus Aircraft Cleaning Guidance 7/18/2009 473
    465. Cabin Air Quality – Risk of Contagious Viruses Suspected SARS Passenger coming into Frankfurt Airport 7/18/2009 474
    466. Pandemic Influenza A(H1N1) 09 Virus Ship Cleaning Guidance 7/18/2009 475
    467. Pandemic Influenza A(H1N1) 09 Virus Irish Marine Notice May 8 2009 7/18/2009 476
    468. Pandemic Influenza A(H1N1) 09 Virus Sydney Harbour Cruise Ship Quarantine? • The Pacific Dawn has already been blamed for a spike in Australian swine flu cases after authorities last week allowed 2,000 passengers to disembark in Sydney despite a suspected swine flu outbreak aboard • At least 46 passengers and crew aboard a previous Pacific Dawn cruise that docked at Sydney a week ago have been infected with the virus • June, 1, 2009 A cruise ship carrying three crew infected with swine flu agreed not to dock in northern Australia According to information received from SHIPSAN, there has been 12 cruise ships with influenza A(H1N1) cluster outbreaks since the beginning of the pandemic, the first one being reported on May 25, 2009 Pacific Dawn: Passengers line the upper deck of the P&O Cruises Pacific Dawn ship as it docks at Darling Harbour in Sydney 3 days later • Embarked to emergency medical teams testing for Influenza A(H1N1)! 7/18/2009 477
    469. EU SHIPSAN TRAINET • EU SHIPSAN TRAINET project which started in 2008 and will be completed in May 2011 • This project foresees the development of: a) Harmonised communicable diseases surveillance including ILI syndrome by using standardised reporting forms b) A manual providing hygiene standards (e.g. for disinfection and cleaning), and outbreak management guidelines for airborne diseases c) Training of port health personnel and crew members on hygiene issues and outbreak management d) A communication network for collection and sharing of surveillance and ship inspection data among competent authorities • Eurosurveillance, Volume 14, Issue 21, 28 May 2009 • Perspectives • Preparedness for the prevention and control of influenza outbreaks on passenger ships in the EU: the SHIPSAN TRAINET project communication 7/18/2009 478
    470. Pandemic Influenza A(H1N1) 09 Virus Surveillance • A quarantine officer monitors passengers walking through a temperature screening checkpoint at Suvarnabhumi airport in Bangkok on April 24 Thermal Scanning 7/18/2009 479
    471. Pandemic Influenza A(H1N1) 09 Virus Surveillance • Monitor ... a thermal camera monitors the body temperature of passengers to identify possible swine flu infections at Incheon International Airport, South Korea / AP 7/18/2009 480
    472. Pandemic Influenza A(H1N1) 09 Virus Surveillance Around the World • A passenger goes through a disinfection process at the arrival terminal at the Juanda airport in Surabaya, in Indonesia's East Java province April 27, 2009 July, 12, 2009, thermal scanning in airports to decrease due to new mitigation policy strategy published from WHO! 7/18/2009 481
    473. Pandemic Influenza A(H1N1) 09 Virus Travel Advisories 7/18/2009 482
    474. What are the differences between Pandemic Influenza A(H1N1) 09 Virus and the Common cold? Symptoms Influenza A(H1N1) Common Cold Onset Suddenly Slowly Fever Characteristically High (≥38oC or Rare 100oF) Headache Prominent Rare General aches and pain Usual, often severe Rare Fatigue, weakness Can be prolonged for a number Quite mild of weeks Extreme exhaustion Early and prominent Never Stuffy nose Sometimes Common Sneezing Sometimes Usual Sore throat Sometimes Common Chest discomfort, cough Common, can be severe Mild to moderate, hacking cough Diarrhoea, vomiting Commonly Not associated with the common cold in adults 7/18/2009 484
    475. Personal Steps To Take If you Experience Flu-like Symptoms • Contact hospital or healthcare facility prior to going to allow phone triage and allow time to have precautionary measures in place before arrival! 485 7/18/2009
    476. Pandemic Influenza A(H1N1) 09 Virus Adult Emergency Warning Signs for Consult or Re-consult • In adults, emergency warning signs that need urgent medical attention include: • Difficulty breathing or shortness of breath • Coughing up bloody sputum • Pain or pressure in the chest or abdomen • Sudden dizziness • Drowsiness , disorientation or confusion • Severe or persistent vomiting • Fever for 4-5 days and not resolving or once feeling better and then developing a high fever If you have taken the basic care steps outlined above and you start to feel worse, or if after a few days you are not feeling better, you may need further advice from your doctor. Contact you doctor by phone or the FluInformation Line (Freephone 1800 94 11 00) 7/18/2009 486
    477. Pandemic Influenza A(H1N1) 09 Virus Children Emergency Warning Signs for Consult or Re-consult • In children emergency warning signs that need urgent medical attention include: • Fast breathing or trouble breathing • Bluish skin colour • Not drinking enough fluids • Not waking up or not interacting • Being so irritable that the child does not want to be held • Flu-like symptoms improve but then return with fever and worse cough • Fever with a rash 7/18/2009 487
    478. Pandemic Influenza A(H1N1) 09 Virus in Educational Institutions/Schools 7/18/2009 488
    479. Pandemic Influenza A(H1N1) 09 Virus Co Mayo , “St John's National School” • St John's National School in Breaffy near Castlebar, Co Mayo • 7 year old girl in first class has now been quarantined and is responding well to treatment at home • Transmission occurred from relative returning from abroad • Theses children meet Influenza A(H1N1) contact case definition and post- exposure prophylaxis protocol! • Therefore anti-viral medication will now be provided to 28 St John's National School in Breaffy children who were in the girl's class • The HSE said that the school remains open! Unless the Department of Public Health advises the school to close • Parents voluntarily have removed some children as a precautionary measure • All children will see there GP upon returning to school ! • Contact HPSC immediately upon probable or confirmed case in schools!  Influenza A(H1N1)virus has been identified at a National School in Co Roscommon. (July, 2, 2009) • Roxboro NS is a five-teacher school with more than 130 pupils 7/18/2009 489
    480. Pandemic Influenza A(H1N1) 09 Virus Irish School Recommendations • This virus currently appears to be acting like seasonal influenza in terms of the severity of illness and transmission of infection. Given this information, schools can remain open with appropriate isolation of the individuals at home or close school at their discretion, based on public health and community assessment • Other recommendations for schools are as follows: • Each morning, parents and caregivers should assess all family members and especially school-age children for influenza-like illness (defined above) • School staff should assess themselves for influenza-like illness • Students or staff with influenza-like illness should stay home and not attend school for at least 7 days even if their symptoms resolve sooner • If after 7 days, the student or staff continues to have acute symptoms, he or she should Mekkah Stamps, 6, (left) and Mark stay home until 24 hours after these symptoms resolve Vazquez, 5, (right) prepare to serve snacks while wearing protective gloves • Schools should observe students and staff for influenza-like illness at school as a prevention against swine flu at • Students and staff who are ill should be removed from the classroom and sent home Children's House daycare • If a student or staff is ill with other symptoms, they should stay home at least one day to observe how the illness develops • Students and staff with influenza-like illness should stay home and not go into the community unless they need medical care. Ill students should not attend extracurricular activities, community activities or child care • Environmental services should follow routine cleaning and disinfection procedures for all school buildings. No special cleaning or disinfection products are recommended. Environmental services staff should use appropriate personal protective equipment including gloves when using chemical cleaners or disinfectants • Childcare facilities should clean and sanitize frequently-touched surfaces, (such as desks, doorknobs, computer keyboards, toys) routinely and if they become visibly soiled Adapted from CDC School (K – 12) Dismissal and Childcare Facilities 7/18/2009 490
    481. Pandemic Influenza A(H1N1) 09 Virus Irish School JI-6 th Year Check List Example 1.0 Mitigation and Actions Prevention: Completed In Progress Not Started  Create a committee to produce a plan for the preschool or child care program to deal with pandemic flu • The committee should include (if possible • Staff members • Representatives from the local school districts • Director of the program or preschool • Representative from the family child care organization • Parents/family members Completed In Progress Not Started  Assign staff to identify reliable sources of information; watch for public health warnings about flu, program closings, and other actions taken to prevent the spread of flu  Contact the local health department [find a list of local health officers at (Outside Source)] to learn who in your area has legal authority to close child care programs if there is a flu emergency  Review your facility’s disaster and mass casualty plan and determine if any changes need to be made to respond to pandemic flu.  Identify all the ways a flu pandemic might affect your program and develop a plan of action  Identify individual(s) in your program who will educate and supervise children, staff, and families about washing hands, following hygiene/cough etiquette, obtaining seasonal influenza vaccine, and staying home when sick  Develop and implement procedures for routinely sanitizing toys, furniture, and surface areas in your facility  Develop communication and dissemination plans for staff and families, including information about schedule changes, busing changes, and possible school or center closures  Encourage families to have a backup plan for finding care for their children if the program is closed during a flu pandemic or if their child is ill. Give them ideas about where they might seek help based on your knowledge of the local child care community L earn about services in your area that can help your staff, children, and their families deal with stress and other problems caused by a flu pandemic. Contact the local mental health department  Stage a tabletop drill with key staff members to test your plan and then improve it as needed. Repeat the drill from time to time. Consider volunteering to help in tests of community plans  Talk to other child care and preschool programs in your area to share information that could make your plan better. Discuss ways programs could work together to produce a stronger plan and pool resources  Anticipate the potential fear and anxiety of staff, children, and families due to rumors and misinformation, and plan communications accordingly. Consider developing key messages for various scenarios Not everything on this list will apply to every child care agency and preschool. This list will serve as a guide to child care agencies as they develop their own plans. It is important for all child care agencies to communicate with and know the rules and policies of local agencies, such as the local 7/18/2009 health department and local office of emergency services. Both of these agencies will have 491 important roles if there is a pandemic
    482. Pandemic Influenza A(H1N1) 09 Virus Irish School JI-6th Year Check List Example 2.0 Preparedness: Actions Completed In Progress Not Started  Give staff and children’s families reliable information in their language and at their reading level on the issues listed below:: How to recognize a person who may have the flu and what to do if they think they have the flu How to care for ill family members  Teach staff, children, and their families how to limit the spread of infection by using good hand washing; covering the mouth when coughing or sneezing; and cleaning toys frequently  Educate staff and families about pandemic flu and the school plan. Explain why you need to have a plan. Give them a chance to ask questions  Plan how you would deal with program closings, staff absences, and gaps in learning that could occur during a flu pandemic  Plan ways to help families continue their child's learning if your child care program or preschool is closed  Plan ways to continue basic functions if your program is closed  Keep on hand a supply of surgical masks and several days’ supply of soap, paper towels, tissues, and cleaning products you will need to help control the spread of infection  Tell families that experts recommend yearly flu shots for all children six months to five years old and for anyone who cares for children in that age range  Encourage staff to get flu shots each year  Review procedures for communicating with staff, children, and families  Review the plan for identifying ill children and staff, isolating and masking them as necessary, and sending them home Identify or develop educational materials for families and staff on topics such as how to support their child(ren) with recovery from pandemic flu, common symptoms and constructive ways to cope with stress 7/18/2009 492
    483. Pandemic Influenza A(H1N1) 09 Virus Irish School JI-6th Year Check List 3.0 Response: Actions Completed In Progress Not Started  Tell families to let your program know if their children are sick or when a family member is sick with taccurate records of when children or staff are absent. Include a record of the kind of illness that caused the absence (e.g., diarrhea/vomiting, coughing/breathing problems, and rash)  Use a standard set of steps for checking children and adults each day as they arrive to see if they are sick. Make it clear that any child or adult who is ill will not be admitted  Have a plan for keeping children who become sick at your program away from other children, such as a fixed place for a sick room, until the family arrives. Masking affected children is also advisable  Require staff members to stay home if they think they might be sick. If they become sick while at the program, require them to go home and stay home  Require ill children to stay at home until their flu symptoms have gone and they feel ready to come back to your program  Hold staff meeting(s) to provide information on the extent of infection in your program and potential changes that may take place.  Conduct timely debriefings with the program pandemic committee to identify lessons learned and make necessary changes to the response plan 4.0 Recovery: Actions Completed In Progress Not Started  Hold staff meetings and provide information on the extent of pandemic flu in the community  Announce counseling support services that are available to staff. Utilize employee assistance programs for coping with loss and stress  Announce counseling support services that are available to children and families  Provide rest places for those staff and children who tire easily  Make educational materials available to families and staff on topics such as how to support their child with recovery from pandemic flu, common symptoms of loss and grief, and constructive ways to cope with stress  Identify children, families, and staff who may need long-term physical and mental health support or intervention, and refer them to community resources to provide these services  Monitor the effects of cumulative stress on caregivers  Consider offering health and mental health services, if available, by community university, or public/nonprofit mental health agencies, and identify funding to support these services  Modify work roles and responsibilities or consider adding volunteer or support staff as needed  Document “lessons learned” and incorporate them into revisions and training 7/18/2009 493
    484. Public Health Management of Pandemic Influenza A(H1N1) 09 Virus in Educational Institutions • Guidelines for Departments of Public Health on the management of a probable/confirmed case of Influenza A (H1N1) in an educational institution/school/childcare setting update July ,16, 2009 • Topics covered:  Public Health guidance for planning for human infections with Influenza A (H1N1) in crèche/preschool settings  Interim Public Health recommendations to the Department of Education for Educational Institutions in preparing for human infections with the 2009 Influenza A (H1N1)  Public Health guidance for planning for human infections with Influenza A (H1N1) in residential educational institutions http://www.hpsc.ie/hpsc/A- http://www.hpsc.ie/hpsc/A-  Interim Public Health guidance for Z/EmergencyPlanning/AvianPandemicInfluenza third level institutions in preparing for Z/EmergencyPlanning/AvianPandemicInfluen Pages 1-12 /SwineInfluenza/AdviceforHealthProfessionals/ pandemic influenza za/SwineInfluenza/AdviceforHealthProfessio PublicHealth/Guidance/File,3820,en.pdf nals/PublicHealth/Guidance/File,3809,en.pdf 7/18/2009 494
    485. HPSC Checklist for Third Level Institutions 7/18/2009 495
    486. HPSC Checklist for Third Level Institutions 7/18/2009 496
    487. Recommendations Regarding Prevention and Management of ILI in Residential Summer Camps • Interim guidance to Public Health authorities regarding day camps and residential summer camps for the prevention and management of influenza-like illness (ILI) suspected to be due to Influenza A(H1N1)v Recommendations Actions regarding Rationale: Reports of illness among school aged children and transmission within the school setting have been noted. With similar age groups typically attending day camps, it is Prevention and possible that the risk of transmission of H1N1 flu virus in the day camp setting may be similar to that seen in the school setting. In residential camp settings the risk of transmission may Management of ILI be higher due to the increased proximity and prolonged contact among campers, staff and volunteers in residential summer camps Completed In Progress Not Started Education  Camp Nurse should organise pandemic education with organizers  Consider development and implementation of a training program for camp staff regarding communicable disease control including specific information on how to recognize and report possible cases of ILI.  Have relevant age appropriate educational materials and information for campers available. Screening  Passive and active screening (laminated poster are available from HSE upon request) To help prevent entry of H1N1 flu virus into the camp setting, consider advising all camp attendees, prior to the camp start date, of the following:  Individuals who have had ILI within 7 days prior to arrival will not be allowed to attend.  Individuals who have been a contact of a case of ILI within the 7 days prior to arrival may attend camp and will be monitored (either self monitoring or actively monitored, whichever is most appropriate for the situation) closely for symptoms of ILI.  Consider active screening of all newly arriving camp attendees by asking if they have ha